0 ABC-family_proteins_mediated_transport 0.41 4.67 3.34 5 1.69 7.24 4.78 3.58 9.62 4.64 7.05 1.45 2.81 8.27 9.61 4.91 9.95 9.42 
1 ABCA_transporters_in_lipid_homeostasis 8.27 4.36 3.91 6.04 9.02 1.53 2.92 3.82 4.21 7.16 7.18 8.95 4.47 7.26 7.71 5.38 8.69 9.12 
2 Mitochondrial_ABC_transporters 6.67 2.99 0.35 8.94 7.03 8.11 3.22 3.33 6.73 6.64 1.41 7.11 2.53 8.68 5.47 6.44 6.62 7.57 
3 Apoptotic_execution__phase 0.37 8.59 7.23 7.41 5.29 7.78 3.16 0.35 1.9 8.42 2.88 1.06 0.4 9.42 2.64 6.48 4.46 8.05 
4 Activation_of_DNA_fragmentation_factor 8.9 7.29 3.7 3.5 0.06 1.01 3.93 5.48 6.29 6.23 0.84 9.54 7.56 8.4 9.66 3.76 9.31 3.08 
5 Apoptotic_cleavage_of_cellular_proteins 9.44 4.39 6.26 3.23 5.37 5.38 1.18 0.82 9.29 5.41 8.33 1.15 6.39 6.58 7.04 9.3 9.77 3.06 
6 Apoptotic_cleavage_of_cell_adhesion__proteins 6.73 3.86 0.21 7.45 9.24 0.72 2.7 8.29 7.77 5.73 0.97 5.12 9.86 2.9 1.61 6.36 3.55 7.67 
7 Breakdown_of_the_nuclear_lamina 6.55 5.74 0.31 0.52 3.5 1.5 9.41 7.24 9.66 4.3 1.07 1.91 0.07 3.37 4.57 2.87 7.53 3.83 
8 Caspase-mediated_cleavage_of_cytoskeletal_proteins 9.45 9.09 2.09 7.58 2.21 5.88 4.22 9.46 5.06 0.3 4.13 1.68 9 5.91 7.62 6.55 4.1 3.59 
9 Stimulation_of_the_cell_death_response_by_PAK-2p34 6.24 5.37 5.48 4.83 5.95 0.41 6.02 3.5 2.91 8.36 3.74 0.2 5.96 0.21 3.48 1.99 6.68 4.84 
10 Caspase-8_activation 2.81 7.34 0.53 9.99 4.18 9.38 9 7.88 1.27 4.67 7.28 8.93 6.48 4.83 8.07 4.21 3.1 6.17 
11 Dimerization_of_procaspase-8 8.13 5.14 3.09 6.16 9.35 4.51 6 2.49 5.19 5.56 7.98 3.03 2.24 0.08 8.44 6.09 9.89 7.02 
12 FasL/_CD95L_signaling 1.95 4.85 0.93 3.43 5.23 5.87 3.14 5.03 4.48 2 4.58 6.18 5.8 7.96 7.98 2.81 5.89 7.98 
13 TNF_signaling 0.09 1.57 4.72 6.22 5.38 2.92 0.38 1.79 1.9 6.57 9.58 1.91 8.15 8.88 1.56 5.11 2.02 6.34 
14 TRAIL__signaling 2.72 0.55 3.28 6.46 3.62 8.86 8.75 4.33 8.69 1.42 8.44 4.16 8.81 9.98 3.22 6.51 0.21 6.99 
15 Regulation_by_c-FLIP 5.57 4.76 8.92 3.89 0.75 7.12 6 5.1 0.03 8.69 8.61 6.88 4.01 7.89 2.55 4.23 0.02 5.85 
16 Activation_and_oligomerization_of_BAK_protein 1.82 2.85 0.88 4.26 6.17 7.57 8.32 9.32 1.69 1.54 7.21 1.89 9.76 3.29 3.68 6.92 4.25 5.55 
17 Activation_of_BAD_and_translocation_to_mitochondria_ 4.34 5.49 4.41 5.12 1.45 0.6 7.18 7.53 1.39 4.23 2.79 9.96 6.87 5.29 5.49 4.37 8.66 9.49 
18 Activation_of_BIM_and_translocation_to_mitochondria_ 1.93 1.95 2.97 4.16 2.86 1.05 4.88 2.82 4.55 7.34 1.14 7.01 3.16 6.71 7.86 2.63 3.13 3.55 
19 Activation_of_BMF_and_translocation_to_mitochondria 1.85 0.53 9.12 8.08 8.32 9.45 3.13 7.56 3.21 5.58 6.46 9.82 4.81 1.44 1.96 2.22 1.29 1.61 
20 Activation_of_NOXA_and_translocation_to_mitochondria 5.35 4.5 1.73 4.66 0.44 6.59 2.92 4.39 2.53 0.24 1.54 5.1 7.45 6.49 1.86 3.13 4.74 0.22 
21 Activation_of_PUMA_and_translocation_to_mitochondria 1.68 0.18 7.87 9.05 9.58 3.91 2.02 6.25 4.77 4.14 3.14 8.24 3.34 8.74 3.72 1.59 8.33 0.7 
22 Activation,_myristolyation_of_BID_and_translocation_to_mitochondria 4.87 2.97 5.18 1.77 7.73 2.7 7.63 6.68 1.92 9.85 1.02 4.8 2.13 6.27 8.02 0.99 5.27 6.25 
23 Activation,_translocation_and_oligomerization_of_BAX 5.43 9.24 0.23 9.72 0.61 1.81 0.03 4.32 5.05 5.93 7.25 0.31 4.92 1.42 2.22 2.86 0.64 9 
24 Cytochrome_c-mediated_apoptotic_response 1.87 3.6 4.13 9.74 2.7 1.7 2.35 8.33 7.11 7.6 8.96 6.67 2.85 5.5 1.4 6.94 6.95 6.24 
25 SMAC-mediated_apoptotic_response 0.19 1.25 5.76 6.94 6.58 3.02 3.71 4.66 6.78 5.93 8.51 4.84 0.18 4.64 1.19 1.52 8 0.87 
26 BH3-only_proteins_associate_with_and_inactivate_anti-apoptotic_BCL-2_members 0.6 9.26 0.1 7.57 1.7 3.15 5.76 2.27 0.43 7.58 1.64 1.09 8.82 0.86 5.65 4.87 5.77 4.74 
27 Permeabilization_of_mitochondria 6.25 6.27 6.29 9.28 4.23 5.2 9.02 9.62 1.23 5.96 7.37 2.61 1.95 5.25 2.64 2.6 2.02 1.16 
28 Release_of_apoptotic_factors_from_the_mitochondria 0.3 3.26 0.11 7.71 4.11 5.47 1.53 5.2 7.9 9.24 1.88 7.63 9.4 8.51 6.62 8.29 9 7.13 
29 Regulation_of_PAK-2p34_activity_by_PS-GAP/RHG10 9.58 5.78 3.65 0.07 4.77 2 0.58 4.39 3.03 7.6 3.57 3.24 4.77 1.08 1.13 8.87 8.01 8.5 
30 Regulation_of_activated_PAK-2p34_by_proteasome_mediated_degradation 4.6 4.28 9.93 3.84 4.05 5.4 1.11 7.04 8.35 3.56 0.72 3.5 8.23 4.85 5.56 2.16 6.26 3.57 
31 Role_of_DCC_in_regulating_apoptosis 5.26 3.57 3.37 2.71 8.69 3.61 8.96 0.22 6.17 1.12 7.17 6.96 5.85 0.41 4.23 1.29 2.29 5.65 
32 Passive_Transport_by_Aquaporins 5.59 9.32 2.96 8.55 0.53 9.62 5.84 7.34 6.54 9.72 4.57 3.69 5.32 9.63 6.07 4.83 9.11 6.35 
33 Regulation_of_Water_Balance_by_Renal_Aquaporins 0.67 8.48 6.75 9.38 2.23 1.42 7.54 5.11 7.41 1.75 4.59 8.25 2.21 8.7 6.26 9.34 2.05 7.83 
34 Transport_of_Glycerol_from_Adipocytes_to_the_Liver_by_Aquaporins 8.5 3.98 2.79 7.01 1.93 7.34 6.37 5.34 5.56 9.93 1.76 7.05 9.62 5.48 8.81 3 4.13 6.41 
35 Scavenging_by_Class_A_Receptors 8.55 8.55 1.42 4.62 6.11 8.77 4.24 6.78 7.52 4.43 2.96 6.73 0.4 3.13 8.75 0.72 8.18 6.1 
36 Scavenging_by_Class_B_Receptors 0.17 9.32 1.12 6.95 1.69 8.31 0.4 4.88 6.85 0.9 4.97 5.89 9.9 1.45 3.53 3.14 6.51 7.4 
37 Scavenging_by_Class_F_Receptors 0.44 2.58 3.35 7.59 1.92 6.05 2.64 1.81 5.03 8.29 7.75 6.08 2.92 9.97 5.49 5.56 5.61 6.27 
38 Scavenging_by_Class_H_Receptors 4.67 5.41 1.29 2.4 8.13 1.74 6.01 0.77 2.15 6.83 2.13 9.92 8.24 6.01 3.92 7.59 6.7 4.28 
39 Scavenging_of_Heme_from_Plasma 0.27 0.84 0.75 7.86 4.98 9.7 2.87 8.47 6.04 5.03 2.21 6.63 7.06 3.63 0.1 1.71 4.89 2.4 
40 p53-Dependent_G1/S_DNA_damage_checkpoint 1.64 5.42 6.19 9.13 5.91 7.04 8.18 2.32 7.5 2.05 9.75 5.39 3.03 4.22 0.98 2.47 5.84 6.48 
41 p53-Independent_G1/S_DNA_damage_checkpoint 9.71 8.64 9.13 0.75 5.45 7.12 5.46 6.78 7.69 2.62 5.19 9.85 2.89 9.44 8.65 5.4 2.45 5.08 
42 Activation_of_ATR_in_response_to_replication_stress 3.18 8.7 6.01 3.23 1.32 4.72 1.52 0.87 5.7 7.63 9.01 1.03 4.23 5.27 6 9.69 0.15 5.65 
43 G2/M_DNA_damage_checkpoint 0.28 5.43 3.47 0.88 9.43 6.37 4.09 4.63 0.49 6.81 5.88 3.42 6.08 0.6 2.21 7.58 9.54 8.88 
44 G2/M_DNA_replication_checkpoint 1.46 6.9 9.49 8.43 4.3 6.2 7.48 0.67 5.36 7.83 0.35 2.26 1.85 0.38 8.53 6.29 2.24 7.48 
45 Amplification_of_signal_from_the_kinetochores 9.23 3.59 2.57 7.66 9.44 9.55 3.18 7.26 4.11 0.25 3.55 0.01 5.49 4.96 5.84 5.15 9.64 3.42 
46 Inhibition_of_the_proteolytic_activity_of_APC/C_required_for_the_onset_of_anaphase_by_mitotic_spindle_checkpoint_components 0.75 9.13 1.42 1.96 9.48 0.72 4.26 6.06 1.73 4.29 4.04 7.05 6.26 8.12 3.75 0.93 5.65 0.36 
47 Mitotic_Metaphase_and_Anaphase 7.36 1.41 8.14 9.94 2.56 6.52 9.36 8.38 4.82 3.55 0.15 1.31 2.3 8.41 6.25 0.11 6.37 1.86 
48 Mitotic_Prometaphase 6.9 6.5 6.62 6.34 8.93 3.53 4.16 4.52 0.08 2.62 2.33 4.54 3.03 6.34 3.03 2.56 1.48 1.24 
49 Mitotic_Prophase 3.17 2.13 1.09 0.28 2 0.8 3.18 8.58 0.5 1.55 3.61 2.64 9.03 6.76 6.43 9.09 9.02 5.61 
50 Mitotic_Telophase/Cytokinesis 4.89 9.48 2.82 6.53 6.74 2.2 4.02 9.23 8.31 3.69 8.78 2.59 0.08 6.19 9.71 0.03 9.45 7.81 
51 DNA_Replication_Pre-Initiation 5.04 3.92 6.85 3.13 6.98 5.89 7.22 9.38 0.37 4.1 4.61 2.34 5.08 9.61 9.59 4.93 5.15 2.69 
52 G0_and_Early_G1 9.37 8.69 0.58 7 9.71 2.64 1.17 2.15 5.55 8.15 3.3 0.39 2.12 2.88 0.82 9.54 0.85 7.1 
53 G1_Phase 4.84 7.74 3.8 8.15 9.51 5.41 1.15 6.79 1.1 8.98 0.73 7.88 9.77 1.32 9.56 6.89 1.13 0.08 
54 G1/S_Transition 9.41 7.9 7.23 3.63 0.28 1.84 7.78 2 0.71 8.85 9.74 0.71 3.33 8.67 1.53 2.95 1.68 8.25 
55 G2_Phase 6.76 6.29 6.5 5.98 3.09 6.93 6.86 0.8 1.16 2.49 6.67 5.28 6.79 8.64 4.21 4.05 8.26 8.16 
56 G2/M_Transition 5.16 7.26 6.66 0.87 6.81 9.64 3.4 6.86 0.21 6.62 7.21 0.64 3.09 4.15 9.02 8.73 1.24 9.41 
57 Association_of_licensing_factors_with_the_pre-replicative_complex 7.45 7.62 4.23 5.31 8.06 2.68 3.18 6.02 9.07 3.07 4.81 0.12 1.36 6.3 1.14 8.09 0.84 5.56 
58 Removal_of_licensing_factors_from_origins 2.9 2.93 9.96 1.52 0.54 3.45 7.08 2.48 4.91 7.12 1.31 1.14 4.39 9.58 7.22 7.04 9.95 0.52 
59 APC/C-mediated_degradation_of_cell_cycle_proteins 2.69 4.79 2.38 4.23 9.18 8.66 6.59 4.98 4.86 1.96 4.62 6.33 1.58 0.22 1.46 3.92 0.37 9.25 
60 Cyclin_A:Cdk2-associated_events_at_S_phase_entry 6.47 4.58 6.02 8.07 0.98 8.3 2.92 6 2.78 7.99 3.52 4.48 8.82 5.4 3.15 5.75 7.62 5.67 
61 Establishment_of_Sister_Chromatid_Cohesion 3.36 3.97 4.18 8.97 8.28 8.51 8.16 2.3 4.49 9.25 6.58 2.29 5.2 9.4 5.6 1.47 1.62 6.55 
62 Synthesis_of_DNA 6.75 7.92 3.61 7.54 3.98 1.46 7.14 9.46 1.88 5.69 6.38 6.63 0.75 5.15 5.21 4.75 6.15 5.28 
63 Ubiquitin-dependent_degradation_of_Cyclin_D 2.34 5.7 9.05 4.64 5.57 9.62 1.61 5.24 5.49 4.69 3.3 9.23 3.5 3.33 9.25 9.1 7.37 3.36 
64 Meiotic_Synapsis 3.37 2.78 3.93 6.36 7.14 1.64 5.91 9.49 1.35 5.05 3.37 0.04 3.37 6.23 6.64 9.7 6.08 5.68 
65 Deposition_of_New_CENPA-containing_Nucleosomes_at_the_Centromere 2.81 0.85 1.52 3.73 6.52 1.94 8.76 8.26 3.96 5.72 2.49 6.4 1.74 8.19 9.43 6.11 9.41 2.89 
66 Extension_of_Telomeres 4.19 5.65 8.05 5.85 2.16 4.5 6.15 6.09 0.64 1.66 8.93 0.74 5.09 3 6.95 5.73 5.89 1.61 
67 Packaging_Of_Telomere_Ends 1.72 9.68 3.58 0.31 2.68 4.26 5.1 4.22 7.74 7.79 9.1 5.52 1.82 3.91 4.95 7.64 8.74 3.64 
68 Adherens_junctions_interactions 9.02 2.55 4.6 4.74 9.72 8.21 1.22 5.47 5.77 7.89 6.05 1.95 5.94 9.5 3.43 7.54 4.81 0.12 
69 Tight_junction_interactions 6.72 4.39 4.28 9.12 7.62 9.67 4.08 4.15 9.08 2.23 7.59 4.34 2.04 4.86 3.19 9.58 9.45 8.06 
70 Cell-extracellular_matrix_interactions 1.66 7 3.67 6.92 7.87 5.32 5.56 9.74 4.47 0.21 2.83 2.22 3.31 3.76 5.83 9.48 7.23 9.82 
71 Localization_of_the_PINCH-ILK-PARVIN_complex_to_focal_adhesions 0.18 7.76 2.2 1.11 1.82 8.56 4.9 9.25 3.24 4.86 6.77 9.69 6.43 5.34 6.77 6.68 0.68 9.91 
72 Regulation_of_cytoskeletal_remodeling_and_cell_spreading_by_IPP_complex_components 1.96 7.83 8.28 7.27 4.26 8.71 6.97 6.12 7.03 0.27 4.08 5.45 5.08 1.85 2.38 2.37 4.43 3.13 
73 Type_I_hemidesmosome_assembly 5.01 8.5 1.28 1.11 6.5 1.49 1.92 4.54 8.69 6.81 4.65 2.67 7.13 7.93 6.34 4.72 9.72 8.3 
74 DSCAM_interactions 9.01 4.42 1.77 8.77 7.7 7.02 3.64 3.81 5.9 8.23 2.37 0.23 1.79 5.95 1.69 3.27 0.42 3.1 
75 Nephrin_interactions 1.82 0.58 9.26 4.87 6.7 5.28 6.51 2.58 2.13 8.6 7.83 2.86 7.42 6.1 4.72 1.28 4.34 8.41 
76 Signal_regulatory_protein_(SIRP)_family_interactions 7.18 5.03 8.67 8.65 9.38 8.81 2.57 7.5 6.14 5.98 4.58 6.61 0.63 7.56 8.07 2.78 4.89 4.35 
77 DNA_Damage/Telomere_Stress_Induced_Senescence 3.65 0.75 5.86 3.86 8.33 3.6 3.3 0.48 9.28 4.92 4.33 8.4 7.66 7.35 8.1 5.99 8.37 8.92 
78 Formation_of_Senescence-Associated_Heterochromatin_Foci_(SAHF) 9.82 3.28 3.52 3.69 2.44 7.94 6.08 2.52 6.47 4.32 5.35 2.08 2.64 4.97 2.43 6.49 0.15 8.41 
79 Oncogene_Induced_Senescence 1.89 1 8.12 6.48 5.23 8.51 4.74 6.33 8.91 2 8.54 9.9 6.97 9.19 7.8 5.78 9.31 5.44 
80 Oxidative_Stress_Induced_Senescence 3.4 4.87 8.99 5.25 4.83 5.38 4.92 1.93 2.52 0.11 5.6 8.34 8.4 4.97 7.85 5.29 5.4 8.05 
81 Senescence-Associated_Secretory_Phenotype_(SASP) 7.91 3.92 2.1 5.49 5.78 9.79 9.71 2.77 0.73 1.93 6.2 4.97 8.26 2.76 7.9 5.82 5.78 1.59 
82 Oxygen-dependent_Asparagine_Hydroxylation_of_Hypoxia-inducible_Factor_Alpha 4.18 4.89 1.59 4.49 9.24 0.72 3.8 0.08 9.67 2.08 4.77 5.03 3.7 6.07 1.96 0.74 7.22 6.11 
83 Oxygen-dependent_Proline_Hydroxylation_of_Hypoxia-inducible_Factor_Alpha 0.19 7.61 0.56 8.9 1.63 6.83 7.16 9.32 4.52 7.41 9.54 8.13 8.62 3.96 4.6 6.15 9.04 5.99 
84 Regulation_of_Gene_Expression_by_Hypoxia-inducible_Factor 1.36 6.8 1.98 0.32 3.87 5.84 2.4 5.17 0.06 6.7 2.41 8.82 2.49 5.23 7.58 1.05 6.21 0.95 
85 Circadian_Clock 2.96 9.16 6.78 1.78 5.79 0.58 5.77 7.5 0.07 7.29 0.81 9.95 6.78 6.76 7.53 8.99 7.84 5.65 
86 BMAL1:CLOCK/NPAS2_Activates_Circadian_Expression 0.93 6.08 1.72 2.43 9.29 5.14 1.68 0.55 1.91 9.73 9.22 7.48 6.51 9.86 1.44 4.46 5.77 5.17 
87 Circadian_Repression_of_Expression_by_REV-ERBA 6.29 9.16 8.74 7.91 4.69 9.12 1.46 6.93 0.91 8.15 9.49 8.57 6.4 0.52 2.36 5.51 4.87 2.26 
88 RORA_Activates_Circadian_Expression 1.62 9.55 1.83 3.94 1.8 0.97 0.65 0.65 5.13 2.61 5.78 0.78 8.78 1.4 6.11 9.47 4.45 1.7 
89 Depurination 9.75 4.89 7.5 1.49 3.33 8.65 2.14 2.82 0.07 4.32 8.96 3.67 5.22 8.82 8.1 6.41 2.31 1.87 
90 Depyrimidination 7.05 4.79 3.21 5.38 3.51 4.47 2.08 6.46 2.76 7.59 1.89 4.22 6.66 4.86 4.55 0.28 6.14 8.6 
91 Resolution_of_AP_sites_via_the_multiple-nucleotide_patch_replacement_pathway 2.53 7.77 3.48 5.03 8.61 4.31 0.82 4.55 1.97 1.06 7.52 8.21 2.96 2.81 0.21 4.55 9.47 1.24 
92 Resolution_of_AP_sites_via_the_single-nucleotide_replacement_pathway 3.18 1.35 3.76 7.74 8.59 9.98 0.74 2.53 9.22 6.35 6.43 8.88 1.53 2.32 7.47 6.8 9.26 6.78 
93 Translesion_synthesis_by_HREV1 4.5 8.01 9.61 1.99 8.55 3.63 7.16 5.73 5.61 2.45 4.73 2.74 5.5 3.53 1.81 2.87 6.99 1.1 
94 Translesion_synthesis_by_Pol_eta__ 6.43 4.65 1.72 5.29 9.81 1.12 4.76 3.81 2.47 8.9 6.71 8.05 3.72 0.32 9.89 3.2 1.65 4.31 
95 Translesion_synthesis_by_Pol_zeta 6.58 2.93 2.06 5.78 9.48 2.06 1.71 1.66 3.96 6.97 0.2 6.94 5.29 7.88 1.09 9.84 9.69 9.78 
96 DNA_Damage_Reversal 6.17 0.15 6.26 6.84 1.68 9.06 9.28 0.97 1.18 3.9 1.99 7.85 4.86 1.99 4.2 7.1 2.71 8.13 
97 ABH2_mediated_Reversal_of_Alkylation_Damage 4.15 0.85 3.18 5.8 3.31 2.67 3.87 4.44 1.86 5.07 3.6 8.27 0.74 4.31 1.52 2.71 2.68 6.93 
98 ABH3_mediated_Reversal_of_Alkylation_Damage 8.85 3.37 3.11 6.04 6.77 4.06 7.68 0.22 4.13 0 5.42 5.37 0.38 3.88 3.55 2.89 6.47 1.81 
99 Homologous_recombination_repair_of_replication-dependent_double-strand_breaks 0.93 5.84 9.87 7.61 4.93 2.17 5.01 4.82 4.47 6.65 7.53 1.04 0.84 0.95 5.25 2.21 9.64 7.81 
100 Homologous_recombination_repair_of_replication-independent_double-strand_breaks 8.72 1.06 6.56 3.43 5.93 0.8 0.8 8.68 4.11 7.13 9.68 2.51 2.16 0.79 7.68 0.4 5.31 9.33 
101 Nonhomologous_End-joining_(NHEJ) 7.79 6.63 2.59 6.53 9.36 0.95 3.65 8.74 7.2 8.35 6.8 9.76 4.55 7.25 0.71 8.08 5.59 1.56 
102 Processing_of_DNA_ends_prior_to_end_rejoining 6.02 8.32 9.05 4.4 3.75 5.62 8.85 9.62 0.8 8.36 7.97 2.02 5.08 0.8 3.4 0.76 0.58 4.93 
103 Fanconi_Anemia_pathway 7.4 5.46 4.74 7.73 0.97 8.8 3.35 0.72 4 7.07 9.55 6.66 1.41 5.88 4.81 1.68 3.15 3.96 
104 Regulation_of_the_Fanconi_anemia_pathway 2.25 0.09 0.12 1.36 4.55 7.62 0.43 7.42 0.21 9.22 5.12 2.48 0.18 3.68 7.17 7.14 6.5 2.9 
105 DNA_Damage_Recognition_in_GG-NER 3.35 7.59 1.69 8.95 3.03 6.4 9.79 1.99 1.05 7.91 6.61 6.81 6.52 7.53 0.33 0.29 9.87 0.42 
106 Dual_incision_reaction_in_GG-NER 2.53 0.83 4.2 8.14 7.18 2.44 0.63 2.29 6.52 8.64 7.69 4.7 0.05 0.47 5.94 4.87 3.26 2.76 
107 Formation_of_incision_complex_in_GG-NER 3.23 5.4 6.79 9.9 5.88 7.1 2.71 9.45 2.21 4.7 1.83 5.89 9.55 9.78 7.79 0.06 2.62 1.35 
108 Gap-filling_DNA_repair_synthesis_and_ligation_in_GG-NER 4.87 1.96 0.33 0.88 9.35 7.79 9.93 7.9 9.62 9.65 0.01 1.05 8.07 5.67 6.69 1.34 6.71 4.57 
109 Transcription-coupled_NER_(TC-NER) 9.98 5.45 5.97 2.18 8.38 8.44 3.72 5.63 0.28 2.64 8.01 7.23 4.9 6.04 6.01 2.27 1.97 6.92 
110 Dual_incision_reaction_in_TC-NER 7.71 3.63 3.01 3.63 7.21 5.65 4.21 4.45 6.1 4.95 7.41 0.22 8.12 1.51 0.15 0.55 3.93 7.38 
111 Formation_of_transcription-coupled_NER_(TC-NER)_repair_complex 2.79 8.82 6.08 6.54 8.22 7.07 2.45 3.38 1.44 2.9 3.39 1.54 6.04 6.23 2.25 0.78 7.24 9.81 
112 Gap-filling_DNA_repair_synthesis_and_ligation_in_TC-NER 3.3 7.33 2.23 5.94 1.3 8.46 9.87 4.45 8.05 6.16 7.5 4.89 3.38 9.63 1.35 6.97 2.09 6.3 
113 Activation_of_the_pre-replicative_complex 2.24 9.08 7.37 4.74 9.2 3.72 2.93 8.55 7.34 5.61 0.56 6.06 1.84 0.75 3.82 1.19 7.41 4.32 
114 Assembly_of_the_pre-replicative_complex 6.84 7.79 2.79 2.83 6.67 8.36 1.25 1.18 7.37 0.28 1.19 5.77 7.37 0.91 5.56 7.95 0.6 9.01 
115 Association_of_licensing_factors_with_the_pre-replicative_complex 7.93 4.32 1.36 5.8 8.75 9.07 1.84 0.74 7.19 7.9 4.76 0.41 3.51 3.29 2.9 9.74 0.72 5.91 
116 Removal_of_licensing_factors_from_origins 1.89 7.87 4.9 2.39 8.93 0.53 0.63 6.81 9.03 0.05 1.76 4.79 6.95 1.39 4.68 9.98 0.83 6.39 
117 CDK-mediated_phosphorylation_and_removal_of_Cdc6 5.15 6.21 9.93 8.26 7.22 8.38 8.28 5.81 3.99 9.78 8.91 0.23 9.43 8.34 2.43 3.49 7.02 7.07 
118 Orc1_removal_from_chromatin 5.02 1.41 6.87 3.46 8.91 6.37 4.13 4 8.16 6.9 1.62 9.35 1.26 4.1 8.77 3.82 2.6 1.89 
119 DNA_replication_initiation 7.05 8.74 6.63 7.22 1.95 5.66 3.6 0.38 5.88 8.11 2.45 4.67 4.25 8.67 1.89 5.42 0.63 5.47 
120 Lagging_Strand_Synthesis 5.02 6.17 0.99 0.23 2.26 2.03 0.48 0.51 5.7 6.36 4.58 9.67 4.56 4.05 5.31 9.62 8.19 9.75 
121 Leading_Strand_Synthesis 5.56 5.31 4.95 0.44 5.91 8.03 3.88 9.15 4.5 3.19 2.72 7.91 3.83 1.33 7.75 6.42 5.69 3 
122 Unwinding_of_DNA 9.54 0.78 5.85 2.57 3.33 8.93 4.9 1.03 7.5 2.33 7.22 2.71 6.11 9.9 3.38 6.41 2.58 0.47 
123 Switching_of_origins_to_a_post-replicative_state 3.52 6.58 4.79 3.02 6.83 9.9 0.02 5.68 4.22 8.95 1.35 0.08 3.61 7.42 1.94 6.99 1.88 1.78 
124 CDK-mediated_phosphorylation_and_removal_of_Cdc6 0.42 3.57 9.41 8.47 4.69 3.45 3.8 9.13 9.64 7.1 0.61 3.85 0.73 5.04 4.62 7.03 1.02 0.69 
125 Orc1_removal_from_chromatin 1.54 5.29 5.52 0.74 1.49 7.3 2.44 8.44 0.49 1.18 0.65 3.63 5.52 7.73 4.7 7.31 7.47 5.11 
126 L1CAM_interactions 8.69 3.98 4.98 1.03 3.52 6.79 0.53 0.43 5.22 0.88 5.63 8.34 8.5 0.22 2.4 9.11 4.92 6.51 
127 CHL1_interactions 5.8 4.77 6.16 8.76 1.78 2.2 6.15 3.48 7.98 1.79 6.35 8.57 8.83 6.62 9.02 2.62 4.2 7.7 
128 Interaction_between_L1_and_Ankyrins 0.22 2.73 8.41 6.86 8.88 9.17 7.17 8.92 6.98 2.67 7.49 0.65 3.89 9.32 6.19 0.81 0.03 1.3 
129 Neurofascin_interactions 0.28 6.31 5.89 1.52 6.3 1.72 8.64 4.07 2.95 4.28 6.81 4.9 6.1 1.77 0.71 2.36 4.59 6.43 
130 NrCAM_interactions 8.4 6.33 0.37 8.93 6.3 2.74 9.93 7.82 2.03 4.61 2.9 6.62 3.07 9.97 1.51 4.23 8.9 7.17 
131 Recycling_pathway_of_L1 6.4 7.03 5.66 8.83 6.61 6.59 2.45 3.86 6.51 7.65 6.01 8.4 2.09 4.97 2.83 2.5 0.58 4.21 
132 Signal_transduction_by_L1 1.75 5.81 7.87 2.71 2.87 9.99 5.04 9.79 1.38 7 5.3 4.61 1.18 2.05 5.4 8.28 4.59 6.22 
133 NCAM_signaling_for_neurite_out-growth 3.98 7.6 0.98 9.35 4.81 6.14 5.67 4.93 5.96 1.61 7.46 5.38 6.7 5.38 4.76 5.55 9.17 3.71 
134 NCAM1_interactions 7.6 7.52 7.58 4.33 2.55 0.65 7.26 4.01 0.34 7.59 3.93 5.48 2.73 7.92 1.93 9.33 1.37 1.03 
135 RAF/MAP_kinase_cascade 6.9 2.11 6.94 6.68 6.27 4.98 9.89 2.48 8.79 6.47 1.49 9.31 6.69 8.75 5.98 4.49 4.36 5.99 
136 Netrin-1_signaling 1.23 4.43 7.31 1.54 8.61 4.34 3.85 9.67 8.16 3.93 7.04 8.66 9.53 3.08 2.23 6.84 7.92 6.67 
137 DCC_mediated_attractive_signaling 0.48 4.69 9.3 8.11 8.14 0.9 4.27 7.43 6.04 5.99 4.74 1.95 5.06 1.58 5.89 8.58 8.09 8.89 
138 Netrin_mediated_repulsion_signals 4.47 0.4 8.18 3.64 9.75 0.26 0.89 5.03 0.66 4.12 8.4 5.7 6.76 3.95 6.41 9.86 6.51 1.09 
139 Role_of_second_messengers_in_netrin-1_signaling 1.87 0.83 0.85 3.9 2.5 6.86 7.55 3.81 1.28 5.02 2.77 8.62 4.24 5.65 8.72 8.32 8.85 4.28 
140 CRMPs_in_Sema3A_signaling 6.46 8.89 4.78 8.83 9.25 2.65 2.6 0.45 7.78 8.21 8.55 5.2 9.27 7.73 1.34 2.51 6.75 3.36 
141 Other_semaphorin_interactions 3.34 0.01 7.37 3.1 9.74 5.9 3.56 0.71 0.8 9.35 1.45 2.82 8.25 7.18 5.73 7.12 0.37 9.98 
142 SEMA3A-Plexin_repulsion_signaling_by_inhibiting_Integrin_adhesion 9.05 1.62 7.17 6.92 5.39 0.47 9.46 1.03 2.31 1.15 8.39 8.58 8.29 6.45 3.94 1.99 6.45 2.72 
143 Sema3A_PAK_dependent_Axon_repulsion 6.75 8.62 0.72 7.73 4.8 2.38 8.97 5.42 6.08 2.03 2.77 1.25 1.34 4.01 0.78 3.82 1.69 7.36 
144 Sema4D_in_semaphorin_signaling 4.78 9.39 1.38 7.21 4.26 6.63 6.77 5.75 7.24 9.81 7 9.61 8.62 0.02 4.48 0.95 6.84 0.16 
145 Signaling_by_Robo_receptor 1.37 5.07 9.93 2.84 9.44 2.59 8.21 0.58 6.43 6.68 6.77 1.19 8.57 0.41 8.91 2.64 6.23 9.15 
146 Activation_of_Rac 0.72 9.29 8.41 7.15 6.15 5.36 9.57 7.59 7 4.52 0.93 2.41 8.29 4.48 2.27 7.98 2.24 3.24 
147 Inactivation_of_Cdc42_and_Rac 2.74 1.33 8.85 0.38 1.7 8.62 6.29 0.84 9.09 8.78 9.23 0.85 4 0.24 1.93 1.05 4.12 7.65 
148 Regulation_of_Commissural_axon_pathfinding_by_Slit_and_Robo 7.67 4.07 6.77 7.84 7.04 7.9 8.34 8.91 6.21 0.85 7.34 1.9 5.42 9.98 0.86 0.18 6.21 4.24 
149 Role_of_Abl_in_Robo-Slit_signaling 5.97 3.76 2.54 6.69 1.08 9.27 4.93 0.68 3.66 1.02 4.38 6 8.19 3.18 2.9 9.84 3.39 5.56 
150 CDO_in_myogenesis 8.08 6.32 4.78 8.14 7.87 2.39 0.74 0.2 8.27 5.54 9.88 4.41 7.98 6.42 0.02 3.21 1.04 9.46 
151 Regulation_of_gene_expression_in_beta_cells 0.56 5.09 8.33 7.08 7.61 5.33 6.86 8.04 3.85 1.42 8.42 2.6 1.61 6.2 3.43 5.78 1.87 1.13 
152 AKT-mediated_inactivation_of_FOXO1A 0.63 5.91 9.34 4.15 6.56 7.61 0.12 4.11 9.59 2.51 7.38 3.7 1.24 5.07 0.07 5.84 9.51 1.01 
153 Regulation_of_gene_expression_in_early_pancreatic_precursor_cells 4.89 9.58 4.41 7.9 0.13 4.12 8.55 0.6 0.93 4.72 4.02 6.76 5.43 3.73 2.66 6.51 2.75 5.28 
154 Regulation_of_gene_expression_in_endocrine-committed_(NEUROG3+)_progenitor_cells 5.32 7.61 4.69 5.03 7.29 1.07 8.92 4.51 9.53 3.92 5.7 5.19 4.72 4.07 4.94 5.05 4.4 3.83 
155 Regulation_of_gene_expression_in_late_stage_(branching_morphogenesis)_pancreatic_bud_precursor_cells 2.62 4.09 6.07 0.38 3.6 4.71 1.71 6.54 9.47 5.14 5.23 2.29 4.89 7.66 8.87 7.56 6.32 4.7 
156 Signaling_by_NODAL 7.39 6.66 5.22 2.83 1.6 5.53 7.05 0.91 2.59 3.86 6.87 6.29 0.42 3.17 0.45 3.56 3.88 4.52 
157 Regulation_of_Signaling_by_NODAL 1.54 4.66 8.33 7.6 9.19 6.31 7.38 2.67 7.76 0.98 3.14 3.2 0.53 0.07 4.69 2.16 7.22 8.42 
158 Transcriptional_Regulation_of_White_Adipocyte_Differentiation 0.07 4.63 2.6 9.47 7.93 6.3 7.17 0.43 3.76 3.14 6.26 1.17 3.34 6.2 1.71 7.92 9.64 1.54 
159 Abnormal_conversion_of_2-oxoglutarate_to_2-hydroxyglutarate 8.66 6.93 6.64 7.75 0 2.12 1 5.51 4.76 3.79 9.43 8.77 7.89 3.61 3.85 2.72 4.34 1.44 
160 Abnormal_metabolism_in_phenylketonuria 5.61 5.63 5.04 9.46 8.88 3.08 1.57 4.3 1.23 4.64 0.74 3.46 8.37 9.81 3.18 6.11 2.92 5.91 
161 Amyloids 8.32 1.23 4.61 9.91 4.61 3.3 4.98 3.69 2.91 4 1.79 1.17 3.17 9.14 5.95 4.41 9.36 8.67 
162 Botulinum_neurotoxicity 0.28 4.53 9.09 9.73 9.81 5.03 5.69 8.16 8.83 3.67 3.85 4.02 2.3 1.57 6.81 5.67 3.1 8.66 
163 Proteolytic_cleavage_of_SNARE_complex_proteins 6.87 1.71 4.77 2.45 7.64 2.38 6.71 0.47 1.15 5.92 3.11 6.57 4.05 0.53 1.71 5.8 7.4 5.3 
164 BoNT_Light_Chain_Types_A,_C1,_E_cleave_SNAP-25 6.75 3.2 7.9 3.77 9.98 5.86 6.04 4.89 6.31 7.44 3.88 6.1 7.18 9.19 2.59 9.27 6.09 1.19 
165 BoNT_Light_Chain_Types_B,_D,_and_F_cleave_VAMP/Synaptobrevin 4.79 7.16 3 3.96 8.53 4.58 8.3 5.93 8.06 8.49 8.54 2.72 1.6 2.94 0.54 3.33 1.46 2.29 
166 Translocation_of_BoNT_Light_chain 4.71 4.28 5.59 2.41 4.21 6.88 3.66 0.33 6.85 2.7 3.29 2.61 8.6 2.08 9.82 1.62 5.06 8.78 
167 Defective_BTD_causes_biotidinase_deficiency 9.79 8.97 8.87 5.38 4.69 7.83 5.4 7.95 2.66 6.33 5.09 5.57 3.17 1.34 0.53 1.35 2.58 5.93 
168 Defective_HLCS_causes_multiple_carboxylase_deficiency 8.43 6.93 4.66 9.51 1.4 0.94 9.37 1.74 5.12 0.97 5.51 6.95 8.17 4.92 2.92 2.37 5.3 6.13 
169 Defective_AMN_causes_hereditary_megaloblastic_anemia_1 2.96 7.1 3.89 6.28 8.09 7.86 7.44 8.4 1.82 5.69 1.2 3.93 2.92 9.62 2.14 5.27 8.07 1.94 
170 Defective_CD320_causes_methylmalonic_aciduria 7.05 7.13 0.11 9.13 6.93 6.64 2.03 9.95 7.62 3.81 9.46 9.09 0.48 7.68 6.24 5.11 9.54 2.35 
171 Defective_CUBN_causes_hereditary_megaloblastic_anemia_1 1.27 6.33 2.4 8.62 1.27 5.77 8.17 3.4 1.42 1 4 5.58 4.76 1.54 9.35 4.3 8.31 2.95 
172 Defective_GIF_causes_intrinsic_factor_deficiency 5.37 6.23 9.22 9.27 0.29 2.11 2.11 7.54 8.8 2.53 2.93 3.21 7.85 5.28 4.43 0 5.55 6.71 
173 Defective_LMBRD1_causes_methylmalonic_aciduria_and_homocystinuria_type_cblF 2.7 4.52 3.75 6.31 6.4 9.34 0.4 9.86 8.34 2.48 5.39 7.65 7.96 3.12 2.62 0.52 7.31 9.87 
174 Defective_MMAA_causes_methylmalonic_aciduria_type_cblA 4.64 5.57 2.48 5.56 1.7 4.5 1.82 3.01 2.93 0.99 3.32 0.44 3.31 0.75 0.04 0.5 0.26 0.66 
175 Defective_MMAB_causes_methylmalonic_aciduria_type_cblB 7.38 8.01 6.23 8.43 4.41 3.8 6.95 9.18 6.59 3.63 6.28 3.29 0.88 8.54 6.13 9.79 5.69 6.66 
176 Defective_MMACHC_causes_methylmalonic_aciduria_and_homocystinuria_type_cblC 6.79 5.77 8.37 4.02 1.15 2.92 7.23 8.72 4.48 3.23 1.53 9.48 3.95 1.97 5.08 9.08 4.11 9.93 
177 Defective_MMADHC_causes_methylmalonic_aciduria_and_homocystinuria_type_cblD 6.65 7.81 2.02 6.1 8.28 2.56 7.05 9.65 0.23 7.69 7.15 2.53 8.05 6.84 4.78 1.45 8.4 8.33 
178 Defective_MTR_causes_methylmalonic_aciduria_and_homocystinuria_type_cblG 2.85 9 9.68 9.94 6.33 8.85 3.48 2.81 0.32 2.56 9.1 8.72 9.82 9.01 3.06 6.35 8.6 4.71 
179 Defective_MTRR_causes_methylmalonic_aciduria_and_homocystinuria_type_cblE 5.27 1.37 3.43 7.68 2.33 9.95 1.71 6.03 9.42 0.11 8.79 0.34 5.12 5.93 5.3 1.61 2.34 2.58 
180 Defective_MUT_causes_methylmalonic_aciduria_mut_type 9.26 9.06 1.91 4.43 1.88 2.27 7.19 4.84 2.24 0.93 4.35 2.24 0.94 5.82 8.67 6.27 0.05 1.46 
181 Defective_TCN2_causes_hereditary_megaloblastic_anemia 6.86 5.89 5.4 2.37 8.5 7.59 5.78 9.56 6.77 4.03 0.42 3 8.11 2.25 1.43 5.95 0.16 6.15 
182 Retinoid_cycle_disease_events 8.04 0.06 3.68 6.41 3.35 6.98 3.25 3.13 0.23 3.12 6.18 4.57 3.96 3.39 0.86 0.94 8.46 0.43 
183 Biosynthesis_of_A2E,_implicated_in_retinal_degradation 5.22 9.11 2.8 4.55 3.58 8.47 8.7 9.9 8.73 3.27 4.13 4.54 8.96 4.72 4.5 2.41 6.41 6.46 
184 Retinoid_metabolism_and_transport 5.25 2.13 8.24 9.29 6.95 4.03 5.94 9.93 0.67 1.87 6.4 0.79 0.41 1.25 5.34 8.6 0 9.07 
185 The_canonical_retinoid_cycle_in_rods_(twilight_vision) 6.21 6.92 2.93 1.17 7.17 4.03 9.43 8.93 6.39 0.11 9.25 0.28 9.78 7.48 8.5 8.92 4.44 6.54 
186 The_phototransduction_cascade 6.23 3.53 0.36 5.47 3.46 8.26 0.61 9.04 2.38 5.71 8.86 4.05 2.99 0.56 7.28 2.67 7.51 0.19 
187 The_retinoid_cycle_in_cones_(daylight_vision) 9.91 1.66 7.17 8.46 0.93 1.87 4.21 9.12 8.67 2.99 4.44 8.97 2.01 3.28 9.42 1.04 7.68 7.68 
188 Early_Phase_of_HIV_Life_Cycle 6.41 2.96 2.62 7.2 2.44 9.18 6.25 2.19 5.84 1.74 9.84 4.59 1.49 0.14 6.95 5.03 0.32 8.51 
189 Late_Phase_of_HIV_Life_Cycle 5.37 8.14 3.63 6.51 2.19 2.9 9.17 6.83 9.18 5.84 2.52 5.86 2.69 2.48 1.37 3.97 4.24 1.68 
190 APOBEC3G_mediated_resistance_to_HIV-1_infection 0.27 1.48 9.93 3.82 2.71 6.69 8.93 8.77 0.14 1.04 4.84 9.43 4.95 8.11 2.93 8.92 7.98 9.9 
191 Interactions_of_Rev_with_host_cellular_proteins 2.99 8.9 4.93 0.74 5.49 7.74 3.14 1.73 0.69 2.18 8.65 8.33 2.38 9.11 2.52 4.63 5.08 1.49 
192 Interactions_of_Tat_with_host_cellular_proteins 0.88 2.45 2.31 9.2 1.06 2.71 3.68 4.21 2.58 1.57 6.47 9.82 2.38 1.22 7.23 9.06 7.06 1.89 
193 Interactions_of_Vpr_with_host_cellular_proteins 1.56 3.45 3.51 9.23 1.18 5.5 0.97 8.36 5.91 4.06 5.1 8.13 6.51 8.8 8.44 7.43 7.41 2.45 
194 The_role_of_Nef_in_HIV-1_replication_and_disease_pathogenesis 5.78 9.49 7.05 5.14 7.85 2.27 6.24 2.04 3.56 9.17 2.27 5.55 1.02 2.86 4.68 6.98 9.79 4.11 
195 Vif-mediated_degradation_of_APOBEC3G 4.89 7.58 4.9 7.75 4.1 1.32 0.89 2.96 9.5 1.12 1.22 5.29 6.72 8.36 2.77 5.53 9.76 6.7 
196 Vpu_mediated_degradation_of_CD4 0.85 6.52 7.51 3.97 7.51 0.01 4.35 6.93 0.72 9.16 7.16 3.28 5.11 1.25 8.38 2.96 9.39 5.44 
197 _NS1_Mediated_Effects_on_Host_Pathways 0.56 8.26 9.02 7.58 5.88 0.21 5.86 1.08 7.77 6.28 9.79 9.47 5.49 2.8 2.45 1.28 0.62 4.26 
198 Influenza_Virus_Induced_Apoptosis 7.19 6.77 0.91 0.47 7.85 2.31 4.06 6.84 9.54 7.69 7.09 9.56 4.21 9.45 4.65 0.16 8.6 4.97 
199 Influenza_Life_Cycle 3.35 1.9 6.77 0.49 0.05 8.86 3.88 6.75 1.43 3.77 1.3 4.87 5.55 4.82 2.53 0 7.54 2.89 
200 Entry_of_Influenza_Virion_into_Host_Cell_via_Endocytosis 4.88 2.15 0.08 3.1 9.4 7.99 9.97 7.07 4.54 3.04 2.37 4.85 4.99 7.92 6.13 6.12 6.82 9.83 
201 Export_of_Viral_Ribonucleoproteins_from_Nucleus 3.51 1.29 1.37 0.33 6 8.64 6.83 8.57 9.68 7.1 9.68 7.08 6.41 7.32 4.37 6.84 4.99 7.01 
202 Fusion_and_Uncoating_of_the_Influenza_Virion 8.69 5.83 2.56 6.92 6.4 0.87 0.12 8.1 8.2 8.35 6.63 6.15 8.97 6.77 7.74 1.34 5.53 5.33 
203 Influenza_Viral_RNA_Transcription_and_Replication 8.78 2.86 6.24 7.34 0.75 3.49 7.12 9.84 6.24 7.92 5.04 8.22 0.55 9.13 4.62 4.73 0.84 1.6 
204 Transport_of_Ribonucleoproteins_into_the_Host_Nucleus 1.22 0.53 3.97 8.22 7.5 3.37 9.17 0.06 9.31 1.97 5.05 2.36 3.57 5.99 2.9 8.98 9.85 4.47 
205 Virus_Assembly_and_Release 0.84 5.92 7.25 9.96 8.55 8.28 3.38 3.42 4.28 7.95 7.42 0.37 5.06 7.67 0.53 7.93 5.05 1.46 
206 Phagosomal_maturation_(early_endosomal_stage) 6.09 9.24 8.54 4.65 2.39 2.06 2.09 4.92 4.99 1.75 0.36 0.61 6.47 6.18 0.13 7.27 7.12 8.96 
207 Cell_redox_homeostasis 9.09 8.41 1.3 0.9 0.34 9.15 2.86 5.23 6.66 3.44 7.36 0.37 4.16 8.93 9.49 9.71 8.44 7.77 
208 Mtb_iron_assimilation_by_chelation 2.85 2 5.9 2.85 3.25 1.18 6.68 0.06 7.29 0.08 5.41 2.25 5.36 9.8 7.16 4.7 3.84 7.47 
209 Tolerance_by_Mtb_to_nitric_oxide_produced_by_macrophages 3.28 9.36 2.04 7 5.23 3.64 4.11 0.4 2.5 5.04 4.83 7.66 1.41 6.7 8.45 5.06 0.88 2.56 
210 Tolerance_of_reactive_oxygen_produced_by_macrophages 1.07 2.66 8.57 6.78 1.99 6.74 1.55 1.91 9.9 8.32 8.58 9.96 9.17 2.9 9.67 7.07 2.34 2.46 
211 MPS_I_-_Hurler_syndrome 4.62 4.02 2.39 4.26 0.95 9.06 3.14 3.5 5.86 2.79 7.76 8.22 8.79 3.01 8.12 6.76 1.64 3.57 
212 Glycosaminoglycan_metabolism 5.7 0.38 3.12 1.44 5.61 1.8 2 6.43 8.56 0.61 6.47 9.39 8.08 2.9 4.52 9.79 6.18 4.19 
213 MPS_II_-_Hunter_syndrome 0.07 2.84 5.47 9.77 6.75 6.13 7.09 3.71 6.42 3.39 3.36 6.21 5.01 0.34 1.29 3.58 4.36 4.69 
214 Glycosaminoglycan_metabolism 8.97 5.04 7.98 2.02 1.05 2.38 0.32 0.65 5.16 4.81 5.79 0.23 7.27 7.71 3.13 3.82 1.4 8.16 
215 MPS_IIIA_-_Sanfilippo_syndrome_A 4.88 3.19 5.89 5.13 2.59 8.51 2.71 2.83 3.64 0.38 0.12 1.84 7.59 5.01 5.74 7.33 0.59 7.14 
216 Glycosaminoglycan_metabolism 6.49 5.95 5.22 5.41 4.16 3.77 0.52 5.65 8.91 1.38 3.1 9.67 0.55 7.87 2.24 2.22 4.39 4.41 
217 MPS_IIIB_-_Sanfilippo_syndrome_B 6.48 8.04 8.34 3.68 4.41 8.72 6.68 9.74 1.76 1.37 6.33 2.41 7.45 0.18 0.15 9.74 2.52 8.46 
218 Glycosaminoglycan_metabolism 9.56 5.24 9.66 5.81 1.44 2.4 3.34 2.96 8.76 0.27 2.05 0.18 2.91 6.41 4.65 1.91 4.71 2.59 
219 MPS_IIIC_-_Sanfilippo_syndrome_C 7 2.17 0.16 9.43 6.24 0.64 5.05 1.57 5.02 6.66 2.75 0.46 6.32 7.89 0.46 1.45 0.03 1.52 
220 Glycosaminoglycan_metabolism 9.01 3.26 1.53 1.84 6.49 3.5 4.05 3.46 0.25 9.7 3.36 7.95 7.93 3.23 5.32 8.56 8.96 2.1 
221 MPS_IIID_-_Sanfilippo_syndrome_D 7.76 6.92 5.5 2.9 7.95 8.52 3.5 3.15 0.36 3.61 7.6 9.84 7.29 5.34 0.5 0.82 8.06 9.36 
222 Glycosaminoglycan_metabolism 5.84 7.9 6.17 1.82 0.66 1.16 3.88 4.25 1.01 6.1 4.5 9.82 6.21 1.93 0.38 7.54 5.93 8.95 
223 MPS_IV_-_Morquio_syndrome_A 2.8 6.38 1.67 4.2 3.45 8.83 8.65 6.96 8.33 3.9 6.32 1.89 8.39 1.83 8.17 1.29 7.53 6.79 
224 Glycosaminoglycan_metabolism 6.13 6 2.52 1.45 8.61 1.51 3.18 9.63 8.13 9.07 5.54 4.76 6.17 2.11 4.29 2.64 9.66 5.31 
225 MPS_IV_-_Morquio_syndrome_B 9.42 6.98 5.22 1.55 5.87 2.57 1.58 4.64 7.62 5.1 9.46 0.65 3.8 1.65 9.46 5.4 2.97 0.42 
226 Glycosaminoglycan_metabolism 4.64 1.94 5.84 2.7 7.15 2 2.06 1.06 3.02 6.96 8.33 6.11 0.67 4.15 6.45 1.75 3.54 4.48 
227 MPS_IX_-_Natowicz_syndrome 9.19 0.79 9.88 3.21 5.92 5.97 1.97 5.09 6.52 0.71 6.58 1.22 8.59 9.97 9.99 8.99 1.2 3.2 
228 Glycosaminoglycan_metabolism 0.36 9.84 9.12 9.15 9.53 4.85 7.41 1.99 5.67 2.08 8.44 1.69 6.81 8.79 1.08 2.07 2.59 7.06 
229 MPS_VI_-_Maroteaux-Lamy_syndrome 8.49 0.75 0.26 1.24 6.07 7.74 8.84 1.28 5.46 1.45 4.81 7.14 1.49 1.68 3.38 3.07 7.93 5.04 
230 Glycosaminoglycan_metabolism 1.05 6.97 2.17 9.55 6.41 3.43 1.33 0.97 6.79 7.36 5.55 6.33 9.54 9.3 2.52 9.04 2.79 4.88 
231 MPS_VII_-_Sly_syndrome 8.7 7.54 0.72 1.76 7.01 4.15 0.86 2.31 4.8 9.75 2.6 5.14 9.38 6.57 9.9 4.38 9.81 4.47 
232 Glycosaminoglycan_metabolism 2.42 6.18 0.7 6.31 0.61 2.19 7.81 9.9 8.33 6.72 5.63 3.02 5.02 9.28 7.21 8.98 4.47 9.45 
233 Constitutive_PI3K/AKT_Signaling_in_Cancer 4.06 2.22 6.86 7.94 5.77 8.44 6.83 5.47 2.4 4.85 4.64 7.23 3.37 6.53 1.68 1.3 2.55 4.66 
234 PIP3_activates_AKT_signaling 8.58 5.12 6.56 3.18 2.01 1.42 2.76 5.06 7.02 6.84 0.23 2.7 3.12 2.5 4.75 3.11 8.5 1.95 
235 AKT_phosphorylates_targets_in_the_cytosol 4.88 5.2 1.01 1.83 7.98 8.92 8.48 7.84 2.45 1.87 4.62 3.43 2.58 8.59 8.71 0.16 1.72 8.32 
236 AKT_phosphorylates_targets_in_the_nucleus 4.41 6.83 0.88 0.15 9.76 5.16 2.98 0.39 2.83 2.05 9.97 1.46 7.69 6.75 9.17 3.87 0.2 0.3 
237 Negative_regulation_of_the_PI3K/AKT_network 4.42 7.35 3.89 3.73 4.8 0.73 7.77 7.86 3.81 7.85 5.22 3.45 9.79 0.85 7.13 9.35 7.35 8.83 
238 Signaling_by_EGFR 1.86 0.96 6.48 0.85 7.52 5.21 2.6 9.82 6.36 6.88 9.19 2.36 7.92 0.65 2.78 1.98 4.96 3.86 
239 EGFR_downregulation 0.11 9.76 5.47 1.21 2.02 2.45 7.02 5.64 5.39 5.72 2.57 3.7 9.2 6.54 3.59 0.8 2.98 3.91 
240 EGFR_interacts_with_phospholipase_C-gamma 9.6 5.1 5.91 8.67 0.33 6.75 1.36 4.99 7.75 7.9 3.76 2.56 2.72 7.03 0.86 9.67 5.15 5.42 
241 GAB1_signalosome 4.95 5.66 4.56 1.86 4.37 1.98 6.26 3.64 0.85 6.65 9.08 3.4 3.6 8.14 1.54 0.12 7.52 3.38 
242 GRB2_events_in_EGFR_signaling 7.06 5.25 6.3 2.49 1.79 0.79 3.13 8.38 5.17 4.21 1.45 9.91 9.69 8.39 3.08 5.65 7.62 4.73 
243 SHC1_events_in_EGFR_signaling 6.81 9.7 1.47 0.53 7.08 5.08 7.15 4.29 0.66 6.89 6.63 7.71 5.41 2.59 6.31 5.72 5.14 9.66 
244 Signaling_by_constitutively_active_EGFR 9.88 1.7 1.68 1.99 6.55 8.5 4.44 9.36 2.78 4.06 4.27 3.13 5.23 3.71 3.27 0.73 4.61 1.73 
245 Signaling_by_FGFR 9.34 1.02 5.87 4.17 4.63 1.53 1.26 5.95 4.95 2.13 4.06 3.7 8.59 3.05 4.96 8.33 2.23 8.52 
246 Downstream_signaling_of_activated_FGFR 8.79 5.19 1.26 7.93 5.85 4.65 3.71 4.44 1.07 2.71 0.87 0.99 5.19 5.96 7.15 5.52 4.92 7.53 
247 FGFR_ligand_binding_and_activation 2.57 5.9 9.59 3.57 8.86 8.09 8.65 6.86 0.19 2.59 3.13 4.35 0.28 1.01 4.68 8.69 4.56 7.31 
248 Negative_regulation_of_FGFR_signaling 5.78 0.74 3.95 8.43 2.74 3.16 0.24 5.11 5.85 7.22 9.71 0.57 0.95 1.74 0.38 1.83 6.58 2.95 
249 Signaling_by_FGFR_mutants 7.22 9.83 2.31 5.03 2.32 3 5.9 4.8 4.08 5.05 7.02 8.58 8.18 5.57 5.61 1.2 0.28 6.56 
250 Signaling_by_FGFR1_mutants 7.13 3.32 0.92 1.82 4.67 3.2 3.58 0.74 9.87 0.94 9.83 3.64 2.64 7.14 7.46 3.9 4.25 2.55 
251 Signaling_by_FGFR2_mutants 1.63 4.67 7.92 2.31 6.19 8.8 7.18 1.28 9.48 7.2 0.79 0.91 7.66 5.87 8.08 1.26 8.25 1.59 
252 Signaling_by_FGFR3_mutants 5.18 2.2 0.35 3.14 4.56 1.47 1.56 1.34 3.6 7.51 2.08 4.78 2.94 5.89 5.24 9.76 6.94 0.9 
253 Signaling_by_FGFR4_mutants 1.89 3.72 4.19 3.01 7.02 8.44 5.23 5.39 6.09 8.27 6.37 1.86 4.16 8.27 1.69 6.23 8.99 5.14 
254 Loss_of_Function_of_FBXW7_in_Cancer_and_NOTCH1_Signaling 4.15 6.44 4.36 6.69 3.78 6.76 8.58 9.52 8.46 1.37 9.15 9.88 6.16 2.88 3.82 0.74 3.33 9.15 
255 Signaling_by_NOTCH1 0.56 6.56 0.62 6.16 5.24 1.29 4.42 9.84 8.72 0.49 3.96 0.26 5.82 2.02 7.75 4.16 6.65 5.52 
256 Constitutive_Signaling_by_NOTCH1_HD_Domain_Mutants 7.59 7.55 4.17 8.44 5.54 4.43 8.24 9.99 4.22 1.21 7.33 4.13 9.17 7.93 8.73 0.6 1.75 0.74 
257 Signaling_by_NOTCH1 9.85 5.01 6.22 2.08 3.95 0.26 7.2 2.91 9.88 9.29 0.72 9.77 1.93 0.08 2.54 9.22 8.76 1.37 
258 Constitutive_Signaling_by_NOTCH1_HD+PEST_Domain_Mutants 8.16 8.03 0.9 9.12 2.89 2.53 9.79 2.99 3.22 9.02 6.02 3.69 6.54 7.29 7.34 4.38 2.74 2.26 
259 Signaling_by_NOTCH1 4.63 1.34 9.72 3.48 4.53 5.03 3.07 5.18 3.33 4.37 6.95 1.79 6.61 1.44 6.59 9.61 9.07 5.76 
260 Constitutive_Signaling_by_NOTCH1_PEST_Domain_Mutants 4.72 6.45 5.92 9.72 6.28 1.96 8.11 5.35 8.35 2.29 7.16 5.32 9.56 1.58 7.49 6.2 2.96 7.24 
261 Signaling_by_NOTCH1 1.2 5.26 4.06 9.83 4.45 5.74 6.91 5.88 5.38 6.64 1.04 8.77 3.53 9.42 0.04 6.23 8.52 6.25 
262 Constitutive_Signaling_by_NOTCH1_t(7;9)(NOTCH1:M1580_K2555)_Translocation_Mutant 6.11 8.42 7.24 1.49 1.35 5.9 1.46 3.28 8.55 8.04 7.41 9.09 3.81 7.79 1.02 0.83 6.92 5.32 
263 Signaling_by_NOTCH1 3.12 0.99 1.61 0.47 4.05 2.9 5.69 9.59 6.28 1.39 2.28 5.8 4.71 7.78 4.4 4.56 1.48 4.44 
264 SMAD2/3_MH2_Domain_Mutants_in_Cancer 7.45 1.25 2.1 6.98 6.16 1.8 8.15 0.64 2.26 4.72 4.79 5.93 4.82 0.05 5.36 3.33 1.05 5.87 
265 SMAD2/3_Phosphorylation_Motif_Mutants_in_Cancer 7.32 6.38 1.65 0.64 5.18 3.99 0.32 5.08 8.96 4.38 9.78 6.38 2.45 0.59 1.69 7.44 3.62 7.69 
266 SMAD4_MH2_Domain_Mutants_in_Cancer 0.49 5.18 4.67 5.58 1.43 0.61 6.03 1.9 1.86 2.26 6.03 0.04 3 7.68 4.23 3.47 3.96 5.66 
267 TGFBR1_KD_Mutants_in_Cancer 2.3 6.65 1.52 0 6.17 1.73 7.86 6.68 5.97 5.79 2.24 7.28 2.6 1.58 4.25 2.67 3.12 7.34 
268 TGFBR1_LBD_Mutants_in_Cancer 4.52 1.69 5.62 5.7 2.11 2.35 8.9 7.11 0.64 7.5 9.6 5.45 7.67 7.54 7.87 2.17 5.65 9.42 
269 TGFBR2_Kinase_Domain_Mutants_in_Cancer 0.88 2.73 8.15 5.79 8.37 3.88 2.69 8.86 8.3 8.09 6.4 3.21 3.19 8.81 6.26 0.2 4.11 4.54 
270 TGFBR2_MSI_Frameshift_Mutants_in_Cancer 8.93 9.84 3.57 9.99 3.36 8.29 9.5 4.57 4.05 3.65 3.34 0.49 0.94 5.92 2.7 1.19 0.17 3.13 
271 Extracellular_matrix_organization 2.53 1.17 9.77 1.6 5.05 1.53 5.91 5.62 5.76 8.54 0.72 1.34 0.16 0.5 1.93 9.45 8.52 7.47 
272 Assembly_of_collagen_fibrils_and_other_multimeric_structures 5.21 0.61 3.44 2.59 3.66 8.85 4.39 7.18 1.07 2.68 5.54 0.5 4.32 7.99 0.2 7.35 0.98 7.92 
273 Anchoring_fibril_formation 9.16 1.82 0.29 3.16 0.59 7.58 5.83 3.99 1.35 3.57 0.7 2.71 3.42 7.8 8.77 4.06 2.95 6.86 
274 Crosslinking_of_collagen_fibrils 4.03 2.52 7.18 0.35 2.85 4.28 6.78 9.6 1.01 9.49 3.64 3.85 6.26 1.57 7.37 8.41 9.38 5.93 
275 Collagen_biosynthesis_and_modifying_enzymes 0.96 0.33 4.93 7.68 8.73 9.35 1.09 0.96 3.81 5.61 7.39 5.84 9.23 4.99 7.31 8.49 4.42 6.06 
276 Degradation_of_the_extracellular_matrix 8.5 2.87 0.4 7.69 2.23 5.88 4.67 0.83 4 1.58 6.06 9.38 4.63 9.2 3.66 7.58 6.85 0.23 
277 Activation_of_Matrix_Metalloproteinases 2.29 2.98 3.56 4.7 1.75 1.96 6.83 9.88 6.19 9.46 1.9 2.75 4.69 5.19 3.41 1.97 5.45 6.54 
278 Collagen_degradation 1.58 0.58 7.94 7.91 3.41 8.37 9 2.32 6.75 7.36 4.38 9.58 5.8 0.85 0.13 2.84 2.53 7.27 
279 ECM_proteoglycans 2.85 4.26 6.7 5.36 2.81 3.7 5.49 3.48 0.77 1.99 8.35 5.73 1.37 3.51 7.31 6.17 2.33 5.71 
280 Elastic_fibre_formation 3.76 5.29 7.31 0.44 3.42 4.67 0 5.28 9.16 6.34 9.99 7.57 2.4 5.81 6.23 9.41 1.31 7.49 
281 Molecules_associated_with_elastic_fibres 5.39 2.99 5.75 0.99 3.63 2.45 7.26 2.01 4.24 0.83 3.89 7.35 0.24 8.95 7.45 1.7 4.83 7.17 
282 Fibronectin_matrix_formation 3.92 7.52 3.24 7.73 7.4 2.55 4.68 0.7 8.43 0.3 7.56 7.65 1.14 9.8 4.58 3.58 1.24 0.08 
283 Integrin_cell_surface_interactions 3.11 6.67 7.17 9.28 5.9 0.99 5.8 8.7 9.9 4.12 0 0.64 2.75 0.84 6.82 9.11 1.06 8.68 
284 Laminin_interactions 6.44 8.26 4.36 3.66 5.92 9.88 8.38 8.65 2.12 9.47 4.46 6.59 0.52 7.71 2.56 1.1 0.57 6.66 
285 Non-integrin_membrane-ECM_interactions 2.5 6.7 1.45 9.25 1.48 8.74 7.74 0.43 4.29 5.36 7.63 0.16 8.58 9.34 3.01 0.61 6.55 8.15 
286 Syndecan_interactions 1.74 5.82 1.39 0.82 0.24 9 5.75 3.37 3.76 3 4.24 8.64 5.37 6.95 5.25 6.29 8.51 7.88 
287 Binding_of_RNA_by_Insulin-like_Growth_Factor-2_mRNA_Binding_Proteins_(IGF2BPs/IMPs/VICKZs) 7.94 7.44 7.06 0.75 0.71 4.9 8.84 8.19 9.79 1.95 1.58 8.07 8.45 3.74 4.38 1.56 8.2 4.32 
288 Deadenylation_of_mRNA 7.66 2.22 9.57 5.53 2.71 9.55 3.89 6.25 0.29 1.28 0.39 5.27 3.94 4.9 6.48 0.54 5.17 1.92 
289 mRNA_Decay_by_3'_to_5'_Exoribonuclease 5.3 6.18 1.48 0.56 9.9 2.82 7.43 4.39 3.01 4.93 9.27 2.69 3.93 0.33 4.31 5.92 1.35 0.26 
290 mRNA_Decay_by_5'_to_3'_Exoribonuclease 8.42 0.8 6.16 9.61 7.17 9.07 9.2 2.45 1.66 1.21 7.82 7.82 0.06 4.91 8.7 6.15 1.95 1.43 
291 Generic_Transcription_Pathway 7.63 7.71 5.92 9.35 2.17 4.12 8.81 4.67 7.21 9.52 3.22 8.28 2.3 4.29 4.24 6.99 1.53 1.51 
292 Notch-HLH_transcription_pathway 7.94 0.41 2.64 3.83 7.2 1.44 3.88 0.77 2.13 2.02 6.58 2.02 7.53 2.49 0.58 5.75 0.9 6.38 
293 Nuclear_Receptor_transcription_pathway 8.23 3.95 7.01 2.05 5.58 1.23 2.87 0.41 0.26 5.3 2.09 8.2 9.35 0.43 5.31 6.74 9.02 1 
294 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 0.71 7.75 0.09 4.3 7.94 6.22 7.36 8.9 0.15 4.52 7.54 7.82 9.33 1.88 8.55 9.6 9.45 9.23 
295 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 5.42 6.59 4.87 9.43 3.47 5.84 3.89 6.68 7.88 1.98 2.8 4.79 7.07 8.13 8.6 4.47 8.46 2.71 
296 YAP1-_and_WWTR1_(TAZ)-stimulated_gene_expression 1.82 3.44 1.42 4.48 6.36 3.53 5.49 8.88 8.23 8.25 2.51 1.9 6.39 0.46 3.62 7.75 6.24 0.78 
297 snRNP_Assembly 9.85 1.03 7.81 3.77 3.5 0.48 1.7 4.94 2.16 7.29 7.26 0.38 9.15 6.72 3.52 8.62 4.21 6.67 
298 Nonsense_Mediated_Decay_Enhanced_by_the_Exon_Junction_Complex 1.28 4.65 3.29 2.59 0.82 3.89 9.86 4.19 7.35 1.4 6.66 6.32 4.85 8.22 0.03 1.61 8.96 1.41 
299 Nonsense_Mediated_Decay_Independent_of_the_Exon_Junction_Complex 1.5 4.32 8.72 3.61 7.7 3.13 1.65 6.45 1.2 8.1 1.28 9.7 6.21 5.96 0.04 5.14 7.99 2.1 
300 Processing_of_Capped_Intron-Containing_Pre-mRNA 2.69 5.52 2.35 4.71 3.44 8.3 3.82 2.61 3.95 1.51 6.66 0.83 7.1 7.58 3.72 2.95 9.06 0.14 
301 Transport_of_Mature_mRNA_derived_from_an_Intron-Containing_Transcript 4.52 2.84 9.05 8.12 0.21 3.41 5.75 2.9 5.25 6.11 1.67 9.82 7.83 3.87 7.93 0.5 6.79 2.68 
302 Transport_of_Mature_mRNAs_Derived_from_Intronless_Transcripts 2.74 8.84 6.29 3.35 4.6 1.05 5.11 9.92 8.24 5.5 0.16 0.6 8.01 7.59 3.09 9.23 0.67 3 
303 mRNA_3'-end_processing 2.25 2.56 1.4 0.48 6.55 8.07 4.49 4.91 7.6 3.82 8.36 2.19 2.7 6.79 7.25 5.19 8.09 7.01 
304 mRNA_Splicing_-_Major_Pathway 6.31 3.24 8.07 7.25 3.01 2.83 9.69 4.88 1.64 9.63 1.24 5.34 7.7 8.51 9.97 7.24 5.11 0.67 
305 mRNA_Splicing_-_Minor_Pathway 2.65 8.4 3.79 9.55 0.28 6.61 4.32 2.27 1.6 1.39 6.66 2.37 0.48 8.48 4.04 0.48 5.65 2.21 
306 Processing_of_Intronless_Pre-mRNAs 1.33 1.75 2.41 5.14 1.47 3.62 9.54 6.76 4.54 6.58 7.21 7.84 6.88 4.66 1.16 8.56 1.8 4.29 
307 SLBP_Dependent_Processing_of_Replication-Dependent_Histone_Pre-mRNAs 5.37 6.29 3.89 8.43 0.04 1.01 3.84 9.2 9.87 1.36 0.52 5.82 5.28 3.66 4.72 1.93 9.58 1.79 
308 SLBP_independent_Processing_of_Histone_Pre-mRNAs 9.83 9.87 8.23 3.97 0.96 5.94 9.01 6.53 5.2 5.03 4.72 0.2 9.32 9.53 8.24 0.33 0.57 6.65 
309 RNA_Polymerase_I_Chain_Elongation 7.32 2.8 1.67 9.66 6.9 8.68 9.26 8.28 4.79 1.44 7.03 4.49 8.33 0.03 9.1 2.4 0.27 6.1 
310 RNA_Polymerase_I_Promoter_Clearance 5.27 2.82 3.93 1.87 8.63 9.61 5.65 5.99 2.51 3.18 0.81 5.58 1.03 3.58 2.38 1.78 4.64 4.57 
311 RNA_Polymerase_I_Transcription_Termination 5.72 2.21 9.22 7.56 8.67 2.6 2.98 3.43 2.34 8.41 0.19 3.52 0.62 4.11 8.11 7.93 4.05 8.81 
312 RNA_Polymerase_III_Abortive_And_Retractive_Initiation 6.51 7.6 8.98 2.71 8.42 6.94 0.84 5.35 5 9.55 1.55 3.23 6.5 6.88 9.39 0.1 0.17 9.32 
313 RNA_Polymerase_III_Chain_Elongation 9.48 2.1 4.95 4.19 6.48 1.89 1.71 8.51 6.95 2.23 6.37 6.49 8 4.07 1.34 8.84 1.77 8.12 
314 RNA_Polymerase_III_Transcription_Initiation 6.41 3.04 4.96 1.62 5.37 5.51 8.51 7.32 5.65 9.38 4.45 2.28 1.94 5.26 1.78 7.45 9.28 2.05 
315 RNA_Polymerase_III_Transcription_Termination 1.49 2.57 3.12 4.01 1.99 7.27 6.92 3.53 7.95 5.42 5.67 1.49 3.76 2.55 7.42 7.48 1.03 8.15 
316 Mitochondrial_transcription_initiation 0.47 0.73 9.65 7.49 1.37 1.69 3.31 9.7 0.53 7.68 0.52 1.78 1.56 9.81 6.95 5.86 9.29 7.31 
317 Mitochondrial_transcription_termination 2.78 8.59 7.52 0.89 9.58 2.38 0.54 9.72 2.08 6.56 1.71 1.47 5.03 5.11 1.74 8.19 1.07 2.05 
318 POLRMT_chain_elongation 5.99 7.88 2.61 0.45 4.35 4.92 7.32 0.76 6.67 4.03 3.67 8.99 0.54 1.67 2.12 1.14 1.29 7.93 
319 RNA_Pol_II_CTD_phosphorylation_and_interaction_with_CE 9.77 8.54 0.12 8.31 8.89 3.26 6.47 2.99 4.89 6.74 8.36 6.12 3.87 9.57 5.03 4.91 4.82 8.29 
320 RNA_Polymerase_II_Pre-transcription_Events 0.27 3.61 9.52 4.96 6.46 1.83 5.97 5.54 0.32 1.02 9.45 4.76 2.24 0.81 1.95 6.23 6.32 3.43 
321 RNA_Polymerase_II_Transcription_Elongation 6.02 3.69 2.82 9.89 4.37 5.99 0.35 1.79 6.54 6.52 3.99 3.5 1.32 9.45 2.93 8.71 6.49 5.9 
322 Formation_of_RNA_Pol_II_elongation_complex_ 2.04 1.77 7.05 3.19 7.5 5.28 2.28 7.22 6.68 7.85 7.74 1.84 6.51 8.84 0.37 9.15 1.89 6.81 
323 Formation_of_the_Early_Elongation_Complex 0.74 7.59 8.5 5.46 2.6 4.27 2.33 4.21 1.61 8.18 5.46 3.5 2.63 4.61 8.46 4.58 5.94 3.71 
324 RNA_Polymerase_II_Transcription_Initiation_And_Promoter_Clearance 9.45 5.02 2.46 4.2 2.54 9.53 7.6 5.86 4.19 7.35 6.16 1.13 3.35 5.92 0.18 2.65 3.7 3.36 
325 RNA_Polymerase_II_Promoter_Escape 5.25 7.46 6.44 5.12 4.82 8.15 1.05 7.26 2.01 7.73 3.06 0.8 5.93 9.9 5.91 2.14 2.23 8.57 
326 RNA_Polymerase_II_Transcription_Initiation 7 8.49 3.22 2.85 7.62 7.02 2.68 3.74 1.52 8.48 2.35 6.38 7.62 2.37 2.72 7.92 2 3.43 
327 RNA_Polymerase_II_Transcription_Pre-Initiation_And_Promoter_Opening 5.19 4.81 3.7 9.91 1.45 9.84 7.14 0.85 0.79 3.99 2.82 3.86 1.19 6.5 1.93 1.85 5.16 6.08 
328 Cleavage_of_Growing_Transcript_in_the_Termination_Region_ 8.88 4.99 4.25 8.96 7.69 3.31 8.14 5.02 9.7 5.37 5.98 0.77 3.98 8.51 8.88 4.63 0.53 5.05 
329 Destabilization_of_mRNA_by_AUF1_(hnRNP_D0) 7.41 2.67 6.62 6.55 0.81 6.95 6.18 8.72 0.94 6.7 5.38 1.21 4.45 5.23 2.43 3.65 7.18 1.35 
330 Destabilization_of_mRNA_by_Butyrate_Response_Factor_1_(BRF1) 9.37 5.99 4.99 1.92 5.54 1.24 0.31 0.66 4.29 7.22 5.56 8.18 8.75 6.92 9.1 3.61 1.32 7.28 
331 Destabilization_of_mRNA_by_KSRP 5.22 1.49 2.77 8.26 3.48 2.78 7.77 3.38 1.75 9.44 1.25 1.39 8.21 3.4 6.4 9.66 0.81 1.48 
332 Destabilization_of_mRNA_by_Tristetraprolin_(TTP) 5.47 9.51 9.07 5.51 1.1 5.57 0.77 0.09 4.03 5.76 5.4 0.23 5.74 4.54 3.69 9.06 4.85 9.99 
333 Stabilization_of_mRNA_by_HuR 0.48 9.3 5.73 6.58 8.16 8.84 3.73 0.31 6.04 7.83 7.91 4.22 0.1 9.87 3.64 5.68 9.94 5.79 
334 MicroRNA_(miRNA)_Biogenesis 0.23 7.09 6.57 1.41 2.85 4.77 0.23 2.72 8.28 4.35 5.49 5.17 0.09 7.43 8.67 2.65 5.9 8.91 
335 Post-transcriptional_Silencing_By_Small_RNAs 3.69 5.38 6.04 7.76 2.12 9.91 6.93 4.09 6.2 1.97 6.62 1.28 1 7.59 8.42 4.4 0.89 4.94 
336 Small_Interfering_RNA_(siRNA)_Biogenesis 6.42 6.2 4.86 1.46 9.64 4.86 2.71 9.43 4.66 4.74 4.45 7.88 3.49 8.27 9.54 5.04 2.81 2.46 
337 Eukaryotic_Translation_Elongation 7.57 2.85 1.14 3.5 8.32 6.73 9.43 3.12 2.32 8.83 2.39 7.68 5.89 6.83 2.09 9.87 7.95 2.45 
338 Peptide_chain_elongation 9.12 6.39 9.35 2.48 4.79 2.07 2.3 9.54 6.01 9.4 0.43 7.18 4.12 3.77 6.23 4.72 9.83 8.85 
339 Cap-dependent_Translation_Initiation 6.86 7.2 2.57 7.02 4.39 6.06 2.76 9.24 6.52 0.37 0.35 6.99 3.16 8.9 3.67 6.06 2.21 9.75 
340 Cap-independent_Translation_Initiation 5.2 7.92 5.65 5.47 2.58 6.84 5.31 8.29 7.82 7.05 1.62 6.89 9.23 8.7 3.42 2.82 1.96 1.8 
341 L13a-mediated_translational_silencing_of_Ceruloplasmin_expression 9.69 0.72 7.15 0.51 7.36 7.55 1.74 4.77 1.54 7.29 8.82 8.51 7.69 2.37 3.01 6.76 6.04 0.73 
342 Eukaryotic_Translation_Termination 1.61 1.97 5.95 1.25 4.85 0.62 2.29 5.6 7.18 0.73 0.79 7.09 6.62 2.24 5.74 6.82 4.75 8.15 
343 SRP-dependent_cotranslational_protein_targeting_to_membrane 3.43 4.46 5.32 5.68 6.84 3.61 4.72 2.86 2.66 0.89 1.51 6.04 2.33 5.94 0.76 5.98 6.04 5.33 
344 mRNA_Capping 4.68 1.84 4.17 9.64 6.16 0.14 0.66 9.96 8.73 1.48 5.1 3.96 9.41 7.91 8.66 5.89 0.2 3.55 
345 mRNA_Editing:_A_to_I_Conversion 9.48 2.51 0.81 2.71 8.25 2.28 1.73 4.54 3.09 4.3 2.38 9.91 7.39 8.53 4.48 5.67 0.54 8.77 
346 C6_deamination_of_adenosine 4.9 1.97 0.56 7.73 5.89 8.62 5.36 4.29 8.88 5.39 5.85 8.41 1.67 5.2 5.6 0.47 5.81 3.82 
347 Formation_of_editosomes_by_ADAR_proteins 6.06 9.89 7.84 4.03 9.6 4.62 7.32 3.92 8.43 0.63 9.23 6.11 7.4 6.92 4.43 2.7 9.19 8.49 
348 mRNA_Editing:_C_to_U_Conversion 1.12 5.76 8.45 4.86 5.56 6.03 3.64 4.98 5.08 8.78 3.38 7.23 0.05 4.11 1.93 1.17 9.43 2.27 
349 Formation_of_the_Editosome 5.14 2.9 4.16 8.01 3.39 5.44 2.36 0.12 2.74 4.33 7.4 4.01 1.83 1.35 8.28 6.33 4.37 1.34 
350 Cytosolic_tRNA_aminoacylation 5.77 6.71 7.22 2.63 6.59 5.4 3.68 2.82 8.48 3.66 2.9 2.27 4.58 0.71 1.06 3.05 0.01 4.34 
351 Mitochondrial_tRNA_aminoacylation 7.7 5.55 5.07 2.99 7.3 0.75 8.03 4.39 1.94 4.88 6.64 6.73 0.48 3.58 2.8 4.87 7.64 7.13 
352 Cell_surface_interactions_at_the_vascular_wall 0.13 4.52 1.7 9.78 7.66 7.04 4.16 6.49 3.77 8.37 5.37 4.59 4.32 9.55 1.05 5.26 9.37 3.66 
353 Basigin_interactions 9.14 1.55 2.9 4.46 1.82 6.35 0.93 9.36 8.46 2.38 4.56 4.03 7.14 5.99 0.41 9.25 0.74 3.24 
354 PECAM1_interactions 3.44 8.63 7.49 2.76 5.97 3.34 6.47 4.26 0.43 2.44 5.92 7.61 2.69 1.75 1.39 6.96 4.81 4.71 
355 Tie2_Signaling 2.68 7.13 6.66 0.3 8.06 1.09 2.9 0.59 6.84 5.46 7.59 1.03 6.06 3.91 0.93 1.96 5.83 9.5 
356 Dissolution_of_Fibrin_Clot 5.57 4.35 0.12 6.67 8.69 1.65 9.03 9.73 7.91 5.16 1.49 5.15 1.18 2.43 3.88 4.97 7.11 0.91 
357 Factors_involved_in_megakaryocyte_development_and_platelet_production 8.74 5.63 1.25 0.07 3.7 1.21 7.27 6.58 3.36 2.75 2.21 5.76 7.99 9.19 2.41 6.11 7.12 2.09 
358 Kinesins 6.35 2.63 8.3 5.14 3.36 7.83 0.32 9.88 3.39 7.05 6.7 9.4 8.68 3.91 7.28 9.85 5.37 3.2 
359 Common_Pathway 1.24 9.97 3.54 7.03 4.94 5.62 8.65 5.54 7 3.02 7.14 6.29 7.94 0.26 4.63 5.28 7.48 6.79 
360 Extrinsic_Pathway 3.51 1.99 0.03 4.42 2.8 0.16 2.9 0.98 8.58 7.3 5.53 5.51 2.62 4.44 6.49 4.85 0.55 5.72 
361 Intrinsic_Pathway 8.89 8.58 5.52 1.29 6.4 8.6 0.46 6.27 0.44 4.22 9.36 4.73 1.54 3.33 7.56 0.51 3.91 5.34 
362 Platelet_Adhesion_to_exposed_collagen 9.31 3.22 0.79 2.02 1.76 5.8 2.69 3.88 4.29 8.85 0.02 6.1 3.27 2.74 7.6 0.99 0.42 0.55 
363 Effects_of_PIP2_hydrolysis 3.93 0.65 9.28 5.72 2.84 7.26 7.98 5.23 2.01 5.87 0.88 9.97 6.52 1.75 7.5 6.78 4.55 8.93 
364 Arachidonate_production_from_DAG 6.3 4.06 5.31 4.89 1.65 5.21 1.27 9.64 4.4 1.13 3.89 7.1 4.88 7.63 3.2 1.88 8.21 2.64 
365 GP1b-IX-V_activation_signalling 0.03 7.54 7.22 3.16 8.54 5.86 4.25 5.24 8.18 3.02 1.2 6.59 4.88 6.82 3.41 5.74 5 5.66 
366 GPVI-mediated_activation_cascade 2.22 7.54 5.52 8.5 5.16 2.26 4.86 6.02 7.37 9.01 9.01 7.49 9.67 1.02 2.65 8.81 8.43 7.1 
367 Platelet_Aggregation_(Plug_Formation) 5.08 4.89 8.58 1.84 1.21 1.06 5.86 9.87 3.71 4.9 9.72 5.18 0.73 3.53 2.81 6.62 9.96 2.13 
368 Adrenaline_signalling_through_Alpha-2_adrenergic_receptor 4.51 1.15 8.04 7.85 3.33 5.64 5.04 8.37 4.53 7.84 3.33 9.72 9.21 5.44 3.7 2.57 0.88 1.29 
369 Integrin_alphaIIb_beta3_signaling 2.97 3.4 9.23 9.01 3.43 8.76 7.31 5 6.48 6.13 2.53 3.11 6.93 3.32 4.51 8.14 5.99 2.16 
370 Response_to_elevated_platelet_cytosolic_Ca2+ 2.12 8.34 8.49 2.52 9.12 1.41 2.09 4.5 1.8 5.69 5.35 5.62 3.65 1.11 8.17 0.11 7.63 3.21 
371 Disinhibition_of_SNARE_formation 6.06 3.45 4.43 8.5 5.93 6.64 4.42 4.44 8.33 7.36 5.02 0.25 5.59 9.53 0.07 0.06 5.43 1.29 
372 Platelet_degranulation_ 7.51 0.7 3.95 2.28 5.41 0.59 2.2 7.15 9.44 1.78 6.58 3.84 7.38 3.83 6.38 7.37 6.35 0.3 
373 ADP_signalling_through_P2Y_purinoceptor_1 7.82 3.15 0.8 0.21 4.25 7.52 2.04 4.46 4.12 0.04 0.45 8.25 2.44 5.49 9.94 5.29 1.32 0.09 
374 ADP_signalling_through_P2Y_purinoceptor_12 3.16 4.29 7.61 1.33 9.3 7.46 5.32 2.83 8.73 4.39 8.8 8.35 9.87 5.7 5.89 6.29 5.6 5.21 
375 Thromboxane_signalling_through_TP_receptor 5.97 1.89 1.63 4.44 6.21 7.05 8.15 7.13 3.34 9.99 1.37 6.15 1.64 0.58 5.11 3.83 8.46 9.43 
376 Thrombin_signalling_through_proteinase_activated_receptors_(PARs) 7.37 8.31 6.55 2.51 3.51 2.9 0.52 2.95 4.2 0.61 3.6 7.67 2.73 0.34 1.33 1.91 3.01 3.78 
377 Platelet_homeostasis 3.87 8.79 5 6.15 7.09 0.72 0.61 9.52 9.7 8.23 0.64 5.37 0.5 6.1 7.91 9.78 4.43 1.61 
378 Nitric_oxide_stimulates_guanylate_cyclase 8.21 7.18 2.98 1.83 9.33 6.95 7.09 0.72 4.68 7.03 8.64 8.45 8.49 0.5 6.46 1.42 4.44 1.55 
379 cGMP_effects 4.59 7.68 8.85 3.01 7.68 8.47 6.06 1.87 5.35 3.09 3.64 6.33 3.51 1.4 6.25 7.24 3.46 2 
380 Elevation_of_cytosolic_Ca2+_levels 8.38 0.31 2.21 2.17 6.24 5.84 8.15 3.44 3.52 0.19 0.7 3.67 9.19 1.74 4.87 0.3 3.45 7.16 
381 Reduction_of_cytosolic_Ca++_levels 0.44 6.99 1.62 6.85 1.15 3.21 5.02 5.41 8.04 5.73 7.33 4.52 8.11 2.29 2.24 1.59 9.83 6.65 
382 Platelet_sensitization_by_LDL 8.45 9.5 8.26 5.91 8.97 2.13 3.71 9.86 6.62 1.9 5.84 9.06 4.18 6.22 7.19 6.66 2.18 9.91 
383 Prostacyclin_signalling_through_prostacyclin_receptor 9.59 5.66 1.03 2.79 4.98 8.67 3.45 1.03 4.3 0.2 0.25 5.34 8.21 8.33 2.35 2.87 3.93 8.27 
384 Antigen_Presentation:_Folding,_assembly_and_peptide_loading_of_class_I_MHC 3.48 6.24 6.92 9.18 8 2.44 4.31 0.86 6.95 5.08 7.53 5.97 1.92 1.21 8.19 9.07 0.71 0.22 
385 Antigen_processing-Cross_presentation 5.61 9.91 0.52 2.51 5.23 9.65 9.56 9.8 0.61 4.65 5.23 3 8.28 2.35 9.53 6.12 6.82 8.76 
386 Antigen_processing:_Ubiquitination_&amp;_Proteasome_degradation 1.57 2.89 2.92 1.99 7.76 4.61 8.42 1.31 6.6 7 6.38 0.8 6.2 5.45 9.29 1.68 1.41 7.62 
387 Costimulation_by_the_CD28_family 8.34 6.33 2.7 0.82 0 5.6 3.64 1.41 0.99 3.36 6.65 8.33 0.29 8.27 2.54 0.28 3.19 9.84 
388 CD28_co-stimulation 1.1 1.68 4.17 3.97 1.25 4.06 4.1 4.63 0.48 6.9 9.69 3.44 5.99 6.43 1.55 4.64 5.37 5.58 
389 CTLA4_inhibitory_signaling 2.06 9.11 4.14 9.47 2.93 1.29 5.87 0.8 0.85 7.64 2.34 0.76 0.15 1.18 3.84 8.47 6.48 5.47 
390 PD-1_signaling 5.55 8.32 7.81 8.37 4.27 8.96 8.59 3.24 7.99 6.53 7.01 8.41 4.04 7.29 2.15 5.65 6.5 5.32 
391 Immunoregulatory_interactions_between_a_Lymphoid_and_a_non-Lymphoid_cell 0.83 7.19 2.96 4.39 7.78 2.38 2.41 8.03 0.06 6.2 6.7 8.49 2.05 5.24 0.78 7.87 9.84 6.29 
392 MHC_class_II_antigen_presentation 1.39 8.98 9.73 6.38 8.15 0.02 0.41 4.85 0.63 2.11 0.66 8.27 5.83 9.3 5.65 0.82 9.82 8.31 
393 Rap1_signalling 2.35 2.9 8.12 2.56 8.02 4.48 5.13 1.26 4.97 0.64 2.15 2.93 9.07 4.37 4.18 3.38 4.24 0.7 
394 Antigen_Activates_B_Cell_Receptor_Leading_to_Generation_of_Second_Messengers 1.83 3.45 3.28 0.59 4.83 2.21 5.37 5.6 3.49 9.23 8.83 9.05 8.47 3.13 7.86 9.84 4.09 2.34 
395 Downstream_Signaling_Events_Of_B_Cell_Receptor_(BCR) 5 9.7 8.39 1.57 6.68 8.56 4.85 5.92 0.22 7.33 7.35 3.83 8.27 4.99 0.61 0.9 1.35 1 
396 Downstream_TCR_signaling 4.79 5.73 9.06 8.85 2.45 2.09 8.36 9.81 9.39 6.99 1.01 4.07 1.95 2.19 0.84 4.27 3.55 5.6 
397 Generation_of_second_messenger_molecules 1.33 4.52 8 6.03 6.88 3.98 8.75 5.69 3.04 9.9 8.43 5.57 8.57 3.19 8.75 1.49 1.9 9.46 
398 Phosphorylation_of_CD3_and_TCR_zeta_chains 7.98 4.67 3.46 5.09 0.8 4.79 9.81 2.07 7.19 1.38 4.25 6.99 7.7 0.14 5.1 3.55 2.32 7.65 
399 Translocation_of_ZAP-70_to_Immunological_synapse 6.18 7.2 2.37 2.64 7.09 7.03 5.44 0.5 5.41 3.01 3.44 4.27 1.41 9.1 6.96 8.24 6.83 0.98 
400 Growth_hormone_receptor_signaling 6.4 1.31 5.7 7.54 5.35 9.03 4.45 6.09 4.14 0.32 9.17 6.3 3.18 4.32 4.13 0.9 4.61 1.32 
401 Antiviral_mechanism_by_IFN-stimulated_genes 6.35 5.17 6.45 3.21 8.18 8.05 3.33 7.21 2.46 9.7 7.88 3.94 0.08 2.27 8.35 5.77 6.75 2.05 
402 Interferon_alpha/beta_signaling 0.5 6.42 2.54 3.18 3.9 7.24 9.79 3.65 7.54 1.71 0.22 8.44 2.67 5.09 4.1 8.72 5.52 8.74 
403 Interferon_gamma_signaling 9.77 6.97 3.7 9.41 2.67 3.41 6.17 9.68 0.65 3.21 6.55 7.27 9.14 2.83 1.37 9.32 5.49 1.62 
404 Prolactin_receptor_signaling 8.82 0.35 5.92 1.35 9.3 5.34 5.2 7.28 6.88 7.24 6.34 2.33 6.03 1.25 1.22 7.82 7.6 0.65 
405 Interleukin-1_processing 9.3 2.64 4.23 3.22 4.86 9.08 6.38 6.31 5.65 4.26 3.62 5.63 3.78 4.19 8.51 7.41 3.15 0.76 
406 Interleukin-1_signaling 1.68 5.21 0.98 5.87 5.31 2.39 3.39 5.52 8.3 4.74 7.81 7.42 1.18 9 7 2.34 6.06 6.8 
407 Interleukin-2_signaling 7.9 9.23 3.99 1.68 4.85 6.34 4.55 5.44 4.44 7.08 8 2.19 5.18 3.49 9.47 5.8 2.99 4.48 
408 Interleukin-3,_5_and_GM-CSF_signaling 6.84 1.19 1.32 3.4 8.88 7.7 2.97 4.33 1.4 6.22 5.45 5.4 7.27 2.5 0.82 2.47 0.99 0.5 
409 Interleukin-6_signaling 7.3 3.96 3.04 3.31 8.05 0.51 0.82 1.39 7.67 3.7 6.76 1.43 5.56 9.73 1.16 9.57 2.86 3.66 
410 Interleukin-7_signaling 4.33 8.43 6.72 8.14 2.98 4.71 9.37 2.61 8.09 9.2 5.86 3.27 4.41 0.53 3.23 5.28 4.91 5.97 
411 Advanced_glycosylation_endproduct_receptor_signaling 0.99 8.81 8.23 3.1 6.71 5.78 9.93 0.9 6.53 2.34 2.66 2.47 1.13 4.22 7.45 9.74 4.88 0.22 
412 Activation_of_C3_and_C5 3.77 5.19 0.83 9.66 8.05 7.94 6.46 3.24 4.41 0.89 0.98 7.97 0.66 4.6 3.91 5.73 4.65 6.05 
413 Initial_triggering_of_complement 8.06 4.38 3.96 5.18 2.62 9.44 7.26 0.15 8.93 3.23 5.69 1.24 2.18 3.69 4.72 6.7 1.61 0.15 
414 Regulation_of_Complement_cascade 8.25 7.29 4.94 0.37 1.95 8.3 5.49 3 7.01 7.94 5.61 3.03 9.92 9.59 9.48 2.06 6.13 9.69 
415 Terminal_pathway_of_complement 6.39 4.55 5.61 6.51 4.1 6.77 5.76 5.39 2.22 5.02 2.24 1.96 8.49 0.23 9.12 7.23 7.14 3.71 
416 Cytosolic_sensors_of_pathogen-associated_DNA_ 8.08 6.2 9.81 1.56 2.98 1.49 1.45 4.97 4.66 4.43 4.48 3.92 5.31 2.04 6.95 2.94 4.5 1.49 
417 DEx/H-box_helicases_activate_type_I_IFN_and_inflammatory_cytokines_production_ 9.51 5.81 5.98 8.45 6.75 2.45 5.84 4.33 1 3.99 5.67 2.97 0.09 9.41 2.31 0.99 8.98 9.74 
418 LRR_FLII-interacting_protein_1_(LRRFIP1)_activates_type_I_IFN_production 3.87 7.59 2.62 1.45 7.29 6.59 3.24 7.67 9.66 9.68 9.27 0.94 8.49 7.96 5.42 9.23 3.96 4.17 
419 Regulation_of_innate_immune_responses_to_cytosolic_DNA 4.11 3.68 0.48 7.81 8.33 5.74 6.88 8.84 6.68 4.68 4.25 2.04 8.44 9.21 9.6 9.11 9.22 9.51 
420 STING_mediated_induction_of_host_immune_responses 7 3.42 6.3 4.25 4.3 4.51 7.2 1.98 5.27 4.8 4.05 3.82 4.25 6.14 6.12 2.04 1.92 0.09 
421 ZBP1(DAI)_mediated_induction_of_type_I_IFNs 9.38 0.05 8.66 6.66 1.71 0.8 9.64 5.41 0.26 8.86 9.35 7.33 2.51 7.24 0.76 2.92 1.59 9.51 
422 DAP12_interactions 5.96 5.27 8.07 2.87 0.27 9.2 8.05 1.27 8.37 7.1 5.83 8.03 1.37 4.83 3.41 6.35 6.21 2.77 
423 DAP12_signaling 2.78 0.8 4.34 7.11 2.29 8.53 9.3 4.08 7.3 4.48 6.32 1.41 6.7 4.16 0.63 8.18 8.15 9.84 
424 Defensins 5.09 9.74 7.41 8.85 4.08 9.6 7.48 0.85 7.78 1.01 1.71 5.05 4.01 7.96 1.72 1.09 7.31 9.87 
425 Alpha-defensins 6.7 5.25 1.84 8.02 7.27 7.46 6.88 3.52 1.97 9.89 8.95 3.98 9.51 0.18 3.73 2.57 7.19 8.73 
426 Beta_defensins 9.15 0.68 8.83 6.1 8.59 1.25 5.96 8.39 5.83 5.18 1.59 5.18 0.61 1.67 6.03 1.66 9.38 2.26 
427 Fc_epsilon_receptor_(FCERI)_signaling 1.93 8.82 8.76 7.6 7.38 5.57 7.8 5.54 0.78 0.61 8.68 5.21 6.73 0.98 7.57 2.58 4.19 3.45 
428 FCERI_mediated_Ca+2_mobilization 9.01 1.89 2.16 9.56 2.39 7.25 1.25 5.32 1.78 4.21 7.16 7.62 2.87 2.08 7.38 5.3 6.05 4.9 
429 FCERI_mediated_MAPK_activation 7.99 5.69 4.07 2.53 4.13 6.56 7.85 5.83 3.48 5.93 7.99 3.62 6.06 6.66 7.35 2.19 6.71 6.64 
430 FCERI_mediated_NF-kB_activation 5.99 6.08 8.47 0.14 9.14 2.12 5.07 6.22 3.27 4.92 3.2 9.99 8.98 2.71 3.86 1.92 5.52 2.17 
431 Role_of_LAT2/NTAL/LAB_on_calcium_mobilization 5.24 9.88 6.93 0.89 6.88 4.14 2.96 2.68 3.46 3.58 7.37 7.45 5.68 7.97 8.25 6.47 2.21 2.37 
432 FCGR_activation 6.43 9.07 6.7 5.49 5.46 0.39 2.52 0.12 0.2 4.31 4.76 6.91 5.25 8.45 0.99 4.16 7.74 0.56 
433 Regulation_of_actin_dynamics_for_phagocytic_cup_formation 6.77 8.72 7.36 0.08 8.96 3.09 1.32 3.58 7.88 7.44 0.04 9.3 7.27 6.49 5.19 8.68 1.74 9.01 
434 Role_of_phospholipids_in_phagocytosis 3.61 2.55 9.66 9.27 3.13 3.62 7.8 8.18 7.28 2.89 7.13 9.41 2.23 7.96 7.31 8.4 2.31 1.35 
435 Inflammasomes 6.32 5.82 3.82 2.5 6.44 8.52 4.57 6.01 2.68 0.33 7.73 8.94 4.19 5.26 8.83 5.33 7.82 5.12 
436 NOD1/2_Signaling_Pathway 4.36 8.25 0.52 8.12 0.24 8.45 2.96 2.02 7.73 7.58 3.05 6.77 3.58 1.11 2.81 6.5 5.7 9.8 
437 RIG-I/MDA5_mediated_induction_of_IFN-alpha/beta_pathways 2.53 3.27 3.59 7.16 7.97 1.18 7.18 7.77 3.81 0.65 1.52 7.13 3.71 1.76 5.86 8.74 2.42 2.41 
438 NF-kB_activation_through_FADD/RIP-1_pathway_mediated_by_caspase-8_and_-10 5.09 0.97 6.62 2.48 2.42 1.48 5.92 5.36 6.2 6.17 2.29 6.24 7.81 6.38 7.06 5.61 3.5 5.47 
439 Negative_regulators_of_RIG-I/MDA5_signaling 4.58 0.39 9.05 9.81 4.68 4.14 6.01 3.16 2.94 9.67 0.45 1.67 0.39 1.63 6 7.74 4.44 9.99 
440 TRAF3-dependent_IRF_activation_pathway 5.25 0.8 2.17 8.24 4.49 0.86 6.74 2.57 1.85 2.15 0.58 2.75 2.3 5.82 2.11 0.37 2.7 9.62 
441 TRAF6_mediated_IRF7_activation 5.91 0.28 6.61 6.12 6.96 8.76 1 9.58 1.71 1.91 2.48 1.22 6.98 5.5 7.58 7.28 1.45 7.42 
442 TRAF6_mediated_NF-kB_activation 4.38 8.6 4.73 4.77 4.93 6.95 4.04 2.13 0.32 5.25 9.04 2.95 2.21 8.48 1.68 0.84 6.2 0.91 
443 Toll_Like_Receptor_10_(TLR10)_Cascade 8.38 2.32 1.19 3.37 5.66 4.32 2.62 5.34 8.31 6.37 6.94 1.02 0.11 5.14 6.42 2.69 8.34 5.47 
444 Toll_Like_Receptor_2_(TLR2)_Cascade 7.3 5.03 0.41 6.06 4.11 2.97 7.37 1.02 0.15 0.63 1.17 3.17 9.99 1.51 6.43 5.38 7.82 4.54 
445 Toll_Like_Receptor_3_(TLR3)_Cascade 8.87 0.12 9.12 9.22 8.37 1.74 0.91 8.08 7.18 8.51 2.77 6.23 8.52 2.11 2.3 5.89 0.01 0.15 
446 Toll_Like_Receptor_4_(TLR4)_Cascade 4.87 7.28 0.29 9.21 9.87 8.63 3.27 4.88 4.77 7.14 8.46 4.75 0.82 8.31 8.39 6.19 1.69 6.47 
447 Toll_Like_Receptor_5_(TLR5)_Cascade 3.62 4.06 5.6 7.52 9.05 5.61 7.2 3.8 4.41 5.5 3.39 7.38 1.24 9.51 0.05 9.4 9.89 6.25 
448 Toll_Like_Receptor_7/8_(TLR7/8)_Cascade 4.82 1.04 6.53 3.8 4.3 6.11 6.06 0.58 7.87 0.51 3.27 4.3 6.22 7.47 4.07 2.96 7.14 2.05 
449 Toll_Like_Receptor_9_(TLR9)_Cascade 9.49 4.06 8.1 5.15 9.35 5.88 7.85 3.34 9.13 0.23 4.76 9.63 1.77 7.26 9.22 7.07 5.29 2.66 
450 Trafficking_and_processing_of_endosomal_TLR 6.27 4.25 9 2.48 9.75 5.3 7.57 4.13 0.96 0.16 0.92 9.05 2.51 8.07 7.3 7.03 5.47 4.52 
451 Ion_transport_by_P-type_ATPases 2.55 6.84 5.35 5.94 1.46 7.9 0.36 0.47 5.05 6.07 2.78 9.58 2.81 7.46 2.99 4.22 5.92 4.13 
452 Ligand-gated_ion_channel_transport 8.08 0.52 0.41 7.91 5.76 9.24 6.57 7.08 9.46 9.58 6.32 2.63 6.27 8.31 4.41 6.79 6.37 1 
453 Stimuli-sensing_channels 6.37 9.09 7.5 6.54 5.4 5.97 8.27 9.79 0.46 1.39 8.38 0.81 8.98 7.92 2.21 6.97 2.93 8.13 
454 TRP_channels 2.06 9.29 6.93 3.51 8.16 1.94 2.38 9.88 6.75 9.71 4.21 9.8 6.83 9.66 0.99 7.56 6.09 4.66 
455 Iron_uptake_and_transport 6.68 3.59 3.95 1.84 9.28 0.94 3.32 8.66 4.58 2.66 4.63 9.13 4.31 2.86 3.6 1.66 4.49 1.22 
456 Transferrin_endocytosis_and_recycling 2.6 8.83 1.73 9.66 7.06 9.46 4.74 7.08 3.46 6.7 8.2 2.66 0.69 3.78 9.27 0.38 8.84 3.59 
457 Meiotic_Recombination 7.67 9.78 0.3 9.21 1.91 8.9 0.93 4.44 8.09 5.07 0.4 5.23 2.22 6.47 1.5 2.25 2.62 3.82 
458 Meiotic_Synapsis 9.69 7.4 0.01 8.55 3.05 5.26 2.87 8.63 9.79 9.66 4.78 3.45 2.09 8.86 9.06 7.2 6.43 6.06 
459 COPII_(Coat_Protein_2)_Mediated_Vesicle_Transport 4.42 3.61 9.83 9.38 8.17 7.95 7.09 7.99 4.97 7.95 7.42 2.52 3.67 1.4 1.03 8.55 7.55 0.52 
460 Endosomal_Sorting_Complex_Required_For_Transport_(ESCRT) 8.56 4.45 2.62 9.97 6.5 7.89 0.65 7.05 1.27 4.47 4.27 5.03 2.76 2.65 6.75 2.46 7.81 8.03 
461 Gap_junction_assembly 8.15 2.63 7.6 3.16 5.81 7.77 5.33 8.28 7.84 7.03 4.44 4.76 3.74 1.08 5.35 4.02 9.35 4.41 
462 Gap_junction_degradation 7.86 3.93 3.2 4.14 9.44 8.57 9.12 3.04 4.96 6.91 7.06 8.26 2.16 5.83 1.33 5.11 9.76 3.05 
463 c-src_mediated_regulation_of_Cx43_function_and_closure_of_gap_junctions 6.65 2.06 0.98 4.18 6.19 7.91 0.24 4.67 8.5 9.34 4.95 9.75 0.75 6.94 7.87 4.65 7.62 6.39 
464 COPI_Mediated_Transport 5.08 4.6 6.82 5.86 4.95 1.22 9.35 9.48 5.59 1.19 1.38 4.66 3.73 7.5 0.6 3.41 0.93 5.48 
465 Translocation_of_GLUT4_to_the_Plasma_Membrane 4.06 9.18 2.68 2.12 0.65 6.19 1.27 5.71 1.14 0.42 7.5 7.49 7.28 2.61 9.77 7.36 0.25 6.06 
466 Clathrin_derived_vesicle_budding 4.65 7.83 9.53 4.05 6.26 1.53 1.65 5.45 1.27 7.8 4.31 3.8 1.83 3.47 7.23 0.81 0.63 5.44 
467 Golgi_Associated_Vesicle_Biogenesis 2.49 4.26 4.4 6.62 2.91 0.29 6.98 5.98 9.78 7.27 8.25 4.6 2.69 1.8 2.23 3.47 4.02 1.65 
468 Lysosome_Vesicle_Biogenesis 0.82 4.23 0.55 1.87 8.07 8.09 3.3 0.91 1.11 5.44 3.44 0.75 6.89 2.05 7.56 7.24 2.17 8.56 
469 Abacavir_metabolism 0.48 7.6 2.8 6.5 0.88 9.66 0.67 7.78 1.73 8.43 0.48 9.32 5.76 7.63 5.98 3.35 6.16 8.57 
470 Abacavir_transmembrane_transport 9.8 1.66 6.61 4.91 9.33 9.29 0.85 2.5 8.91 6.93 2.88 2.88 7.86 0.57 5.59 8.27 9.1 2.26 
471 Amine_Oxidase_reactions 2.9 2.41 2.64 6.66 0.74 6.92 1.48 4.12 8.92 2.16 1.58 8.27 1.59 0.42 8.39 1.63 4.48 3.96 
472 COX_reactions 2.5 8.96 1.96 6.78 1.08 4.86 4.37 3.03 3.23 0.01 0.41 8.45 6.3 0.94 4 9.93 0.54 3.94 
473 Cytochrome_P450_-_arranged_by_substrate_type 2.04 5.42 1.24 5.69 5.81 6.43 8.27 2.01 5.02 0.23 0.38 5.61 8.34 1.01 2.05 9 7.32 4.56 
474 Ethanol_oxidation 6.36 2.1 9.17 5.93 4.77 7.92 9.1 9.9 4.08 7.75 8.89 0.69 3.91 1.39 8.35 3.06 0.39 1.73 
475 FMO_oxidizes_nucleophiles 0.69 5.73 4.44 8.27 1.95 3.36 3.95 1.02 3.16 0.07 0.22 7.64 9.48 0.08 7.72 0.08 7.9 1.57 
476 Acetylation 0.47 8.31 0.86 6.96 9.06 4.67 8.14 1.9 4.67 6.05 5.11 3.83 6.53 4.39 8.26 9.42 9.29 4.4 
477 Amino_Acid_conjugation 5.27 5.4 8.86 4.43 0.47 1.53 4.7 6.1 6.05 7.09 9.71 4.71 2.42 3.32 8.42 4.2 2.25 8.81 
478 Cytosolic_sulfonation_of_small_molecules 7.18 5.88 3.51 2.52 8.57 8.65 9.75 4.3 3.51 1.02 7.5 7.88 7.47 0.72 2.9 2.19 7.17 9.93 
479 Glucuronidation 7.6 7.56 0.92 6.93 1.99 0.32 8.49 8.73 3.43 9.33 4.44 8.56 4.86 0.25 3.64 0 3.32 0.22 
480 Glutathione_conjugation 1.45 0.53 7.09 8.95 7.47 5.08 3.19 6.34 1.36 1.23 2.44 9.82 4.9 3.75 5.46 4.39 0.48 5.65 
481 Methylation 9.62 1.68 7.19 4.69 9.82 1.13 2.87 3.4 7.66 6.33 2.9 3.21 6.36 6.77 9.95 9.06 4.63 2.49 
482 Cytosolic_Iron-sulfur_Cluster_Assembly 6.2 0.56 1.33 5.66 9.55 0.57 4.21 4.61 5.01 6.6 9.16 1.63 7.38 3.78 3.97 3.34 5.88 4.99 
483 IP3_and_IP4_transport_between_cytosol_and_nucleus 4.7 1.99 1.15 3.66 4.65 2.32 8.74 0.78 3.37 8 8.48 9.93 9.58 7.57 6.71 0.58 6.82 6.17 
484 IP6_and_IP7_transport_between_cytosol_and_nucleus 0.65 7.06 8.2 3.12 2.04 6.02 1.97 1.36 6.43 1.16 9.78 3.06 6.24 1.15 4.73 1.6 6.78 3.36 
485 IPs_transport_between_ER_lumen_and_cytosol 7.19 6.08 1.88 7.82 3.21 6.16 2.23 7.12 1.86 1.7 7.66 0.42 2.68 4.58 8.76 6.62 9.46 9.81 
486 IPs_transport_between_ER_lumen_and_nucleus 7.53 7.04 8.38 5.97 3.22 5.95 9.11 1.15 3.87 2.21 2.37 6.04 5.78 6.4 8.64 5.66 6.94 9.31 
487 IPs_transport_between_cytosol_and_ER_lumen 3.65 7.56 1.84 0.65 1.06 2.65 0 9.84 3.89 4.02 4.11 9.57 8.07 4.07 2.27 6.86 9.43 0.35 
488 IPs_transport_between_nucleus_and_ER_lumen 1.12 2.31 6.77 0.49 2.06 4.01 4.35 5.46 9.59 5.76 8.11 7.08 0.9 1.64 5.97 7.25 1.07 8.83 
489 IPs_transport_between_nucleus_and_cytosol 4.15 3.77 0.94 3.8 3.55 1.68 9.34 3.83 6.11 3.16 4.03 9.48 2 0.41 6.6 2.73 7.23 1.89 
490 Synthesis_of_IP2,_IP,_and_Ins_in_the_cytosol 0.32 2.23 7.87 1.78 7.39 5.03 1.37 8.9 4.63 1.77 8.01 2.03 9.13 8.3 3.14 0.99 9.98 1.03 
491 Synthesis_of_IP3_and_IP4_in_the_cytosol 5.98 1.17 7.9 8.68 3.74 6.92 4.48 1.06 1.84 8.48 9.26 5.67 2.35 4.07 9.77 4.71 2.05 0.3 
492 Synthesis_of_IPs_in_the_ER_lumen 9.2 8.45 4.58 7.59 5.98 0.42 8.08 2.77 0.66 6.33 5.05 2.78 2.9 3.11 4.4 0.17 4.02 8.69 
493 Synthesis_of_IPs_in_the_nucleus 5.43 8.48 2.26 7.6 0.57 8.63 6.46 4.9 6.68 5.26 3.86 6.1 6.49 3.39 8.13 1.62 3.58 2.2 
494 Synthesis_of_pyrophosphates_in_the_cytosol 4.37 8.15 8.75 3.72 8.76 3.9 4.29 5.55 0.1 0.77 7.84 2.75 4.35 9.76 8.4 0.48 5.29 1.9 
495 Integration_of_energy_metabolism 6.33 3.67 6.37 3.23 4.45 0.03 9.94 0.86 7.34 4.52 2.75 5.41 9.25 2.01 8.55 3.04 3.78 3.91 
496 AMPK_inhibits_chREBP_transcriptional_activation_activity 4.33 2.6 7.25 8.26 1.25 6.9 1.89 7.07 9.35 8.47 7.19 8.83 6.14 4.28 3.13 0.48 0.26 6.4 
497 ChREBP_activates_metabolic_gene_expression 7.27 7.09 4.66 5.65 9.65 8.87 4.73 9.76 7.5 6.53 9.53 2.29 5.09 3.43 6 7.71 6.11 7.78 
498 Glucagon_signaling_in_metabolic_regulation 7.63 1.88 5.68 0.02 9.6 9.68 3.73 6.66 3.6 4.18 3.85 0.01 4.85 6.19 9.46 6.13 6.96 3.89 
499 PKA_activation_in_glucagon_signalling 8.94 8.04 1.19 2.19 6.27 0.88 4.61 2.95 6.52 6.43 0.9 7.47 9.65 1.24 2.84 5.25 9.53 7.92 
500 Insulin_effects_increased_synthesis_of_Xylulose-5-Phosphate 1.1 1.97 4.97 8.05 1.12 8.56 2.56 7.3 2.31 0.34 5.01 1.71 4.38 6.56 2.65 2.36 4.69 9.24 
501 PKA-mediated_phosphorylation_of_key_metabolic_factors 3.86 9.72 8.02 6.52 4.71 5.8 9.25 3.8 7.08 5.99 1.37 8.67 7.28 8.12 8.31 6.84 2.93 6.58 
502 PP2A-mediated_dephosphorylation_of_key_metabolic_factors 1.4 8.87 6.88 0.77 5.59 9.59 5.3 6.3 6.76 1.4 6.38 3.91 8.6 2.76 0.6 0.94 3.28 4.37 
503 Regulation_of_Insulin_Secretion 0.53 3.85 1.39 9.27 7.28 1.96 3.04 3.68 3.96 9.75 8.13 1.83 3.91 1.48 6.46 3.33 5.59 1.27 
504 Inhibition_of_Insulin_Secretion_by_Adrenaline/Noradrenaline 7.73 6.01 2.07 4.95 5.52 8.35 4.6 6.52 1.71 5.95 7.2 2.73 0.88 4.67 3.75 1.63 6.12 4.74 
505 Regulation_of_Insulin_Secretion_by_Acetylcholine 6.49 9.3 6.28 3.95 5.83 8.33 1.27 0.45 0 9.85 9.9 7.72 6.38 7.71 7.93 6.96 3.73 0.61 
506 Regulation_of_Insulin_Secretion_by_Free_Fatty_Acids 9.08 7.16 3 7.39 8.27 4.97 8.72 5.78 2.89 7.72 6.93 6.58 9.99 4.78 3.66 6.1 6.42 9.95 
507 Regulation_of_Insulin_Secretion_by_Glucagon-like_Peptide-1 5.67 5.77 8.54 4.54 9.92 6.02 2.26 9.94 0.45 3.74 5.48 8.83 4.44 8.81 9.75 6.7 8.47 3.18 
508 Catecholamine_biosynthesis 0.98 9.67 5.94 5.72 0.67 1.38 9.91 7.89 2.68 4.6 5.12 3 8.12 4.34 6.77 5.75 6.17 8.9 
509 Serotonin_and_melatonin_biosynthesis 0.47 9.9 3.4 7.05 4.84 6.43 8.14 5.64 5 2.98 6.82 8.75 3.7 9.23 4.98 0.51 8.64 6.77 
510 Thyroxine_biosynthesis 0.23 2.6 7.64 1.17 4.67 7.7 9.19 8.55 2.97 7.27 6.65 3 8.88 9.69 8.13 3.98 2.44 3.59 
511 Amino_acid_synthesis_and_interconversion_(transamination) 8.5 4.56 6.05 8.1 4.28 9.13 4.2 8.82 0.32 2.66 3.87 6.31 4.64 5.01 3.8 5.85 7.02 0.73 
512 Serine_biosynthesis 6.53 5.94 2.27 3.88 9.54 8.02 8.66 1.68 1.47 3.71 1.37 6.33 3.12 8.62 3.2 1.01 5.55 6.85 
513 Branched-chain_amino_acid_catabolism 0.86 1.17 7.41 7.63 6.48 9.32 6.67 9.53 1.46 2.13 5.94 7.07 0.75 2.66 7.29 4.82 5.08 8.02 
514 Carnitine_synthesis 4.94 5.71 5.06 6.98 9.55 1.44 4.44 2.24 7.78 1.01 0.31 7.4 3.03 9.25 5.28 5.59 5.89 2.7 
515 Creatine_metabolism 8.49 9.12 7.88 5.63 4 5.41 5.14 5.05 0.44 7.11 3.75 2.84 1.06 2.58 3.97 3.94 1.59 1.23 
516 Glyoxylate_metabolism 4.15 0.96 8.22 2.58 8.73 8.76 3.96 7.06 1.05 7.95 3.87 1.43 1.41 1.39 3.88 8.39 2.77 3.72 
517 Histidine_catabolism 7.52 3.96 6.82 7.71 5.85 5.29 5.84 4.47 8.68 9.39 9.99 6.15 5.22 2.42 7.12 7.07 6.31 8.48 
518 Lysine_catabolism 4.54 9.71 4.9 2.09 4.58 9.25 7.27 8.68 9.64 5.55 9.05 2.89 2.07 3.55 3.96 3.23 3.41 0.49 
519 Metabolism_of_polyamines 6.34 7.84 4.26 7.86 6.11 8.22 8.69 2.58 4.11 8 8.04 9.85 5.03 3.62 6.08 9.22 0.4 4.01 
520 Agmatine_biosynthesis 9.37 0.12 3.47 9.19 0.91 1.48 1.6 4.05 4.25 0.9 3.3 2.81 8.88 7.95 6.38 4.11 9.84 6.47 
521 Interconversion_of_polyamines 6.55 3.71 5.02 1 7.61 7.17 9.65 5.39 5.01 4.23 8.15 4.09 0.53 0.02 4.31 5.85 0.89 8.07 
522 Methionine_salvage_pathway 9.44 5.35 2.64 8.12 6.27 9.84 7.55 0.95 8.85 4.49 2.38 7.55 4.15 7.41 0.56 6.09 0.19 8.27 
523 Phenylalanine_and_tyrosine_catabolism 8.62 2.48 7.79 3.43 7.31 7.51 2.51 0.96 4.98 9.79 1.38 3.06 9.91 3.01 4.13 7.81 4.51 4.69 
524 Proline_catabolism 2.86 2.77 1.42 5.41 3.55 4.35 6.58 7.99 9.61 3.8 3.74 5.84 5.38 1.13 6.56 5.93 3.73 6.71 
525 Regulation_of_ornithine_decarboxylase_(ODC) 0.31 2.52 2.53 3.99 6.23 1 0.36 6 3.66 1.92 5.46 1.64 3.03 2.81 9.52 8.09 9.33 7.22 
526 Sulfur_amino_acid_metabolism 4.82 0.89 2.42 7.04 8.69 9.4 1.36 0.65 8.05 6.12 6.72 8.26 9.55 6.25 2.1 1.56 3.88 6.46 
527 Cysteine_formation_from_homocysteine 8.68 6.14 4.13 7.96 7.26 0.65 0.85 1.81 8.29 2.56 1.88 7.16 8.38 9.98 9.15 4.99 2.22 7.33 
528 Degradation_of_cysteine_and_homocysteine 4.68 6.29 1.43 9.16 0.28 6.61 7.9 4.24 7.41 4.47 3.47 7.19 0.81 3.82 4.89 1.05 4.03 7.49 
529 Methionine_salvage_pathway 3.9 9.91 1.68 5.45 3.17 3.45 1.67 2.7 5.38 9.86 9.25 2.02 1.82 0.95 6.28 2.55 3.96 7.2 
530 Tryptophan_catabolism 3.41 8.13 5.46 2.78 0.27 9.03 7.24 6.86 9.86 3.65 3.97 8.68 6.16 2.18 3.44 6.04 1.63 8.79 
531 Urea_cycle 0.15 3.72 8.43 8.07 2.17 3.26 0.17 1.8 0.57 8.69 5.36 4.58 7 6.22 2.74 8.35 8.28 9.14 
532 5-Phosphoribose_1-diphosphate_biosynthesis 9.58 8.99 4.27 5.92 9.21 3.4 0.89 5.36 0.43 4.93 1.46 0.21 8.28 0.94 2.18 8.02 9.43 4.96 
533 Digestion_of_dietary_carbohydrate 0.27 2.17 0.85 4.03 6.72 7.76 6.85 7.11 0.66 2.54 3.54 9.42 6.43 5 1.5 8.66 2.09 5.34 
534 Fructose_catabolism 3.98 5 1.82 9.16 6.85 6.93 2.53 9.24 6.21 2.48 1.11 2.75 0.43 1.03 6.23 1.16 7.23 2.85 
535 Galactose_catabolism 2.03 7.12 1.17 0.84 4.69 8.07 9.66 1.04 5.84 3.81 0.65 3.72 6.3 5.6 0.87 7.15 9.45 9.93 
536 Gluconeogenesis 6.21 8.42 4.65 2.49 1.58 1.48 7.66 0.7 4.96 6.93 7.03 9.67 6.83 4.6 7.14 4.44 4.15 7.14 
537 Glycogen_breakdown_(glycogenolysis) 9.24 9.61 7.25 2 6.67 7.72 2.49 8.17 2.18 8.13 3.58 3.79 4.69 0.86 4.75 7.24 2.46 1.87 
538 Glycogen_synthesis 5.17 2.82 0.71 3.4 5.01 2.35 6.25 2.73 9.47 0.06 3.88 9.17 2.43 3.38 1.84 9.57 6.39 0.94 
539 Glycolysis 2.6 5.31 2.53 6.65 2.37 3.9 9.71 0.27 4.97 4.6 1.84 4.91 0.99 4.91 9.4 8.9 1.06 4.13 
540 Chondroitin_sulfate/dermatan_sulfate_metabolism 4.98 2.23 7.9 5.62 1.25 2.21 9.95 9.46 5.78 7.54 2.01 5.23 4.13 0.98 5.46 6.87 4.78 2.12 
541 Heparan_sulfate/heparin_(HS-GAG)_metabolism 9.18 4.82 6.84 7.14 3.56 0.19 4.58 1.27 7.3 4.01 8.26 8.92 7.66 0.24 5.44 7.55 1.02 6.19 
542 Hyaluronan_metabolism 2.88 3.84 4.21 7.56 6.35 6.68 1.99 4.1 2.13 5.08 1.35 9.15 5.62 3.54 3.02 2.34 1.15 4.1 
543 Keratan_sulfate/keratin_metabolism 2.63 0.74 0.92 9.84 8.81 9.48 0.4 4.24 3.01 7.81 7.02 2.93 8.96 0.2 9.01 4.55 9.79 9.78 
544 Transport_and_synthesis_of_PAPS 0.14 0.07 6.73 6.99 0.66 0.68 9.85 5.24 7.64 5.87 6.29 1.18 1.11 6.02 3.22 0.42 1.87 9.42 
545 Hexose_transport 4.97 1.88 3.72 8.38 6.13 9.33 3.48 8.31 5.5 5.96 6.59 6.09 0.29 1.17 3.24 9.06 3.21 1.89 
546 Glucose_transport 2.25 7.38 4.09 4.69 8.81 2.39 1.07 6.29 9.13 1.54 6.85 0.5 3.93 2.49 7.94 2.02 0.08 9.34 
547 Pentose_phosphate_pathway_(hexose_monophosphate_shunt) 7.27 6.72 7.07 4.96 9.42 9.72 6.5 0.08 8.19 6.21 4.83 7.27 5.73 7.05 6.44 1.58 3.75 6.44 
548 Arachidonic_acid_metabolism 4.91 9.34 7.52 9.83 2.24 9.86 4.63 3.31 9.01 7.53 9.55 3.26 5.96 7.28 2.51 0.61 0.1 4.8 
549 Synthesis_of_(16-20)-hydroxyeicosatetraenoic_acids_(HETE) 1.53 0.27 8.91 4.91 2.52 8.09 7.26 2.69 1.34 8.63 1.3 7.21 6.67 0.49 0.17 6.65 0.11 7.25 
550 Synthesis_of_12-eicosatetraenoic_acid_derivatives 9.08 1.62 0.5 5.24 2.15 5.99 6.7 4.55 7.11 2.21 6.8 0.37 5.69 8.07 5.35 6.66 0.92 8.82 
551 Synthesis_of_15-eicosatetraenoic_acid_derivatives 0.49 1.06 5.94 3.24 4.44 0.7 2.59 0.33 9.56 0.93 8.91 0.22 6.05 8.87 7.57 4.98 0.28 4.46 
552 Synthesis_of_5-eicosatetraenoic_acids 9.2 2.97 1.29 9.74 0.89 8.59 8.64 4.79 4.72 8.69 4.08 8.17 6.63 2.22 8.18 1.83 1.77 8.2 
553 Synthesis_of_Hepoxilins_(HX)_and_Trioxilins_(TrX) 6.78 4.54 4.64 8.47 8.03 8.24 6.26 6.63 9.91 2.92 4.92 9.54 0.3 2.49 3.75 4.25 4.93 2.91 
554 Synthesis_of_Leukotrienes_(LT)_and_Eoxins_(EX) 1.62 7.71 5.37 1.4 8.88 3.54 3.63 9.67 6.36 4.61 5.19 5.13 1.06 2.85 7.5 7.04 6.4 9.72 
555 Synthesis_of_Lipoxins_(LX) 3.53 4.65 0.45 3.06 1.26 5.57 2.96 5.46 8.8 7.96 4.84 6.93 1.94 6.05 0.59 8.38 5.56 1.79 
556 Synthesis_of_Prostaglandins_(PG)_and_Thromboxanes_(TX) 2.96 7.82 7.29 5.56 0.42 8.4 5.36 2.79 0.94 5.43 3.06 5.32 3.79 5.9 6.35 8.81 5.16 5.77 
557 Synthesis_of_epoxy_(EET)_and_dihydroxyeicosatrienoic_acids_(DHET) 1.73 0.17 9.78 2.03 6.81 8.23 2.32 5.75 6.32 1.4 5.31 3.86 3.61 3.97 9.53 8.09 0.35 1.21 
558 Recycling_of_bile_acids_and_salts 5.37 7.43 5.33 3.06 3.96 7.86 0.35 6.73 4.34 4.07 8.04 8.07 9.52 6.26 3.31 5.69 8.08 5.31 
559 Synthesis_of_bile_acids_and_bile_salts 7.31 7.07 1.46 6.78 9.42 1.45 3.3 9.61 0.47 7.7 4.26 3.87 6.14 6.86 7.05 5.39 3.65 5.21 
560 Cholesterol_biosynthesis 0.44 5.02 0.57 1.2 7.16 0.38 1.31 3.88 3.44 4.39 5.35 9.01 9.88 8.91 1.4 2.32 8.34 4.41 
561 Fatty_acid,_triacylglycerol,_and_ketone_body_metabolism 7.65 3.56 8.33 7.86 5.28 6.09 3.63 3 0.05 5.3 1.31 8.1 7.05 7.97 9.18 3.16 9.96 8.89 
562 Import_of_palmitoyl-CoA_into_the_mitochondrial_matrix 8.33 6.18 7.03 7.11 4.6 1.35 6.9 4.2 6.46 8.6 4.45 5.9 1.45 3.7 0.13 8.36 1.1 0.68 
563 Ketone_body_metabolism 9.06 7.07 9.56 7.01 4.79 4.94 2.54 1.26 1.13 6.46 4.43 9.14 5.15 7.87 0.9 1.97 5.69 4.33 
564 Mitochondrial_Fatty_Acid_Beta-Oxidation 1.48 1.3 2.04 8.62 8.36 4.6 2.3 6.11 3.09 5.68 0.3 1.38 9.32 0.01 1.02 1.91 4.06 8.04 
565 Regulation_of_Lipid_Metabolism_by_Peroxisome_proliferator-activated_receptor_alpha_(PPARalpha) 5.79 6.73 2.1 9.65 0.37 2.19 8.18 0.49 7.12 6.46 7.18 0.38 2.89 6.9 0.33 6.72 9.89 4.53 
566 Triglyceride_Biosynthesis 5.44 1.65 5.03 7.7 5.69 7.39 9.68 8.37 2.24 4.56 3.88 3.66 2.96 6.58 5.86 4.2 8.32 0.25 
567 Digestion_of_dietary_lipid 2.76 3.09 0.91 8.42 7.21 7.87 1.09 3.89 3.83 7.21 5.87 3.77 9.24 4.38 9.14 6.62 8.55 1.77 
568 Hormone-sensitive_lipase_(HSL)-mediated_triacylglycerol_hydrolysis 7.06 4.19 6.43 3.02 6.12 5.21 6.92 4.07 2.18 1.44 7.48 4.15 8.79 5.21 4.48 6.51 0.87 4.75 
569 Lipoprotein_metabolism 8.79 8.58 5.83 9.46 1.87 4.07 2.88 9.25 3.95 8.6 3.2 3.9 7.67 6.56 3.54 6.72 4.46 1.56 
570 Trafficking_of_dietary_sterols 8.79 5 2.93 2.03 3.09 5.08 5.85 2.89 2.71 5.8 1.27 5.5 9.41 5.02 7.93 9.94 1.57 6.21 
571 Androgen_biosynthesis 1.56 8.03 4.66 8.28 2.88 0.12 7.64 9.35 0.72 8.33 9.2 0.02 2.02 0.48 5.06 9.13 3.61 2.1 
572 Estrogen_biosynthesis 7.84 0.64 5.85 7.71 3.92 0.12 9.38 7.89 1.01 7.69 8.09 5.88 7.74 7.74 8.67 8.38 4.56 1.98 
573 Glucocorticoid_biosynthesis 2.28 7.53 7.09 8.64 7.2 8.09 1.25 9.05 0.07 4.18 9 7.28 8.78 8.27 4.03 9.55 7.39 5.4 
574 Mineralocorticoid_biosynthesis 0.19 6.8 3.93 2.57 7.92 7.26 2.37 3.59 5.39 9.81 5.52 3.83 4.42 9.79 8.07 8.89 7.8 2.65 
575 Pregnenolone_biosynthesis 7.83 7.94 4.63 0.13 9.25 9.61 3.97 3.61 4.85 0.95 0.07 1.56 5.44 6.05 6.24 0.56 8.92 2.5 
576 Vitamin_D_(calciferol)_metabolism 0.85 4.2 4.31 5.16 7.86 0.34 4.91 6.47 6.17 9.47 8.89 0.92 2.96 8.34 2.23 1.72 0.48 0.23 
577 Peroxisomal_lipid_metabolism 2.91 1.66 2.61 9.81 9.41 4.61 4.43 2.45 6.96 2.29 3.73 9 6.5 7.03 8.28 7.31 9.41 5.23 
578 Alpha-oxidation_of_phytanate 9.42 7.1 3.88 0.13 7.88 4.79 0.73 2.2 7.37 5.55 8.14 4.31 0 9.97 4.11 0.08 9.17 2.02 
579 Beta-oxidation_of_pristanoyl-CoA 1.28 2.45 6.39 6.29 6.99 9.33 5.96 8.84 0.76 7.29 4.13 6.03 5.91 4.03 9.64 6.95 2.98 0.42 
580 Beta-oxidation_of_very_long_chain_fatty_acids 5.4 2.45 4.64 2.22 8.15 8.6 9.89 7.7 7.49 2.97 0.91 0.24 2.52 3.21 7.4 7.13 8.35 3.16 
581 NADPH_regeneration 4.89 7.96 5.48 6.64 8.58 5.43 0.81 5.8 4.07 4.36 6.7 6.62 8.63 1.66 4.63 0.55 5.98 7.72 
582 Plasmalogen_biosynthesis 3.31 8.61 3 4.93 0.41 6.49 6.44 2.37 0.82 6.19 6.67 4.63 8.16 6.1 0.42 6.19 4.13 8.8 
583 Glycerophospholipid_biosynthesis 1.08 3.06 8.47 8.06 4.52 6.96 5.71 5 3.77 4.56 5.35 0.11 5.87 1.02 0.84 4.23 8.83 3.13 
584 PI_Metabolism 9.32 0.79 5.82 0 6.16 3.58 8.43 8.07 9.09 4.15 7.65 5.3 0.72 3.17 0.58 2.81 2.72 2.57 
585 Regulation_of_Cholesterol_Biosynthesis_by_SREBP_(SREBF) 7.57 7.4 1.07 3.11 2.57 3.93 9.71 5.87 7.43 4.68 8.02 0.88 2.98 5.82 2.52 9.77 4.57 3.85 
586 Activation_of_Gene_Expression_by_SREBP_(SREBF) 2.93 7.16 6.28 3.94 2.91 7.71 1.07 9.12 3.32 5.09 2.92 6.77 2.27 2.05 0.91 6.91 1.83 8.81 
587 Glycosphingolipid_metabolism 2.7 6.32 6.04 3.18 1.14 6.13 3.74 8.49 1.52 8.27 9.15 3.37 7.88 2.55 1.77 8.51 9.68 5.84 
588 Sphingolipid_de_novo_biosynthesis 3.77 2.46 0.2 4.06 1.62 7.45 7.45 3.41 4.32 0.58 4.94 1.54 0.94 5.13 5.38 3.98 5.05 3.39 
589 Ubiquinol_biosynthesis 2.51 0.73 8.47 2.19 4.79 2.17 1.45 4.46 6 4.98 7.97 1.41 9.25 8.4 1.99 0.09 6.56 4.43 
590 Linoleic_acid_(LA)_metabolism 9.92 6.9 4.74 4.58 0.79 2.88 9.73 3 0.64 6.54 0.67 9.3 8.26 8.52 6.75 1.77 7.34 6.2 
591 alpha-linolenic_acid_(ALA)_metabolism 8.93 0.23 9.4 9.59 1.18 0.28 3.76 9.45 4.53 0.35 5.65 8.26 6.7 7.12 8.8 5.26 9.59 4.6 
592 NOSIP_mediated_eNOS_trafficking 9.77 2 2.74 7.83 7.81 5.06 9.87 5.01 5.68 1.92 7.14 7.41 7.05 6.94 1.3 2.3 6.14 5.98 
593 NOSTRIN_mediated_eNOS_trafficking 1.39 5.46 7.62 7.67 8.54 4.48 8.28 5.3 2.24 6.92 1.14 8.87 9.6 1.14 2.45 4.64 6.43 8.19 
594 Tetrahydrobiopterin_(BH4)_synthesis,_recycling,_salvage_and_regulation 3.26 9.48 5.44 8.63 9.7 4.55 3.6 9.08 8.98 0.63 5.84 9.25 5.58 9.14 1.3 4.79 8.03 3.99 
595 eNOS_activation 7.85 0 6.51 5.54 9.8 8.88 9.08 8.52 6.6 8.29 2.43 2.82 0.65 8.81 4.74 3.8 5.7 6.39 
596 Metabolism_of_nucleotides 3.52 6.41 6.44 7.75 0.72 0.33 6.94 1.41 7.09 5.95 8.26 3.45 2.04 7.77 7.89 2.5 7.78 1.6 
597 Phosphate_bond_hydrolysis_by_NUDT_proteins 5.71 0.6 1.04 7.16 5.97 1.88 7.16 7.56 0.28 9.29 9.3 3.46 7.87 0.94 1.14 2.78 5.68 5.33 
598 Purine_catabolism 2.2 8.91 3.23 2.46 7.78 0.89 6.98 6.16 9 3.57 5.32 7.03 9.62 9.82 5.96 7.59 5.41 7.61 
599 Purine_ribonucleoside_monophosphate_biosynthesis 4.25 1.84 4.15 7.52 5.24 0.18 0.93 3.74 5.69 8.99 8.97 7.98 6.34 3.27 7.25 3.72 6.88 5.51 
600 Purine_salvage 5.57 9.8 4.91 8.61 9.88 7.39 2.6 1.99 5.7 4.11 2.33 0.26 4.52 9.46 9.21 6.8 6.36 0.36 
601 Pyrimidine_biosynthesis 7.45 9.25 5.23 9.76 3.42 5.99 7.24 9.29 8.51 6.28 6.67 1.98 3.57 2.41 1.5 4.52 1.49 6 
602 Pyrimidine_catabolism 4.91 8.11 4.14 7.53 2.1 7.42 5.53 2.28 7.64 2.15 2.13 9.49 5.24 4.42 1.54 2.17 9.4 1.12 
603 Pyrimidine_salvage_reactions 1.84 4.49 6.28 4.63 9.63 3.97 2.87 0 7.86 4.43 4.38 2.18 1.2 9.12 8.97 6.05 9.46 7.89 
604 Synthesis_and_interconversion_of_nucleotide_di-_and_triphosphates 5.7 3.37 4.35 9.9 7.97 1.92 3.17 9.03 2.3 8.65 9.52 7.19 2.97 6.54 5.28 2.74 1.83 5.61 
605 Heme_biosynthesis 9.13 1.54 8.24 6.98 5.5 3.9 1.48 3.56 1.24 9.01 3.18 9.05 7.68 1.4 1.87 1.55 7.28 6.55 
606 Heme_degradation 3.35 4.85 6 6.29 7.54 8.01 0.75 8.15 9.37 5.31 4.61 6.1 0.47 9.81 4.55 6.74 8.38 5.88 
607 Biotin_transport_and_metabolism 8.11 7.21 0.16 3.15 3.12 6.97 3.31 9.43 6.08 9.74 0.69 4.52 0.16 6.64 8.59 6.86 5.51 0.87 
608 Cobalamin_(Cbl,_vitamin_B12)_transport_and_metabolism 8.72 3.45 9.63 3.76 9.01 8.13 8.89 6.32 1.88 0.12 5.39 9.9 6.57 7.18 6.15 7.17 8.59 0.72 
609 Metabolism_of_folate_and_pterines 6.45 4.49 6.71 1.68 0.81 1.71 6.06 8.52 3.86 9.44 2.4 5.31 7.78 8.79 6.73 6.59 7.92 2.98 
610 Molybdenum_cofactor_biosynthesis 3.87 0.21 6.02 6.2 1.16 8.47 6.22 9.25 0.02 1.2 8.99 8.34 8.04 9.69 2.83 5.68 5.38 4.74 
611 Nicotinate_metabolism 1.56 0.17 2 5.79 4.32 4.48 0.47 0.44 0.09 5.46 5.56 2.7 2.41 0.39 2.93 1.96 5.13 0.31 
612 Vitamin_B1_(thiamin)_metabolism 1.21 9.72 8.96 3.28 2.88 7.39 4.15 3.99 7.55 1.84 6.58 4.84 5.25 9.75 6.89 3.71 7.94 3.85 
613 Vitamin_B2_(riboflavin)_metabolism 9.44 9.2 7.75 1.61 3.24 9.71 4.66 2.35 9.59 5.4 4.43 0.56 6.54 4.97 3.39 7.09 0.57 3.02 
614 Vitamin_B5_(pantothenate)_metabolism 3.23 0.37 3.38 9.16 6.97 4.91 4.02 1.89 6.87 9.97 1.2 5.67 9.49 9.26 5.23 5.91 8.48 0.35 
615 Vitamin_C_(ascorbate)_metabolism 6.91 7.44 6.58 5.12 0.98 7.72 3.55 7.71 4.09 7.53 4.48 7.45 3.04 5.12 9.16 8.55 1.98 7.62 
616 Vitamins_B6_activation_to_pyridoxal_phosphate 1.57 1.96 4.18 1.64 7.04 3.18 5.45 8.13 6.95 1.54 4.33 2.54 6.18 8 4.29 5.61 9.32 3.58 
617 Mitochondrial_Iron-Sulfur_Cluster_Biogenesis 5.46 2.6 9.43 7.23 8.17 7.12 9.06 8.31 0.39 1.09 7.3 0.9 3.37 7.21 9.75 2.74 1.16 6.81 
618 Electron_Transport_from_NADPH_to_Ferredoxin 2.57 4.65 6.43 9.59 4.5 6.21 9.78 9.56 1.34 2.74 7.47 2.95 4 8.61 4.63 2.55 8.14 0.5 
619 Uptake_of_Carbon_Dioxide_and_Release_of_Oxygen_by_Erythrocytes 9.68 9.26 0.17 7.85 9.32 2.7 8.94 0.12 2.92 9.84 5.36 4.61 1.02 4.99 4.17 1.09 7.52 4.9 
620 Uptake_of_Oxygen_and_Release_of_Carbon_Dioxide_by_Erythrocytes 6.38 9.44 9.66 7.7 6.03 2.55 4.37 9.22 4.87 4.77 2.09 5.63 2.73 0.31 3.72 5.86 0.91 5.58 
621 Reversible_Hydration_of_Carbon_Dioxide 3.92 9.63 4.62 1.83 4.15 8.48 5.35 3.97 0.25 7.07 1.84 4.44 0.22 0.73 9.94 8.73 4.04 5.59 
622 Citric_acid_cycle_(TCA_cycle) 9.29 9.93 9.47 3.61 9.28 9.59 4.15 0.16 0.15 4.66 6.62 2.92 0.58 3.98 3.31 1.79 1.88 0.73 
623 Interconversion_of_2-oxoglutarate_and_2-hydroxyglutarate 9.46 0.89 9.8 4.81 5 8.8 4.87 3.41 2.61 2.41 7.98 6.89 5.73 9.08 4.09 9.5 3.08 9.41 
624 Pyruvate_metabolism 4.67 4.25 4.5 7.04 7.36 0.67 0.54 2.85 0.85 9.21 6.28 9.35 2.15 6.04 2.44 0.5 6.55 0.19 
625 Formation_of_ATP_by_chemiosmotic_coupling 8.81 6.19 9.48 6.56 6.31 9.41 1.78 2.73 4.89 4.97 3.38 5.76 6.74 3.25 4.65 8.29 6.5 7.36 
626 Mitochondrial_Uncoupling_Proteins 9.89 2.98 8.83 7.49 4.21 0.39 4.37 7.34 3.84 2.15 0.22 7.87 1.93 8.42 0.22 3.16 1.22 9.25 
627 Respiratory_electron_transport 1.79 2.91 2.71 8.71 9.04 4.93 1 4.62 0.83 8.9 2.89 4.17 3.91 0.18 0.2 3.03 3.75 6.67 
628 Mitochondrial_Protein_Import 3.92 0.32 1.08 6.41 9.98 2.58 1.13 6.93 0.01 6.87 5.16 6.18 7.18 6.68 5.36 7.47 5.23 7.97 
629 Synthesis,_Secretion,_and_Inactivation_of_Glucagon-like_Peptide-1_(GLP-1) 0.73 5.52 6.15 2.56 9.28 1.15 6.19 3.43 2.48 7.1 5.44 2.1 1.04 0.4 3.37 0.12 0.34 7.44 
630 Synthesis,_Secretion,_and_Inactivation_of_Glucose-dependent_Insulinotropic_Polypeptide_(GIP) 2.17 0.68 2.35 1.04 0.32 8.16 6.91 1.97 1.46 8.53 2.23 4.78 2.33 9.62 9.9 4.28 1.24 9.81 
631 Insulin_Processing 4.89 4.25 9.84 2.86 5.35 9.96 6.62 3.63 5.35 6.67 4.37 1.55 5.75 1.54 9.7 6.63 4.6 7.63 
632 Metabolism_of_Angiotensinogen_to_Angiotensins 3.16 0.94 1.47 5.18 5.09 6.64 1.12 5.24 9.34 8.06 3.81 5.9 6.34 4.15 8.62 5.8 9.19 5.26 
633 Peptide_hormone_biosynthesis 3.7 8.5 9.44 0.18 7.16 0.61 4.22 0.06 8.26 7.03 0.39 8.1 2.14 7.51 4.32 9.85 6.84 3.01 
634 Glycoprotein_hormones 5.35 5.02 9.63 5.64 0.12 4.4 7.11 5.37 7.78 7.81 3.34 0.51 0.4 7.1 5.38 5.07 3.49 9.51 
635 Synthesis,_Secretion,_and_Deacylation_of_Ghrelin 3.5 6.06 7.95 1.71 6.21 0.88 6.75 7.25 8.07 6.28 2.65 7.86 3.73 2.89 1.85 9.81 6.55 6.87 
636 Asparagine_N-linked_glycosylation 3.94 5.06 7.16 0.91 6.51 2.87 2.42 1.82 9.71 5.52 0.95 2.21 3.01 3.87 7.27 3.25 1.4 0.91 
637 Biosynthesis_of_the_N-glycan_precursor_(dolichol_lipid-linked_oligosaccharide,_LLO)_and_transfer_to_a_nascent_protein 8.3 9.57 0.51 3.04 6.72 5.21 0.17 8.55 0.23 2.51 5.78 3.98 8.86 3.88 3.21 0.11 1 0.28 
638 N-glycan_trimming_in_the_ER_and_Calnexin/Calreticulin_cycle 5.09 8.22 5.78 9.59 9.53 0.59 3.68 0.41 6.17 4.6 2.53 6.5 5.86 8.07 5.26 7.49 2.73 9.64 
639 Transport_to_the_Golgi_and_subsequent_modification 8.25 2.7 8.95 9.22 9.46 7.46 5.31 5.7 3.1 2.68 8.08 2.59 0.7 4.53 3.04 2.56 4.54 0.03 
640 O-linked_glycosylation_of_mucins 0.01 1.43 1.19 7.34 3.44 8.28 9.93 1.91 3.4 9.57 5.17 4.65 3.72 0.31 7.06 5.88 9.55 5.45 
641 Termination_of_O-glycan_biosynthesis 6.54 8.23 0.18 6.87 0.96 4.07 9.51 9.22 8.04 1.9 3.81 9.1 7.98 1.17 4.44 0.12 9.14 1.64 
642 Gamma-carboxylation,_transport,_and_amino-terminal_cleavage_of_proteins 1.54 5.93 0.59 6.57 3.86 4.79 1.15 0.56 5.4 2.82 3.39 8.27 5.66 5.82 9.31 0.9 7.13 2.31 
643 Hypusine_synthesis_from_eIF5A-lysine 6.04 6.84 1.58 5.04 7.48 1.58 0.83 5.52 4.98 5.07 1.53 4.74 5.22 6.85 1.84 5.41 7.55 9.39 
644 The_activation_of_arylsulfatases 2.53 6.76 9.03 8.03 4.34 7.82 3.31 7.46 8.7 2.55 0.64 4.1 6.8 3.6 7.78 2.27 3.82 1.1 
645 Attachment_of_GPI_anchor_to_uPAR 0.87 2.3 8.42 7.03 9.53 7.17 3.12 1.7 2.15 6.71 7.29 2.06 2.01 7.94 0.84 9.15 6.67 0.1 
646 Synthesis_of_dolichyl-phosphate_mannose 6.37 9.69 4.84 2.82 3.26 1.58 3.11 9.04 4.45 4.52 6.81 7.33 3.5 1.38 9.72 8.37 8.59 5.61 
647 Synthesis_of_glycosylphosphatidylinositol_(GPI) 7.56 0.04 6.49 5.7 2.33 7.54 5.49 8.06 4.04 9.29 4.95 1.66 9.25 4.68 1.25 8.04 6.44 7.06 
648 Processing_and_Activation_of_SUMO 6.99 6.42 1.98 2.51 2.34 5.62 0.34 8.42 4.07 5.89 5.97 4.36 1.89 5.44 8.51 2.64 9.73 9.79 
649 Association_of_TriC/CCT_with_target_proteins_during_biosynthesis 8.55 1.27 7.97 5.4 7.25 1.5 4.86 9.96 0.06 7.61 3.39 9.28 3.15 2.35 0.71 9.63 4.54 3.88 
650 Cooperation_of_Prefoldin_and_TriC/CCT__in_actin_and_tubulin_folding 4.3 2.66 6.05 0.65 9.03 8.32 5.84 7.38 8.88 2.82 5.34 4.96 8.67 3.02 3.31 4.7 3.2 2.88 
651 Post-chaperonin_tubulin_folding_pathway 4.12 4.41 5.3 0.37 9.02 0.35 8.78 4.28 3.55 4.92 2.97 6.73 0.78 2.74 8.1 8.19 5.86 0.91 
652 Regulation_of_Insulin-like_Growth_Factor_(IGF)_Transport_and_Uptake_by_Insulin-like_Growth_Factor_Binding_Proteins_(IGFBPs) 5.04 5.29 5.98 2.48 6.37 8.57 4.52 6.45 9.95 2.73 8.75 0.22 8.94 6.82 8.33 6.6 2.5 9.85 
653 Eukaryotic_Translation_Elongation 6.44 3.83 8.06 9.11 5.07 2.06 0.82 6.92 8.08 8.94 3.81 1.59 7.53 4.8 4.18 7.13 2.71 4.94 
654 Peptide_chain_elongation 0.43 5.64 6.79 2.94 7.98 6.94 7.44 5.11 2.23 0.34 9.39 6.04 9.75 4.4 2.34 2.32 8.12 1.31 
655 Cap-dependent_Translation_Initiation 0.98 2.81 3.69 4.68 8.82 7.19 0.79 9.73 7.69 1.98 4.67 4.81 7.39 4.91 7.14 6.82 3.33 9 
656 Cap-independent_Translation_Initiation 7.95 4.99 3.93 2.27 9.4 6.4 5.72 4.11 4.16 7.62 9.42 4.91 5.83 5.91 3.45 0.28 4.86 3.53 
657 L13a-mediated_translational_silencing_of_Ceruloplasmin_expression 7.42 0.86 4.64 9.33 6.52 6.24 1.81 7.6 8.74 3.51 3.47 1.73 9.59 8.62 8.18 1.54 5.52 9.43 
658 Eukaryotic_Translation_Termination 6.04 4.76 6.9 1.61 2.93 4.47 0.09 6.35 8.95 4.75 3.52 4 0.01 7.63 6.34 7.47 8.65 0.88 
659 SRP-dependent_cotranslational_protein_targeting_to_membrane 3.04 0.04 2.4 0.77 0.51 6.03 6.37 2.12 6.85 6.85 7.08 2.58 9.15 4.62 4.72 5.02 3.74 8.06 
660 Activation_of_Chaperones_by_ATF6-alpha 4.06 8.23 6.43 3.9 0.61 4.87 2.71 9.88 3.31 4.1 4.7 5.49 4.65 7.72 2.14 2.99 3.3 7.94 
661 Activation_of_Chaperone_Genes_by_ATF6-alpha 6.16 1.75 9.04 9.59 5.27 2.81 9.2 9.38 6.83 9.1 7.27 1.26 8.24 2.4 3.32 5.15 8.59 7.4 
662 Activation_of_Chaperones_by_IRE1alpha 4.79 7.07 4.45 0.25 6.67 9.11 7.4 5.97 1.45 7.7 5.26 2.68 9.17 8.7 4.15 6.43 7 0.22 
663 Activation_of_Chaperone_Genes_by_XBP1(S) 8.52 5.05 1.5 2.28 5.6 3.67 9.45 7.4 8.24 4.66 2.62 0.49 1.07 4.63 0.16 7.35 8.04 9.18 
664 PERK_regulated_gene_expression 5.13 4.08 5.94 0.18 2.47 5.46 7.35 1.52 8.48 5.61 5.68 2.13 9.7 6.89 1.49 7.81 7.11 4.55 
665 Activation_of_Genes_by_ATF4 2.18 7.06 9.34 4.17 5.81 1.22 0.92 7.14 8.73 1.24 9.97 3.87 3.94 9.48 6.86 4.14 9.94 4.29 
666 Smooth_Muscle_Contraction 7.41 7.81 9.23 0.62 4.44 2.59 6.29 0.48 3.53 7.68 2.58 2.47 9.21 7.79 6.01 1.27 1.27 2.11 
667 Striated_Muscle_Contraction 3.52 7.93 6.39 9.35 0.78 0.13 1.44 1.59 6.16 8.02 3.13 5.06 0.98 7.73 8.27 9.05 8.24 7.51 
668 Botulinum_neurotoxicity 8.72 6.52 1.89 8.66 4.18 9.79 4.43 6.76 1.83 9.6 8.52 7.81 9.55 3.96 0.5 9.34 4.22 1.98 
669 Proteolytic_cleavage_of_SNARE_complex_proteins 4.5 7.46 3.36 9.95 5.26 3.46 2.98 6.26 5.7 2.51 8.63 2.64 2.95 3.78 3.8 0.28 8.07 8.76 
670 BoNT_Light_Chain_Types_A,_C1,_E_cleave_SNAP-25 6.59 0.27 0.16 7.19 2.06 5.9 1.57 1.49 4.74 1.54 2.41 6.42 5.77 3.61 9.17 1.95 6.85 3.59 
671 BoNT_Light_Chain_Types_B,_D,_and_F_cleave_VAMP/Synaptobrevin 7.63 5.45 8.58 0.16 8.12 5.51 3.71 9.52 5.44 7.44 6.88 2.75 3.16 8.45 2.71 0.62 9.45 4.3 
672 Translocation_of_BoNT_Light_chain 4.8 0.93 8.98 4.3 6.69 9.59 7.73 4.2 7.85 5.75 6.78 7.19 6.96 6.28 0.89 7.77 0.56 2.83 
673 Ca2+_activated_K+_channels 7.27 4.56 5.67 9.79 8.98 0.57 6.69 3.45 7.48 5.65 0.67 2.21 7.81 0.41 8.04 4.93 7.32 3.85 
674 HCN_channels 9.87 1.93 6.88 1.81 5.01 5.91 3.67 0.06 5.68 3.92 1.5 3.62 1.96 0.98 7.22 9.34 1.29 8.71 
675 ATP_sensitive_Potassium_channels 8.07 1.64 6.66 7.9 6.39 3.18 8.65 3.21 2.69 8.89 0.58 8.79 2.82 0.29 8.04 6.9 6.08 4.76 
676 Classical_Kir_channels 7.97 7.63 1.9 0.01 4.29 2.29 9.47 1.87 4.31 5.03 4.06 0.5 5.95 0.7 0.69 3.22 6.39 9.95 
677 G_protein_gated_Potassium_channels 5.64 1.74 6.4 1.6 6.65 4.86 6.67 7.05 2.14 9.39 8.88 2.65 2.78 4.98 2.18 5.06 7.88 9.04 
678 Potassium_transport_channels 3.36 1.61 6 6.21 2.24 8.33 6.59 3.56 7.32 9.99 6.05 1.94 3.25 1.74 5.33 9.97 9.92 7.56 
679 TWIK_related_potassium_channel_(TREK) 1.85 7.51 8.3 7.24 8.54 1.79 4.72 7.18 7.94 8.47 9.23 8.36 0.72 9.38 5.04 6.62 5.81 3.68 
680 TWIK-related_alkaline_pH_activated_K+_channel_(TALK) 2.79 0.24 8.65 4.27 2.37 5.3 9.91 5.49 2.35 3.76 0.56 1.4 2.9 0.36 8.6 4.77 8.27 0.57 
681 TWIK-related_spinal_cord_K+_channel_(TRESK) 1.07 8.36 9.48 7.61 9.08 7.62 8.48 6.01 6.92 8.88 6.13 4.18 2.49 3.07 4.52 6.12 3.75 6.32 
682 TWIK-releated_acid-sensitive_K+_channel_(TASK) 7.33 5.19 6.19 0.98 2.66 2.5 9.18 5.14 7.56 2.15 8.44 8.63 2.51 8.86 5.41 0.22 4.02 0.9 
683 Tandem_of_pore_domain_in_a_weak_inwardly_rectifying_K+_channels_(TWIK) 9.56 6.59 7.77 4.81 4.94 2.57 2.72 8.71 3.17 4.94 3.04 1.97 0.46 3.63 2.36 2.7 5.36 4.26 
684 Tandem_pore_domain_halothane-inhibited_K+_channel_(THIK) 5.52 2.75 1.03 2.88 8.49 6.55 9.43 7.5 2.37 9.97 5.32 6.43 0.84 3.85 1.61 8.28 7.35 7.56 
685 Voltage_gated_Potassium_channels 9.04 1.1 4.8 6.04 1.54 3.22 7.78 7.47 7.03 4.99 2.27 5.35 3.76 2.93 7.75 7.62 6.34 8.86 
686 Depolarization_of_the_Presynaptic_Terminal_Triggers_the_Opening_of_Calcium_Channels 4.14 6.99 0.14 9.21 4.65 0.05 6.56 8.56 7.05 2.38 1 1.94 8.25 0.02 0.08 5.34 9.33 9.53 
687 Neurotransmitter_Clearance_In_The_Synaptic_Cleft 9.42 3.59 5.95 5.26 2.08 4.8 8.8 2.82 6.57 3.3 9.98 6.25 7.37 2.91 7.65 4.43 3.37 4.97 
688 Dopamine_clearance_from_the_synaptic_cleft 9.28 3.57 7.6 6.16 3.69 7.61 4.69 8.64 0 4.67 9.34 1.06 7.92 7.02 9.85 1.16 2.5 1.67 
689 Serotonin_clearance_from_the_synaptic_cleft 6.25 0.04 5.33 6.95 0.2 5.77 9.9 0.71 9.06 9.76 6.05 3.59 3.12 7.74 6.97 1.03 6.61 3.61 
690 Acetylcholine_Binding_And_Downstream_Events 8.77 2.1 0.84 5.8 4.5 6.24 7.8 7.3 6.07 6.19 0.13 6.74 8.55 1.32 2.92 5.56 9.14 9.42 
691 Activation_of_Kainate_Receptors_upon_glutamate_binding 4.56 4.84 9.02 6.75 6.06 9.72 3.35 2.07 1.54 4.55 8.52 3.54 9.11 8.59 9.56 3.61 8.81 9.58 
692 Activation_of_NMDA_receptor_upon_glutamate_binding_and_postsynaptic_events 4.49 6.15 1.45 7.97 8.61 3.84 8 8.25 7.62 1.82 7.43 8.82 7.5 8.72 8.47 3.68 6.62 6.15 
693 GABA_receptor_activation 8.05 8 0.5 6.59 5.04 1.16 3.22 8.22 1.02 8.31 0.31 9.03 9.15 5.59 5.81 8.81 1.32 7.24 
694 Glutamate_Binding,_Activation_of_AMPA_Receptors_and_Synaptic_Plasticity 4.95 1.97 7.79 2.31 1.72 9.82 5.56 9.82 3.93 5.47 6.55 7.28 7.43 3.62 2.07 0.04 7.74 3.71 
695 Acetylcholine_Neurotransmitter_Release_Cycle 5.86 2.79 8.09 8.19 4.9 0.93 9.16 2.74 3.64 0.47 5.08 4.63 0.46 9.5 8.47 9.38 7.34 4.31 
696 Dopamine_Neurotransmitter_Release_Cycle 8.28 9.54 5.05 1.84 6.59 4.8 2.34 6.98 9.27 7.56 7.87 6.87 1.55 9.83 7.44 5.65 1 9.53 
697 GABA_synthesis,_release,_reuptake_and_degradation 6.74 9.48 8.93 3.63 2.18 2.61 3.68 2.31 4.63 7.08 9.48 9.35 1.05 4.39 0.18 4.28 4.07 7.67 
698 Glutamate_Neurotransmitter_Release_Cycle 2.93 7.04 8.22 0.54 3.13 7.01 7.22 2.09 6.1 2.79 4.42 0.09 9.84 4.32 3.83 9.57 4.02 2.75 
699 Norepinephrine_Neurotransmitter_Release_Cycle 4.3 4.5 4.49 1.23 4.63 7.17 5.26 5 3.8 0.72 3.43 7.94 0.45 1.07 6.62 6.26 4.75 9.81 
700 Serotonin_Neurotransmitter_Release_Cycle 5.38 4.69 6.92 1.88 4.1 5.64 0.32 0.49 8.71 6 6.89 4.71 8.09 0.25 0 9.65 2.77 9.78 
701 Astrocytic_Glutamate-Glutamine_Uptake_And_Metabolism 8.61 0.26 7.02 3.94 7.02 6.25 7.14 7.42 1.73 3.01 9.02 1.73 6.75 3.03 3.24 6.29 6.49 0.29 
702 Electric_Transmission_Across_Gap_Junctions 0.59 5.88 4.49 7.65 1.76 5.61 0.96 4.03 9.48 9.16 0.47 1.03 6.94 6.27 6.74 6.34 2.91 3.59 
703 Conjugation_of_SUMO_to_E1_(UBA2:SAE1) 1.05 7.31 5.87 8.63 8.13 0.05 7.74 7.23 4.85 2.51 3.98 3.47 7.45 3.99 6.86 7.85 7.5 4.14 
704 Proteolytic_Processing_of_SUMO 3.95 3.23 3.8 6.16 8.11 1.66 3.48 0.31 3.88 8.08 9.59 6.38 5.73 0.53 2.03 1.97 4.98 2.77 
705 Transfer_of_SUMO_from_E1_to_E2_(UBE2I,_UBC9) 7.26 3.62 9.64 8.67 0.88 4.65 5.68 3.92 6.36 7.51 4.18 1.05 6.47 3.56 5.69 6.55 5.16 3.03 
706 Acrosome_Reaction 0.12 9.74 0.32 3.26 0.53 3.2 2.74 6.22 4.53 6.5 5 0.08 2.24 7.03 4.08 0.77 6.27 8.76 
707 Interaction_With_Cumulus_Cells 0.21 6.91 4.91 3.65 2.49 3.36 0.07 6.46 4.36 1.26 0.49 2.27 5.22 1.44 7.05 2.2 8.09 7.4 
708 Interaction_With_The_Zona_Pellucida 6.99 5.63 6.11 4.25 2.98 2.4 0.86 4.83 9.25 9.99 6.27 5.73 3.04 7.76 2.44 6.15 2.94 6.96 
709 Sperm_Motility_And_Taxes 7.13 3.52 1.34 2.54 5.32 9.01 7.31 7.77 6.12 1.46 1.29 7.67 2.79 5.92 4.13 2.33 0.04 6.8 
710 Sperm:Oocyte_Membrane_Binding 4.04 6.62 7.04 6.55 5.35 7.8 5.82 3.71 2.37 2.7 7.64 5.65 9.53 1.15 6.6 0.95 7.1 9.95 
711 Hexose_transport 7.05 2.64 0.56 8.71 8.11 5.01 5.25 6.97 7 4.51 0.6 1.62 4.51 8.1 2.28 4.35 6.81 6.6 
712 Glucose_transport 0 0.3 5.15 7.1 3.61 2.78 2.47 7.42 5.25 0.2 7.62 1.18 0.39 3.8 1.45 6.72 3.11 1.43 
713 Regulation_of_Glucokinase_by_Glucokinase_Regulatory_Protein 8.07 0.35 2.2 5.37 1.42 4.52 5.82 4.78 2.25 4.96 6.89 2.97 7.7 0.41 8.79 1.01 4 6.23 
714 Transport_of_glucose_and_other_sugars,_bile_salts_and_organic_acids,_metal_ions_and_amine_compounds 0.05 4.72 7.07 2.89 0.73 3.41 5.87 4.61 5.86 3.69 0.93 5.24 5.6 3.59 0.95 9.85 8.46 0.32 
715 Facilitative_Na+-independent_glucose_transporters 5.67 6.76 7.02 6.77 7.99 6.74 3.31 1.99 0.03 7.51 2.76 6.42 9.5 3.98 7.28 6.68 0.49 4.56 
716 Class_II_GLUTs 9.73 0.68 0.46 7.23 2.78 1.37 4.45 0.93 6.44 5.85 8.37 6.9 5.87 9.08 2.85 8.42 2.17 3.19 
717 Inositol_transporters 6.82 0.71 9.3 0.77 3.72 1.49 0.72 3.63 8.45 6.5 9.46 4.35 5.29 6.64 4.5 0.99 4.84 5.29 
718 Metal_ion_SLC_transporters 7.39 0.78 4.49 5.23 0.18 2.52 5.35 7.4 1.64 0.38 2.65 3.11 4.73 7.97 5.89 2.07 1.91 7.79 
719 Zinc_transporters 1.48 2.36 2.26 6.49 5.72 1.8 8.43 7.87 5.23 2.11 7.35 6.25 7.49 7.58 2.17 3.35 0.08 6.69 
720 Na+-dependent_glucose_transporters 9.14 3.2 5.9 7.51 1.52 5.82 5.22 0.82 1.25 8.69 5.02 0.91 2.09 9.05 7.97 1.15 2.43 8.77 
721 Na+/Cl-_dependent_neurotransmitter_transporters 2.85 8.83 4.6 4.93 7.59 3.37 3.72 9.02 4.25 3.15 4.25 4.28 0.75 9.55 3.41 6.53 2.1 5.96 
722 Organic_anion_transport 5.91 8.45 2.66 1 6.05 5.92 6.07 5.23 7.77 5.03 5.97 3.71 1.69 5.57 1.74 9.12 3 6.97 
723 Organic_cation_transport 8.52 3.85 2.17 3.22 3.68 8.96 0.02 3.98 0.26 2.87 1.54 4.11 5.7 9.39 2.18 4.17 2.87 6.45 
724 Proton-coupled_monocarboxylate_transport 1.94 3.91 8.94 5.58 1.5 0.69 7.17 9.23 9.02 0.34 1.68 4.42 7.95 0.64 5.39 8.76 4.39 5.73 
725 Rhesus_glycoproteins_mediate_ammonium_transport 6.33 4.52 5.17 4.99 5.89 6.7 9.85 3.54 8.16 6.99 6.24 0.35 4.98 1.72 9.47 7.52 5.56 8.13 
726 Sodium-coupled_sulphate,_di-_and_tri-carboxylate_transporters 2.08 3.15 4.45 1.01 1.14 4.85 9.31 1.38 3.06 2.4 1.4 4.34 5.17 7.11 5.5 9.59 4.64 6.68 
727 Transport_of_inorganic_cations/anions_and_amino_acids/oligopeptides 6.12 9.87 5.46 0.74 8.98 5.89 9.37 4.2 3.95 3.14 2.32 7.65 7.52 3.91 2.95 7.06 4.2 1.74 
728 Amino_acid_transport_across_the_plasma_membrane 2.51 9.17 8.62 9.92 3.52 0.19 3.99 1.62 7.08 0.88 4.13 4.18 2.69 0.57 5.27 5.96 0.94 7.63 
729 Bicarbonate_transporters 4.33 3.44 3.74 7.38 8.98 8.06 7.3 3.49 4.52 9.57 6.84 0.8 1.72 7.52 8.43 1.69 6.35 4.83 
730 Cation-coupled_Chloride_cotransporters 9.17 9.44 1.08 7.32 5.79 1.92 5.59 6.21 0.52 8.03 4.21 4.25 4.28 1.41 0.77 7.25 3.82 9.11 
731 Multifunctional_anion_exchangers 2.78 5.61 8.96 2.55 0.54 1.27 8.06 3.34 3.47 6.19 2.65 6.83 3.52 8.83 1.46 7.74 2.5 7.62 
732 Organic_anion_transporters 7.78 8.07 7.56 8.47 3.23 7.2 7.35 3.47 6.6 3.68 2.22 9.79 8.01 7.7 3.93 3.63 8.02 0.69 
733 Proton-coupled_neutral_amino_acid_transporters 9.99 3.8 7.89 5.09 4.1 7.34 3.66 9.62 1.58 7.22 8.78 9.51 8.59 7.37 9.61 3.18 0.43 9.37 
734 Proton/oligonucleotide_cotransporters 0.6 6.1 7.97 1.06 4.47 8.29 7.63 6.83 7.04 8.99 9.85 9.39 9.92 2.06 9.27 9.16 4.58 6.27 
735 Sodium-coupled_phosphate_cotransporters 0.17 3.94 6.09 8.78 7.01 5.49 3.45 6.66 6.21 5.55 4.01 9.39 9.65 9.87 3.99 7.19 5.19 6.21 
736 Type_II_Na+/Pi_cotransporters 5.24 5.78 0.29 1.33 5.54 7.93 6.87 1.21 3.95 2.18 9.82 7.29 0.28 9.3 6.4 8.39 2.34 3.67 
737 Sodium/Calcium_exchangers 8.29 4.79 4.75 0.23 5.77 2.88 3.77 4.88 0.35 1.16 9.38 2.81 7 6.85 1.72 2 9.25 1.84 
738 Sodium/Proton_exchangers 9.75 4.7 7.15 1.5 1.78 4.17 5.8 2.96 4.11 8.73 8.7 7.16 5.62 1.97 8.93 3.42 6.61 8.78 
739 Transport_of_vitamins,_nucleosides,_and_related_molecules 6.54 1.12 2.49 0.75 0.35 4.68 9.03 4.39 4.94 4.97 9.81 6.48 5.52 7.17 8.23 8.57 1.72 6.74 
740 Transport_of_fatty_acids 3.58 4.83 1.04 6.6 2.16 8.23 1.88 7.77 6.87 7.36 2.87 5.3 4.54 5.35 1.34 3.78 3.86 7.18 
741 Transport_of_nucleosides_and_free_purine_and_pyrimidine_bases_across_the_plasma_membrane 1.81 2.12 7.5 8.56 9.39 6.66 5.53 7.05 9.85 8.67 1.15 0.98 2.84 5.16 7.26 4.64 9.07 6.51 
742 Transport_of_nucleotide_sugars 2.1 4.38 1.95 9.51 0.2 1.84 0.65 6.92 7.99 7.46 6.47 0.78 5.39 9.59 2.67 5.4 3.25 8.78 
743 Transport_of_organic_anions 4.28 2.07 1.03 7.54 5.67 7.95 2.58 8.57 8.57 0.69 9.22 7.04 3.81 8.21 0.89 5.17 0.73 5.74 
744 Conjugation_of_SUMO_to_E1_(UBA2:SAE1) 0.46 8.05 3.24 2.68 1.03 2.47 7.14 6.13 7 9.44 7.47 8.99 9.42 2.96 4.73 2.41 8.56 7.09 
745 Proteolytic_Processing_of_SUMO 9.13 4.52 8.93 1.75 3.56 9.72 8.26 1.47 8.86 2.83 4.77 6.12 8.94 8.53 0.31 9.99 8.96 9.53 
746 Transfer_of_SUMO_from_E1_to_E2_(UBE2I,_UBC9) 4.7 2.22 9.75 2.55 9.42 4.16 1.19 0.66 5.36 6.54 4.74 0.64 6.51 3.85 3.04 0.47 8.19 6.1 
747 DAG_and_IP3_signaling 8.29 4.34 9.35 5.7 2.86 4.05 2.31 7.23 6.2 1.73 7.82 6.94 3.48 6.99 1.64 3.03 1.9 2.19 
748 CaM_pathway 8.79 9.51 6.13 7.68 8.12 4.08 6.46 1.47 8 8.94 5.96 0.43 7.64 6.35 7.47 8.39 5.2 8.11 
749 Calmodulin_induced_events 6.44 3.46 2.94 2.98 0.25 7.89 9.55 9.55 9.86 7.88 6.1 8.74 7.02 0.58 4.42 1.88 1.98 2.94 
750 Integrin_alphaIIb_beta3_signaling 5.6 9.98 8.62 2.98 2.32 9.47 0.77 2.33 1.52 0.1 6.32 7.46 3.97 6.15 8.34 7.54 6.11 5.37 
751 GRB2:SOS_provides_linkage_to_MAPK_signaling_for_Intergrins_ 0.78 1.34 2.15 1.4 1.52 2.17 6.95 2.32 5.13 2.67 8.68 1.37 5.77 7.23 8.07 8.48 1.14 2.71 
752 p130Cas_linkage_to_MAPK_signaling_for_integrins 4.18 0.9 3.07 1.29 0.32 8.72 6.58 5.87 6.95 4.87 1.58 6.07 2.85 7.84 0.27 7.44 8.41 9.79 
753 PIP3_activates_AKT_signaling 8.55 3.17 4.67 6.55 9.73 7.51 9.43 8.69 9.6 6.25 7.34 2.94 7.46 2.23 6.06 6.98 8.13 8.02 
754 AKT_phosphorylates_targets_in_the_cytosol 4.51 8.75 3.54 6.67 3.89 0.65 9.61 5.98 3.48 9.04 5.44 8.66 5.85 2.62 1.43 5.98 9.03 6.41 
755 AKT_phosphorylates_targets_in_the_nucleus 7.87 2.86 9.94 2.88 5.21 5.89 9.91 1.93 9.9 1.89 8.92 5.15 1.65 5.81 0.81 5.89 1.36 0.02 
756 Negative_regulation_of_the_PI3K/AKT_network 9.27 2.87 7.86 2.18 9.92 2.07 6.53 0.85 5.84 6.15 7.99 2.04 6.74 1.32 5.47 5.19 4.3 8.99 
757 ERK1_activation 7.09 5.37 8.49 5.43 6.62 0.71 1.49 8.14 3.61 0.49 5.95 1 0.04 7.12 1.42 2.24 2.19 5.13 
758 ERK2_activation 6.42 4.54 2.65 6.96 2.13 0.29 1.13 2.32 6.12 2.9 1.97 5.78 2.01 8.04 7.08 5.73 0.44 8.65 
759 MEK_activation 4.65 2.53 7.92 2.33 6.74 3.51 7.52 4.1 6.14 5.55 1.05 4.75 2.74 4.83 5.77 8.54 1.1 5.64 
760 RAF_phosphorylates_MEK 6.96 5.59 5.71 8.02 0.14 2.58 3.36 1.6 8.06 1.72 4.38 8.96 2.41 3.6 2.24 9.2 0.86 7.81 
761 RAF_activation 1.11 8.86 3.12 7.34 2.05 4.7 5.04 7.78 5.44 2.25 8.45 3.65 3.38 0.32 8.02 3.27 7.02 3.61 
762 Signaling_by_Activin 7.99 0.91 6.13 1.37 8.18 0.03 5.54 9.63 7.99 4.42 1.15 7.36 3.01 2.26 9.54 0.79 1.96 0.4 
763 Antagonism_of_Activin_by_Follistatin 9.06 7.99 0.36 1.64 7.49 5.55 5.83 6.29 9.17 7.81 6.09 8.2 7.7 3.1 1.19 5.99 8.68 5.56 
764 Signaling_by_BMP 8.23 1.3 2.18 7.17 7.02 9.77 4.34 4.68 0.23 2.41 6.81 3.78 4.82 2.07 1.97 9.9 4.76 0.33 
765 Signaling_by_EGFR 7.21 0.8 1.58 5 2.41 4.34 2.08 1.26 2.39 3.76 2.87 0.37 7.57 5.7 0.2 7.51 3.24 1.99 
766 EGFR_downregulation 9.35 5.8 1.32 0.61 4.52 5.6 2.77 4.86 7.17 1.01 4.46 6.68 3.76 6.17 9.56 2.01 6.34 2.84 
767 EGFR_interacts_with_phospholipase_C-gamma 5.17 4.88 0.68 8.61 6.13 5.44 7.73 1.09 0.56 5.06 6.17 1.32 5.05 6.33 3.37 7.78 2.11 3.3 
768 DAG_and_IP3_signaling 4.9 9.85 9.98 6.68 8.34 8.01 3.73 6.33 1.36 2.12 4.53 8.05 7 8.04 8.4 8.47 1.35 5.45 
769 GAB1_signalosome 5.95 8.22 7.48 5.03 1.96 1.01 9.03 3.67 8.97 3.38 5.16 8.53 0.93 5 1.95 4.5 5.32 6.75 
770 PIP3_activates_AKT_signaling 4.67 8.35 0.49 0.2 1.65 7.14 7.17 5.73 0.43 2.59 4.27 0.54 7.36 4.58 6.98 4.73 8.41 1.23 
771 GRB2_events_in_EGFR_signaling 4.27 1.95 7.09 3.86 3.71 1.23 1.69 7.64 5.55 4.34 0.95 6.53 3.74 8.2 7.11 1.79 2.03 9.1 
772 RAF/MAP_kinase_cascade 7.18 8.51 5.24 9.76 4.39 3.71 6.14 0.62 6.72 5.52 3.3 3.21 3.1 7.85 6.51 5.71 4.11 4.83 
773 SHC1_events_in_EGFR_signaling 3.05 5.87 2.22 4.55 9.57 1.73 5.64 9.61 4.54 9.02 2.87 3.3 1.47 0.22 8.28 9.51 3.14 9.75 
774 RAF/MAP_kinase_cascade 2 3.07 0.89 4.62 1.25 3.07 2.43 6.79 1.06 8.25 8.93 6.54 4.65 0.2 8.09 8.19 5.34 5.5 
775 Signaling_by_ERBB2 8.51 6.29 0.6 5.01 7.38 7.46 3.77 1.58 0.81 9.49 8.37 4.07 1.03 3.22 9.59 9.15 6.59 2.55 
776 Downregulation_of_ERBB2:ERBB3_signaling 2.89 8.04 8.52 8.83 6.45 4.92 9.93 9.71 1.04 4.2 9.64 2.34 8.86 4.25 3 1.21 2.78 3.07 
777 GRB2_events_in_ERBB2_signaling 9.31 7.35 5.59 0.56 7.89 9.95 4.03 2.09 1.06 7.92 8.83 3.31 0.22 8.48 9 9.53 6.15 8.28 
778 RAF/MAP_kinase_cascade 9.68 7.84 4.46 7.63 6.4 4.75 1.22 9.69 4.56 1.36 0.97 3.77 7.63 9.38 9.37 5.1 4.09 8.64 
779 GRB7_events_in_ERBB2_signaling 4.78 0.31 9.58 1.83 5.08 1.86 9.97 2.99 2.24 7.54 3.08 5 1.86 6.67 5.78 1.5 6.38 1.41 
780 PI3K_events_in_ERBB2_signaling 6.95 8.09 6.03 4.87 4.19 9.55 0.82 9.99 3.7 3.22 4.67 1.99 3.57 6.39 9.42 6.42 7.8 7.51 
781 PIP3_activates_AKT_signaling 3.02 5.59 0.2 8.51 4.34 4.28 3.39 5.55 0.3 0.39 6.76 7.19 5.35 8.58 9.03 1.1 7.66 2.05 
782 PLCG1_events_in_ERBB2_signaling 5.75 3.7 2.15 7.6 9.63 2.19 6.67 2.57 0.69 8.83 5.55 5.15 6.95 6.35 6.77 5.28 1.36 7 
783 DAG_and_IP3_signaling 4.04 1.99 2.01 5.28 5.07 9.13 8.52 1.37 2.26 0.73 9.75 4.34 4.04 4.03 4.21 0.85 3.44 3.11 
784 SHC1_events_in_ERBB2_signaling 0.22 2.21 1.83 3.97 6.01 5.5 8.86 5.14 5.35 6.89 5.64 1.96 1.53 5.4 0.77 5.71 3.4 4.25 
785 RAF/MAP_kinase_cascade 3.21 7.45 6.28 1.98 9.19 8.19 4.71 9.01 3.5 7.76 3.8 0.21 2.05 2.42 2.68 7.52 7.04 8.18 
786 Signaling_by_ERBB4 4.71 3.42 7.82 9.13 5.14 0.67 3.94 6.92 3.44 9.8 4.47 9.19 2.86 8.56 6.07 7.82 7.56 2.12 
787 Downregulation_of_ERBB4_signaling 9.41 8.4 4.24 4.63 6.34 6.53 8.05 7.76 5.81 4.81 0.36 8.37 1.18 0.49 5.93 6.45 0.53 0.86 
788 Nuclear_signaling_by_ERBB4 3.22 2.87 3.34 7.03 9.08 1.49 1.6 0.28 4.15 4.92 2.38 5.29 6.1 4.05 7.42 2.15 2.49 4.41 
789 Prolactin_receptor_signaling 5.6 3.13 7.42 7.03 6.81 9.01 6.71 7.94 2.81 3.38 5.75 8.26 5.53 3.53 0.3 9.35 8.25 1.75 
790 PI3K_events_in_ERBB4_signaling 2.05 8.53 4.49 0.89 5.73 6.04 1.26 5.13 2.64 5.2 8.88 4.33 6.03 6.81 1.7 0.61 6.33 8.35 
791 PIP3_activates_AKT_signaling 8.33 0.14 5.95 8.48 8.56 2.59 4.87 1.64 0.27 9.07 1.83 4.26 2.75 7.69 8.28 1.18 4.34 9.35 
792 SHC1_events_in_ERBB4_signaling 4.58 2.98 6.15 8.23 4.85 6.77 3 9.25 7.56 9.36 2.38 5.28 9.18 4.19 9.49 2.03 5.46 7.52 
793 RAF/MAP_kinase_cascade 7.09 1.11 2.59 4.61 3.39 3.48 7.08 7.76 0.6 0.15 2.24 4.14 8.91 2.7 8.45 5.09 8.57 0.34 
794 Signaling_by_FGFR 2.02 0.51 0.18 4.6 4.54 2.55 2.77 0.67 1.23 9.18 0.6 7.97 2.68 6.24 4.38 5.16 5.86 1.96 
795 FRS2-mediated_cascade 4.73 6.83 7.73 6.01 8.28 1.61 0.73 4.31 8.75 7.41 5.19 7.73 4.36 7.47 0.38 9.64 9.7 7.49 
796 PI-3K_cascade 5.93 5.16 8.39 5.9 7.78 7.82 8.56 9.95 1.19 8.82 9.16 5.87 0.21 0.65 5.33 7.92 1.63 8.13 
797 Phospholipase_C-mediated_cascade 4.98 4.78 2.16 6.08 8.68 6.36 3.43 6.9 9.75 5.85 7.77 7.19 2.03 1.45 3.07 2.01 1.4 4.96 
798 SHC-mediated_cascade 8.02 6.02 6.07 6.38 2.37 0.76 2.15 6.91 5.79 2.12 2.06 9.65 9 6.92 6.55 0.31 1.88 5.29 
799 FGFR1_ligand_binding_and_activation 4.68 3.48 4.93 2.28 2.99 9.65 8.99 8.36 8.15 8.72 8.14 3.88 2.04 9.78 5.8 0.25 9.38 9.73 
800 FGFR2_ligand_binding_and_activation 5.34 5.92 2.14 5.25 2.04 3.01 3.73 6.63 8.58 3.5 6.91 1.4 9.17 5.29 6.28 9.81 1.53 8.84 
801 FGFR3_ligand_binding_and_activation 5.04 5.59 8.13 5.16 6.28 3.29 1.06 4.55 2.54 2.51 8.87 0.77 8.97 6.57 5.36 3.4 2.26 2.72 
802 FGFR4_ligand_binding_and_activation 0 6.04 4.26 2.25 4.53 9.64 1.98 9.16 5.63 3.94 4.19 7.42 1.24 0.56 4.22 8.3 8.54 4.77 
803 Klotho-mediated_ligand_binding 9.79 5.56 0.21 1.45 7.87 3.23 1.95 5.33 5.8 2.18 0.13 3.7 8.36 3.73 5.36 4.5 7.17 6.25 
804 Negative_regulation_of_FGFR_signaling 4.12 0.76 8.08 7.27 9.11 8.91 0.35 2.48 9.81 2.09 8.53 7.31 5.19 3.52 3.95 0.03 4.09 2.66 
805 Spry_regulation_of_FGF_signaling 2.68 9.24 6.73 3.85 2.74 1.27 3.48 3.29 8.26 5.96 5.39 0.77 1.82 0.15 0.07 2.95 1.2 9.66 
806 G_alpha_(12/13)_signalling_events 9.76 4.68 0.18 5.22 6.12 1.03 6.36 7.73 7.66 9.89 9.9 9.87 7.33 9.93 6.62 1.08 6.47 3.05 
807 G_alpha_(i)_signalling_events 5.48 1.92 7.02 3.93 5.56 6.6 8.97 9.42 3.4 4.2 0.54 2.94 9.35 8.17 9.35 7.89 8.01 2.29 
808 G_alpha_(q)_signalling_events 6.82 8.67 5.8 7.25 7.17 4.53 2.26 0.07 9.3 5.68 4.44 1.87 6.08 7.18 9.3 7.03 0.1 6.42 
809 G_alpha_(s)_signalling_events 2.84 1.49 9.63 4.86 9.05 0.4 4.5 4.15 8.61 9.51 3.55 5.03 1.68 4.41 9.34 9.95 4.61 3.78 
810 G_alpha_(z)_signalling_events 1.88 7.9 9.93 4.29 3.19 0.62 0.53 7.3 2.73 9.58 2.28 7.45 0.56 6.84 8.41 8.32 0.16 0.59 
811 G-protein_beta:gamma_signalling 8.67 1.78 8.66 2.28 4.74 1.37 8.04 7.04 7.91 8.69 1.92 5.13 3.27 3.17 3.85 4.98 2.25 5.65 
812 Olfactory_Signaling_Pathway 9.96 1.47 2 0.97 5.24 8.82 4.42 6.57 1.68 7.27 7.22 8.05 7.29 3.03 6.43 8.51 8.22 9.71 
813 Class_A/1_(Rhodopsin-like_receptors) 0.86 5.58 4.74 1.69 6.94 8.66 5.21 5.79 1.94 6.14 9.82 9.83 5.14 0.64 0.65 3.28 7.98 6.71 
814 Class_B/2_(Secretin_family_receptors) 8.64 4.9 3.88 3.41 2.19 3.47 0 6.51 0.04 0 7.69 4.1 8.47 4.14 9.77 2.63 0.22 1.95 
815 Class_C/3_(Metabotropic_glutamate/pheromone_receptors) 2.52 9.59 6 8.83 1.17 9 5.79 7.11 5.74 5.18 7.83 4.03 0.31 8.61 5.65 3.03 0.01 6.45 
816 Gastrin-CREB_signalling_pathway_via_PKC_and_MAPK 1.6 1.84 4.11 2.83 3.71 1.52 3.64 1.52 3.16 4.6 2.34 5.56 4.95 9.88 7.31 5.48 8.85 2.48 
817 EGFR_Transactivation_by_Gastrin 3.54 2.95 9.34 7.52 4.68 9.26 1.09 8.45 5.87 5.62 5.24 5.19 6.42 2.9 1.84 9.43 7.3 3.33 
818 G_alpha_(q)_signalling_events 5.89 5.1 4.37 0.12 8.45 3.08 1.46 4.6 4.05 7.41 5.13 6.75 1.45 5.62 8.95 4.8 5.05 2.36 
819 RAF/MAP_kinase_cascade 3.79 6.24 6.2 8.86 3.53 7.67 3.32 5.56 7.19 1.72 6.33 6.94 7.03 4.56 5.79 5.05 3.49 0.31 
820 Opioid_Signalling 4.34 7.6 9.69 3.28 1.93 8.63 3.35 3.22 6.91 3.13 7.73 6.23 9.07 6.66 3.8 6.62 6.66 1.27 
821 DARPP-32_events 2.59 4.19 5.09 2.76 5.28 0.58 3.25 3.42 3.44 8.68 6.52 7.87 1.14 9.61 0.92 2.15 9.99 7.67 
822 G-protein_activation 4.58 4.41 8.2 3.45 1.47 0.52 6.83 6.83 9.89 8.34 1.27 7.25 4.49 2.3 4.31 0.23 5.04 2.97 
823 G-protein_mediated_events 2.52 8.93 1.56 6.24 8.7 0.42 3.52 2.19 7.96 6.57 3.7 3.69 4.99 1.77 7.28 5.46 9.46 4.73 
824 Signaling_by_Hippo 6.81 9.33 8.99 1.81 2.22 4.44 3.95 8.4 1.77 9.97 0.38 3.39 6.92 9.14 4.29 2.6 8.68 5.7 
825 Signaling_by_Insulin_receptor 5.37 4.74 1.52 1.13 6.53 1.52 6.69 8.22 4.71 4.48 9.96 2.36 0.39 3.78 3.1 7.08 8.91 8.21 
826 Insulin_receptor_recycling 0.06 4.16 3.86 2.77 3.68 9.86 9.12 6.86 1.45 8.7 7.13 8.48 6.79 8.86 8.01 6.83 9.14 7.65 
827 IRS-related_events 5.23 1.17 1.64 7.02 1.85 2.58 6.45 4.78 0.84 8.35 2.89 1.91 6.36 4.02 9.74 8.86 5.78 1.08 
828 SHC-related_events 8.56 4.31 2.28 3.36 3.27 8.95 1.13 0.56 1.89 0.35 3.9 6.78 9.68 9.19 6 8.65 3.43 9.69 
829 Signal_attenuation 8.82 3.11 7.55 2.24 8.81 5.64 4.91 7.99 3.1 7.48 3.8 2.06 8.76 8.86 7.84 3.23 8.28 4.27 
830 Signaling_by_Leptin 9.35 9.32 5.25 9.25 2.36 8.48 2.31 5.62 8.02 7.67 1.94 3.47 4.7 7.2 3.06 3.36 5.66 4.1 
831 ERK_activation 4.22 1.59 0.26 2.44 8.97 4.05 9.46 9.44 5.36 4.99 6.09 7.89 0.54 0.44 0.57 6.05 1.97 8.31 
832 MEK_activation 2.78 2.23 0.61 1.6 8.31 4.86 2.74 6.92 4.26 5.77 4.01 0.85 5.51 8.83 9.78 6.18 6.25 1.42 
833 RAF_activation 3.49 4.74 5.52 1.16 9.34 5.46 5.62 2.55 2.91 0.7 7.07 2.9 2.64 6.29 7.78 1.91 8.16 0.88 
834 Pre-NOTCH_Processing_in_Golgi 9.35 9.3 3.91 6.67 3.3 3.01 6.86 3.33 5.73 2.46 0.15 5.81 7.89 4.06 5.85 8.53 7.73 9.55 
835 Pre-NOTCH_Processing_in_the_Endoplasmic_Reticulum 5.66 1.96 1.87 2.8 3.55 9.43 5.99 0.43 2.15 2.79 5.13 3.12 1.68 2.17 6.18 4.76 2.19 6.81 
836 Pre-NOTCH_Transcription_and_Translation 9.18 7.17 5.78 8.8 6.57 7.76 0.43 3.29 3.36 0.1 0.3 1.58 1.13 9.07 2.79 0.96 1.09 9.52 
837 Activated_NOTCH1_Transmits_Signal_to_the_Nucleus 1.01 0.55 3.72 9.04 6.58 3.83 3.38 5.14 2.93 2.11 8.49 8.77 7.8 7.82 1.67 4.79 0.69 7.84 
838 NOTCH1_Intracellular_Domain_Regulates_Transcription 2.9 5.06 7.67 5.49 8.57 0.68 1.48 3.33 2.36 8.7 5.78 4.63 7.27 4.95 5.87 6.63 3.62 5.93 
839 NOTCH2_Activation_and_Transmission_of_Signal_to_the_Nucleus 5.53 7.14 8.85 5.57 1.02 9.91 5.23 9.39 5.23 1.93 6.68 0.77 5.83 8.9 1.2 1.48 9.39 1.06 
840 NOTCH2_intracellular_domain_regulates_transcription 5.6 7.54 2.99 8.09 5.03 9.54 0.15 9.93 5.21 1.97 1.39 2.07 5.3 0.47 7.48 6.91 0.98 2.65 
841 Signaling_by_NOTCH3 7.8 0.37 2.32 0.8 1.76 2.43 0.21 3.65 5.84 0.73 2.59 6.3 7.34 7.36 8.94 3.1 4.19 8.1 
842 Signaling_by_NOTCH4 9.69 4.89 3.34 4.85 7.47 1.78 5.9 4.54 0.67 9.52 2.11 3.68 0.02 5.98 4.8 3.16 1.93 5.38 
843 Signaling_by_PDGF 1.95 9.71 9.07 4.97 7.35 2.27 4.44 3.29 1.46 0.46 3.85 1.1 4.11 8.17 3.14 0.17 8.63 3.79 
844 Downstream_signal_transduction 9.74 3.9 2.04 4.29 0.94 6.77 2.61 2.09 3.96 0.44 3.19 5.89 6.21 1.63 7.79 5.22 5.49 4.56 
845 DAG_and_IP3_signaling 9.74 5.04 8.74 6.03 5.89 5.89 6.44 0.6 1.49 1.02 2.19 5.32 5.13 2.92 6.17 1.54 0.53 9.47 
846 PIP3_activates_AKT_signaling 1.21 0.39 3.39 3.19 6.25 4.59 6.92 1.04 3.56 3.22 8.58 6.79 4.83 1.29 2.03 8.49 4.45 2.62 
847 RAF/MAP_kinase_cascade 5.28 7.88 2.84 4.31 5.43 9.6 7.54 2.41 3.9 7.12 3.32 8.52 4.09 3.13 1.26 8.36 0.05 2.1 
848 Rho_GTPase_cycle 8.79 5.32 2.62 4.36 7.03 8.3 6.38 4.03 7.9 3.98 5.99 4.62 4.46 0.96 6.19 4.76 7.71 0.95 
849 Signaling_by_SCF-KIT 9.38 1.76 9.22 5.67 8.76 5.34 8.56 1.65 8.15 6.22 0.13 0.86 7.07 0.33 3.6 7.81 3.56 6.49 
850 PIP3_activates_AKT_signaling 1.25 9.53 7.52 0.62 6.29 0.46 5.38 3.34 8.6 8.11 5.66 8.93 3.44 2.2 7.17 0.93 6.48 3.84 
851 AKT_phosphorylates_targets_in_the_cytosol 3.16 8.31 2.36 4.46 7.84 5.31 0.76 4.84 7.08 3.49 1.16 5.6 1.11 8.32 7.82 9.38 1.84 3.59 
852 AKT_phosphorylates_targets_in_the_nucleus 1.68 6.89 4.35 4.82 3.67 6.29 7.28 9.18 5.56 1.1 0.02 0.8 3.26 5.47 3.33 7.79 8.32 8.05 
853 Negative_regulation_of_the_PI3K/AKT_network 3.32 6.47 6.13 7.09 9.3 3.57 2.01 8.19 6.31 0.97 2.26 4.81 2.69 4.79 1.91 4.71 9.08 9.45 
854 ERK_activation 0.4 6.88 3.55 0.71 2.7 5.97 8.79 5.28 2.03 8.24 7.45 7.29 5.49 7.24 9.79 1.4 0.07 8.91 
855 MEK_activation 4.11 8.98 2.89 1.12 5.24 1.15 0.1 7.26 2.33 7.09 7.23 4.4 6.11 2.52 4.13 1.07 7.41 5.13 
856 RAF_activation 8.94 8.81 1.73 5.5 2.96 2.71 4.14 9.05 8.34 2.81 2.13 9.67 1.79 1.41 5.44 2.19 5.24 7.49 
857 Regulation_of_KIT_signaling 5.97 0.47 5.41 5.69 8.82 9.78 4.03 9.4 6.33 7.22 1.85 2.22 3.75 5.8 9.16 5.3 5.16 3.54 
858 TGF-beta_receptor_signaling_activates_SMADs 2.44 0.88 6.29 4.76 4.47 8.54 2.57 3.46 3.68 0.19 8.41 9.77 2 4.84 2.36 3.08 6.92 0.5 
859 Downregulation_of_TGF-beta_receptor_signaling 4.49 3.89 8.8 9.16 1.02 0.04 7.45 8.17 5.6 2.47 0.65 8.72 2.04 6.35 3.83 2.28 0.3 4.82 
860 TGF-beta_receptor_signaling_in_EMT_(epithelial_to_mesenchymal_transition) 2.29 9.54 3.76 7.49 5.82 5.33 1.66 4.68 3.19 8.28 9.51 8.75 2.61 4.97 7.5 9.19 1.12 9.1 
861 Downregulation_of_SMAD2/3:SMAD4_transcriptional_activity 8.81 9.3 4.15 1.24 2.58 8.99 2.2 1.4 5.73 8.82 9.77 3.21 8.41 6.02 0.27 6.21 0.34 4.4 
862 SMAD2/SMAD3:SMAD4_heterotrimer_regulates_transcription 4.53 9.07 8.06 3.95 0.32 6.61 3.67 9.8 7.46 1.51 1.85 9.52 1.41 7.63 8.04 4.27 9.06 8.95 
863 Signaling_by_Type_1_Insulin-like_Growth_Factor_1_Receptor_(IGF1R) 2.43 2.55 9.65 8.6 9.26 0.7 2.19 2.16 9.42 1.57 7.69 0.31 1.99 4.73 0.78 3.49 3.3 3.34 
864 IRS-related_events_triggered_by_IGF1R 9.64 6.95 7.72 6.46 8.03 6.98 5.77 0.47 5.51 6.84 2.05 1.44 9.31 2.58 7.16 2.84 2.69 1.61 
865 SHC-related_events_triggered_by_IGF1R 8.4 9.68 2.28 7.46 7.96 4.1 6.96 4.23 5.75 6.27 7.12 7.47 2.66 0.39 5.86 4.74 9.57 3.85 
866 VEGF_ligand-receptor_interactions 2.47 3.47 3.35 6.36 4.68 7.11 9.25 5.2 0.56 8.61 6.93 5.22 8.75 0.04 3.24 9.03 8.2 1.89 
867 Neurophilin_interactions_with_VEGF_and_VEGFR 2.92 7.3 5.9 6.39 6.01 0.04 5.4 9.73 4.22 1.31 6.82 6.06 2.2 2.71 3.58 2.19 7.55 0.24 
868 VEGF_binds_to_VEGFR_leading_to_receptor_dimerization 3.34 7.18 7.72 5.56 0.84 8 8.46 4.48 3.03 7.15 9.59 1.56 9.72 2.74 1.34 8.92 3.17 8.15 
869 Degradation_of_beta-catenin_by_the_destruction_complex 7.59 9.64 2.09 3.47 0.3 4.13 8.13 6.03 5.91 6.29 3.44 4.16 4.85 2.27 1.33 6.39 5.94 7.39 
870 Beta-catenin_phosphorylation_cascade 2.04 3.87 9.67 4.15 9.22 3.84 9.96 3.35 5.87 7.14 1.46 8.49 9.81 2.21 1.91 1.25 9.91 4.06 
871 WNT_ligand_biogenesis_and_trafficking 4.42 3.23 6.17 7.37 3.75 8.14 8.06 7.24 2.93 5.96 9.27 5.48 6.7 0.46 8.42 3.83 6.63 1.82 
872 Asparagine_N-linked_glycosylation 6.43 7.7 7.21 0.71 4.97 6.68 0.4 6.57 3.01 4.26 6.18 1.24 6.22 9 8.25 9.41 7.44 6.48 
873 ER_to_Golgi_Transport 0.76 4.31 5.74 6.78 0.67 6.6 7.9 8.12 5.54 3.17 2.77 9.94 9.68 1.49 9.22 9.28 1.6 7.16 
874 NGF_processing 7.67 7.43 6.47 3.15 5.41 3.66 4.23 1.64 7.67 0.3 7.72 7.56 2.26 5.76 7.02 4.19 6.43 4.93 
875 Activation_of_TRKA_receptors 0.46 1.23 1.77 3.98 5.32 5.75 5.57 1.82 4.96 6.62 7.6 9.8 3.03 7.2 5.48 3.01 3.84 9.28 
876 Nuclear_Events_(kinase_and_transcription_factor_activation) 7.41 8.09 8 6.98 0.17 4.45 2.27 8.96 3.34 8.26 9.96 4.32 3.94 3.71 1.27 7.92 2.49 1.08 
877 PI3K/AKT_activation 3.97 1.72 8.19 5.85 7.52 6.31 2.36 4.13 6.47 2.48 7.6 6.13 5.55 7.75 0.22 5.88 3.71 6.73 
878 PLC-gamma1_signalling 6.6 3.12 9.5 1.28 4.2 5.32 7.44 9.18 2.13 1.91 0.22 6.51 3.17 5.73 6.77 4.85 4.3 0.61 
879 Retrograde_neurotrophin_signalling 5.91 4.48 9.74 7.79 7.28 2.63 1.79 7.03 3.52 5.45 5.83 1.33 5.7 5.91 6.09 9.42 6.6 3.96 
880 Signalling_to_ERK5 3.8 1.99 3.92 3.5 3.39 3.53 8.67 7.89 1.65 0.25 6.35 6.1 4.54 6.81 9.91 8.42 1.42 7.66 
881 Signalling_to_ERKs 9.77 7.47 5.82 5.07 7.83 7.97 0.96 7.1 2.59 9.8 0.07 6.33 3.59 2.86 6.55 6.28 1.97 4.56 
882 Signalling_to_STAT3 2.45 6.33 8.46 7.74 1.94 7.6 0.41 9.7 3.48 7.32 0.46 7.17 9.89 8.22 4.03 9.4 3.68 4.81 
883 Cell_death_signalling_via_NRAGE,_NRIF_and_NADE 0.48 5 3.86 4.13 5.74 6.25 9.26 6.64 4.69 2.52 3 9.86 6.14 5.23 3.3 0.95 5.66 7.41 
884 Ceramide_signalling 5.78 4.42 6.29 0.14 4.94 1.84 9.73 3.84 3.06 2.99 2.15 6.43 6.34 7.61 6.26 0.3 5.16 9.4 
885 NFG_and_proNGF_binds_to_p75NTR 3.89 8.7 5.98 9.94 9.99 9.26 0.75 5.04 1.41 0.96 6.18 4.83 7.56 7.71 8.07 0.31 1.76 9.1 
886 Regulated_proteolysis_of_p75NTR 7.43 5.24 1.08 0.27 4.3 0.77 1.23 9.12 1.71 9.31 1.9 6.34 8.62 8.18 0.78 0.1 1.84 5.69 
887 p75NTR_negatively_regulates_cell_cycle_via_SC1 8.45 5.81 8.92 0.16 7.04 9.74 9.01 2.21 9.6 5.83 9.13 8.56 1.22 1.53 3.32 3.84 3.71 0.08 
888 p75NTR_regulates_axonogenesis 0.08 1.73 5.75 0.58 6.99 5.59 4.6 7.37 8.81 4.06 7.55 4.38 5.39 0.12 2.55 8.97 6.72 4.17 
889 p75NTR_signals_via_NF-kB 5.05 9.82 8.28 2.53 6.1 5.38 2.39 0.75 4.82 4.95 9.67 1.48 1.05 5.56 0 6.65 2.93 1.85 
890 Retinoid_metabolism_and_transport 5.62 4.29 1.16 1.7 5.72 1.3 4.98 0.33 6.8 6.99 3.64 4.25 8.79 7.38 2.46 2.72 7.42 2.04 
891 The_canonical_retinoid_cycle_in_rods_(twilight_vision) 5.62 6.36 4.41 9.13 4.74 7.13 7.43 4.16 2.4 0.82 1.42 4.66 1.95 4.23 8.73 2.38 3.49 8.69 
892 Activation_of_the_phototransduction_cascade 4.79 5.49 4.28 7 0.86 6.86 6.61 8.93 0.55 7.73 3.67 9.47 4.52 1.44 9.51 0.52 7.19 1.95 
893 Inactivation,_recovery_and_regulation_of_the_phototransduction_cascade 0.48 8.39 9.89 7 0.54 0.96 2.51 3.21 4.75 9.21 3.67 9.68 5.45 7.16 4.58 5.19 0.96 1.35 
894 The_retinoid_cycle_in_cones_(daylight_vision) 8.61 0.14 7.54 6.7 2.9 9.85 2.78 6.71 1.56 1.3 5.71 8.34 3.54 3.43 4.29 6.96 4.23 8 
895 ABC-family_proteins_mediated_transport 7.16 5.9 2.22 5.72 5.23 3.22 7.08 7.48 9.02 4.61 4.46 7.28 8.64 5.21 1.09 4.01 6.03 7.64 
896 ABCA_transporters_in_lipid_homeostasis 2.15 5.98 4.25 1.34 7.52 4.35 1 2.08 8.65 8.47 0.41 9.01 9.27 6.6 2.82 3.57 1.91 3.97 
897 Mitochondrial_ABC_transporters 5.39 5.92 0.25 6.91 8.13 4.96 6.18 0 5.22 3.7 7.91 7.84 0.56 3.59 3.11 9.72 9.22 0.45 
898 Passive_Transport_by_Aquaporins 0.64 0.09 5.71 2.67 1.56 7.93 5.8 7.89 6.13 2.09 6.23 9.01 1.43 5.7 1.57 9.55 8.37 8.91 
899 Regulation_of_Water_Balance_by_Renal_Aquaporins 1.82 3.9 7.67 6.87 1.35 9.15 0.98 6.19 3.13 9.74 2.96 7.64 2.23 6.07 0.74 7.9 5.99 5.18 
900 Transport_of_Glycerol_from_Adipocytes_to_the_Liver_by_Aquaporins 1.4 1.03 2.45 2.57 2.16 3.57 0.37 3.65 3.73 3.97 0.48 1.24 3.6 1.26 6.4 1.19 2.28 7.41 
901 Ion_transport_by_P-type_ATPases 2.71 9.48 1.5 7.39 2.29 6.09 7.4 7.64 4.49 3.46 0 9.29 4.58 1.02 8.08 7.6 2.06 9.93 
902 Ligand-gated_ion_channel_transport 4.72 9.29 6.34 7.66 9.53 8.53 8.51 1.39 2.75 3.87 1.01 9.94 1.13 4.83 2.34 7.48 2.28 7.26 
903 Stimuli-sensing_channels 7.09 6.01 7.55 0.61 2.23 2.78 9.13 0.25 5.38 3.42 1.6 8.83 3.65 4.04 7.41 7.34 4.15 2.95 
904 TRP_channels 0.35 4.42 1.75 5.27 1.17 6.49 3.63 0.4 6.14 2.95 5.27 9.24 7.71 3.82 8.49 4.62 7.64 3.43 
905 Iron_uptake_and_transport 2.11 2.12 8.86 1.28 8.16 1.96 8.12 8.9 1.31 2.27 3.12 3.3 2.68 5.53 5.48 4.99 9 8.41 
906 Transferrin_endocytosis_and_recycling 6.54 5.7 6.51 1.52 4.68 6.26 6.96 0.36 4.51 7.21 7.93 3.43 7.35 1.31 7.39 4.43 3.82 2.69 
907 Hexose_transport 9.24 7.28 3.89 0.28 1.83 6.85 9.36 4.23 6.65 4.76 5 7.3 1.78 4.24 3.51 0.21 4.69 6.35 
908 Glucose_transport 9.54 2.93 7.87 9.71 3.33 4.41 8.76 5.72 9.48 7.75 7.12 5.97 7.93 6.96 0.78 9.48 3.62 1.45 
909 Transport_of_glucose_and_other_sugars,_bile_salts_and_organic_acids,_metal_ions_and_amine_compounds 8.67 0.26 5.25 7 9.65 4.79 4.41 6.7 8.24 8.77 5.26 8.58 7.45 6.64 9.68 9.42 2.81 8.73 
910 Facilitative_Na+-independent_glucose_transporters 4.08 2.21 7.16 8.15 4.6 2.29 4.66 7.83 2.08 1.05 1.5 2.69 4.44 6.89 8.69 2.92 9.19 8.32 
911 Inositol_transporters 8.82 0.82 4.69 9.19 2.32 5.92 5.02 6.17 5.26 3.6 1.11 2.87 6.98 9.11 1.32 9.56 1.19 4.46 
912 Metal_ion_SLC_transporters 7.1 2.75 6.09 1.39 8.73 8.72 0.59 9.81 7.3 9.4 5.43 5.45 8.87 7.09 0.14 4.46 5.27 6.77 
913 Na+-dependent_glucose_transporters 4.56 4.48 9.88 5.86 4.46 9.47 3.66 4.06 5.25 5.09 3.54 2.24 4.78 9.45 0.74 7.63 4.85 5.93 
914 Na+/Cl-_dependent_neurotransmitter_transporters 5.03 6.61 9.18 0.12 7.88 4.74 7.43 3.37 8.93 3.62 3.14 1.39 5.67 2.09 3.61 4.21 1.62 9.65 
915 Organic_cation/anion/zwitterion_transport 2.55 8.24 4.93 4.45 5.24 4.18 3.85 3.52 3.05 7.37 8.48 9.08 4.05 5.61 1.99 5.12 1.91 6.98 
916 Proton-coupled_monocarboxylate_transport 5.7 7.72 3.66 5.49 5.59 3.43 0.85 9.04 8.54 6.81 7.78 9.04 5.91 7.06 3.62 0.31 5.65 3.79 
917 Rhesus_glycoproteins_mediate_ammonium_transport 4.21 1.11 9.29 3.48 4.64 3.49 5.69 9.89 9.54 0.17 7.63 7.53 1.58 5.5 0.37 0.72 7.39 7.81 
918 Sodium-coupled_sulphate,_di-_and_tri-carboxylate_transporters 9.75 1.88 2.89 3.58 9.63 2.54 5.09 9.21 3.07 4.42 7.58 2.49 1.96 0.16 4.49 0.83 3.86 2.04 
919 Transport_of_inorganic_cations/anions_and_amino_acids/oligopeptides 2.42 7.19 3.17 6.56 4.52 9.64 9.22 8.57 7.55 1.84 4.6 7.51 4.64 9.6 0.84 8.09 4.68 5.24 
920 Amino_acid_transport_across_the_plasma_membrane 5.51 2.25 6.25 6.79 9.67 5.55 5.57 3.34 3.17 3 0.4 6.23 8.53 5.92 2.08 9.56 7.86 3.16 
921 Bicarbonate_transporters 7.23 8.88 3.32 0.46 5.74 1.61 4.23 0.18 8.75 7.34 3.67 4.06 0.55 5.31 2.8 2.56 9.33 4.83 
922 Cation-coupled_Chloride_cotransporters 2.26 5.74 9.89 2.46 1.65 7.03 2.02 8.11 5.85 9.36 1.23 0.46 9.14 8.17 7.91 8.38 3.46 9.93 
923 Multifunctional_anion_exchangers 4.86 3.77 2.87 1.43 5.81 5.45 6.22 0.91 8.34 9.87 8.96 7.72 9.78 3.56 1.33 5.48 4.08 6.55 
924 Organic_anion_transporters 7.58 2.97 8.38 2.14 7.67 3.4 3.28 3.81 4.84 7.67 9.51 1.17 7.07 5.87 5.56 2.07 0.27 7.68 
925 Proton-coupled_neutral_amino_acid_transporters 6.22 3.9 4.19 7.29 4.77 6.03 4.55 3.34 8.08 8.83 6.62 9.71 2.84 8.04 1.91 7.54 1.97 1.92 
926 Proton/oligonucleotide_cotransporters 0.45 3.57 2.9 2.25 8.25 3.74 7.72 0.53 3.91 1.62 6.64 3.64 8.59 8.27 0.78 9.92 1.82 8.62 
927 Sodium-coupled_phosphate_cotransporters 2.4 9.63 5.55 3.33 4.38 1.36 7.19 7.89 2.09 8.75 6.41 5.78 6.56 3.62 6.94 0.57 5.92 5.52 
928 Sodium/Calcium_exchangers 0.39 4.46 2.54 2.32 9.99 2.72 5.78 7.35 0.8 3.94 9.96 8.61 1.02 2.51 2.66 5.97 3.42 9.92 
929 Sodium/Proton_exchangers 1.58 7.46 6.71 1.6 1.29 2.28 5.22 1.05 7 9 4.47 6.57 9.37 6.77 8.49 3.92 6.69 5.64 
930 Transport_of_vitamins,_nucleosides,_and_related_molecules 3.62 4.52 7.21 0.81 0.65 0.68 6.97 5.33 6.91 6.41 8.21 9.02 2.71 6.01 2.22 6.02 5.11 2.3 
931 Transport_of_fatty_acids 1.07 3.29 1 5.03 9.48 7.01 7.38 1.26 3.82 0.86 4.44 6.82 0.25 6.81 7.04 9.17 7.98 3.37 
932 Transport_of_nucleosides_and_free_purine_and_pyrimidine_bases_across_the_plasma_membrane 9.66 5.84 7.02 3.37 9.97 6.86 0.55 4.57 8.79 8.15 1.59 8.47 4.62 2.86 8.62 2.79 1.83 5.41 
933 Transport_of_nucleotide_sugars 3.59 9.9 6.22 8.78 6.39 9.08 4.02 8.53 6.02 0.08 1.78 8.69 4.74 0.8 4.8 9.76 8.01 8.57 
934 Transport_of_organic_anions 6.93 5.64 1.69 7.08 4.77 1.22 6.97 1.86 1.4 6.72 3.95 8.97 8.9 2.81 5.56 7.11 3.87 3.15 
